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Abstract 
 
Cardiovascular disease (CVD) accounted for 30% of the estimated 58 million deaths 
globally. This proportion is equal to that due to infectious diseases, nutritional deficiencies, 
and maternal and perinatal conditions combined. It is noteworthy that a substantial proportion 
of these deaths (46%) occurred in individuals under 70 years of age, in the most productive 
period of life. In addition, 79% of the disease burden attributed to cardiovascular disease is in 
the same age group.  
High blood pressure is one of the most important preventable causes of premature illness 
and death. It is the major risk factor for stroke, heart attack, heart failure, chronic kidney 
disease and cognitive decline. The risk associated with increasing blood pressure is 
continuous, with each 2 mmHg rise in systolic blood pressure associated with a 7% and 10% 
increased risk of mortality from ischaemic heart disease and stroke respectively. According to 
the international guidelines of the World Health Organization (WHO) and the International 
Society of Hypertension (ISH) individuals may be divided into different groups according to 
the blood pressure value: patients with optimum (<120/80 mm Hg), normal (120–129/80–84 
mm Hg), high (130/139 - 85/89 mm Hg) blood pressure (BP) and hypertensive (140/90 mm 
Hg). Periodic screening of BP in adults is recommended to detect the onset of hypertension
1
, 
so that appropriate measures can be instituted to prevent morbidity and mortality associated 
with raised BP
2
. Due to the absence of definitive data regarding the time course of 
hypertension evolution from lower BP values, current international guidelines vary widely in 
their recommendations for the clinical monitoring of individuals without hypertension. For 
instance, the sixth report of the Joint National Committee on the Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure in the United States (JNC VI) recommends 
that people with high-normal BP should undergo yearly monitoring, whereas those with 
normal or optimum BP should be screened every 2 years. By contrast, the European Task 
Force on Prevention of Coronary Disease proposes that all individuals without hypertension 
should be screened at least once every 5 years. The British Hypertension Society advocates an 
intermediate position: patients with a systolic BP of 135–139 mmHg or a diastolic BP of 85–
89 mmHg should be reassessed yearly, whereas those with lower BP should be assessed at 5–
year intervals.
3,4
 
Essential, primary, or idiopathic hypertension is defined as high BP in which secondary 
causes such as renovascular disease, renal failure, pheochromocytoma, hyperaldosteronism, 
9 
 
or other causes of secondary hypertension are not present. Essential hypertension accounts for 
80-90% of all cases of hypertension; it is a heterogeneous disorder, with different patients 
having different causal factors that may lead to high BP. Life-style, diet, race, physical 
activity, smoke, cultural level, environmental factors, age, sex and genetic characteristics play 
a key role in the increasing risk.  
Conversely to the essential hypertension, secondary hypertension is often associated with 
the presence of other pathological conditions such as dyslipidaemia, hypercholesterolemia, 
diabetes mellitus, obesity and primary aldosteronism. Amongst them, primary aldosteronism 
represents one of the most common cause of secondary hypertension, with a prevalence of 5-
15% depending on the severity of blood pressure. Besides high blood pressure values, a 
principal feature of primary aldosteronism is the hypersecretion of mineralcorticoid hormone, 
aldosterone, in a manner that is fairly autonomous of the renin-angiotensin system. Primary 
aldosteronism is a heterogeneous pathology that may be divided essentially in two groups, 
idiopathic and familial form.  
Despite all this knowledge, there are so many hypertensive cases that cannot be explained. 
These individuals apparently seem to be healthy, but they have a great risk to develop CVD. 
The lack of known risk factors makes difficult their classification in a scale of risk. Over the 
last three decades a good help has been given by the pharmacogenetics/pharmacogenomics, a 
new area of the traditional pharmacology that try to explain and find correlations between 
genetic variation, (rare variations, SNPs, mutations), and the risk to develop a particular 
disease. 
This study was realized with the aim to add new informations on the hypertensive 
susceptibility starting from two different populations: an unselected Italian population, the 
Brisighella population, used for the Brisighella Heart Study, and a selected Australian cohort 
of 251 patients affected by primary aldosteronism.  
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1.0 Cardiovascular system 
 
 
1.1 Heart, vessels and blood pressure  
 
Cardiovascular apparatus is one of the most fascinating and intriguing, for complexity and 
importance, among all systems that regulate our life. It is constituted by an important central 
organ, the heart, and by a wide number of blood vessels, all differing in function and 
structure. The heart and blood vessels form a transportation system that delivers to all cell 
nutrients and oxygen, needed for their proper function, and moves away the products of their 
metabolism, providing a sort of communication between the cells and the environment.  
 
 
 
Fig.1 Frontal view of the heart structure and the most important arteries and veins 
 
The heart is an involuntary muscle, able to contract an relax autonomously with regular 
rhythm, pumping the blood in the pulmonary and systemic circulations. This organ, located 
anteriorly to the vertebral column and posteriorly to the sternum, is surrounded by a double 
wall sac, called pericardium, with a pericardic fluid between them. Outside the parietal 
pericardium there is a fibrous layer called fibrous pericardium. The human heart can be 
divided in three layers: the outer layer called epicardium or visceral, the middle layer, called 
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myocardium, constituted prevalently by contractile cardiac muscle, and the inner 
endocardium, in contact with the blood. The heart (Fig. 1) may be divided in four chambers, 
two atria left (sx) and right (dx) on top, that constitute the base of the organ and similarly 
two ventricles dx and sx in the bottom of the heart, named apex. The two sides of the organ 
dx and sx are separated by a wall, called septum. The two atrium dx and sx communicate with 
the corresponding ventricle below, allowing the blood to flow downwards. However, the heart 
needs a set of valves, located across each atrium and ventricle, to keep the fluid flowing in 
one direction; the dx atrial-ventricular valve is called tricuspid valve and the sx atrial-
ventricular valve is the bicuspid or mitral. There are other two important semilunar valves, 
housed between right and left ventricle and pulmonary and aortic artery, respectively with the 
same function of the others.  
Blood circulation is divided in small and big circulation; the first that starts from the dx 
atrium and receives deoxygenated blood from the systemic circulation through the superior 
vein cava; once the dx atrium is completely filled, blood starts to flow down in the 
corresponding ventricle below, from which deoxygenated blood through pulmonary artery is 
driven in the lug to be oxygenated. From the lug, this blood reach of oxygen and poor of 
anhydride carbonic flows back in the sx atrium by the pulmonary vein. Thus, the big 
circulation starts with the oxygenated blood that has completely filled the sx atrium, from 
which, in the similar way to the right part, it flows down in the ventricle below and get off by 
aortic artery. In both, sx and dx atrium blood is able to flow down in the ventricle located 
below for the 90% of the total volume thanks to the force of gravity. The remaining 10% of 
volume is driven down by the atrial myocytes contraction, atrial systole, reducing the atrial 
volume and in the same time increasing the pressure inside that overcomes the ventricle 
pressure, according to the ideal gas law: P= nRT/V. 
At the end of atrial systole all the blood volume is located in the ventricle below; in the same 
time the semilunar valves, located between the ventricle orifice and aortic artery, are still 
closed, keeping all the volume inside. At the beginning of left ventricle systole, as 
aforementioned, the two physical parameters, volume and pressure change in an inversely-
related manner, volume decreases while the pressure starts to increase overcoming the aortic 
pressure; this leads to the opening of semilunar valves, allowing the blood to flow out in the 
aortic artery. The left ventricle is empty now and ready to receive again blood from the 
overlying atrium. (Fig. 2) 
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Fig.2 Schematic representation of the volume and pressure values changes during a complete 
cycle of contraction-relaxation of the heart. 
 
The heart is an involuntary muscle able to contract autonomously with a regular rhythm 
thanks to own electrical system, constituted by three important structures such as sinus atrial 
node (SAN), atrio-ventricular node (AVN) and His-Purkinjie fibres. SA node is located in 
the right atrium near the entrance of the superior vein cava; it is the most important of this 
system because of presence of particular type of cells, named pacemaker cells, responsible of 
the normal heartbeat, which ranges between 60 and 80 beats for minute. As in all other cells, 
the resting potential membrane of pacemaker cells range between -60 and -70mV that is kept 
by a continuous outflow of K
+
 ions in the extracellular environment. However, this outflow 
decreases during the time leading to a small depolarization of the resting potential membrane; 
in the same time there is a slow inward flow of Na
+
 as well as of Ca
2+
 ions, increasing the 
potential membrane until the threshold potential is reached. At a this moment, the true 
depolarization can start and differently from other exciting cells, in which this phase is 
characterized by Na
+
 channel opening, it is caused by a slow influx of Ca
2+
 ions through L-
type calcium channel; for this reason the depolarization is slower than in neurons. At the end 
of depolarization, Ca
2+
 and Na
+
 channels result to be closed, while the K
+
 ions flow out 
rapidly repolarizing the resting membrane potential. Under normal conditions the 
depolarization wave will be propagated throughout the right atrium, and through the 
Bachmann's bundle to the left atrium, stimulating the atrial myocardium to contract, atrial 
systole. During the atria relaxation, called diastole, since atria are electrically isolated from 
the ventricles and the AV node is the only connection between the two areas, the electrical 
conduction from the AV node to the underlying ventricles is realized with a small delay 
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through the Bundle of His along the septum to the Purkinjie fibres. The conduction delay 
between atria and ventricles is very important for the heart functionality in order to avoid a 
simultaneously contraction. This phenomenon gives the possibility to the atria to contract 
together, allowing the blood flow toward the ventricles. An important characteristic of the 
myocardium cells is the ability to contract immediately and simultaneously with the 
depolarization wave passage. Myocytes of the heart can be considered as a functional 
syncytium because of the electrical impulses propagate freely between cells in every direction, 
so that the myocardium can contract as a single contractile muscle. The free and rapid 
propagation of the electrical impulses can happen thanks to the presence of particular 
junctions, called gap-junctions, between myocytes. Changes of depolarization/repolarization 
frequency of pacemaker cells and contraction strength of myocytes as well as alterations of 
the peripheral vascular resistance and alteration of volemia, including water and Na
+
, K
+
, Cl
-
 
ions levels, have wide effects on the systolic blood pressure values according to the 
physiological definition of blood pressure: 
SBP = Q x TPR 
SBP = systolic blood pressure 
Q = cardiac output  
TPR = total peripheral resistance 
Therefore, SBP is directly proportional to TPR and Q. The latter is defined as a volume of 
blood being pumped by the heart, in particular by the right and left ventricle and represents 
the effective volume that comes back with the vein determining how much blood the heart 
pumps out. 
The principal types of vessels, different in composition and function, include arteries, 
capillaries and veins. Arteries are characterized by three different layers: the innermost layer, 
called tunica intima or internal, which show an elastic membrane and a thin layer of 
endothelial cells directly exposed to the blood; the tunica media, the middle layer, containing 
concentric sheets of smooth muscle tissue in a framework of loose connective tissue, and 
tunica external, or adventitia, the outermost layer of a blood vessel that forms a connective 
tissue sheath. The connective tissue fibres of the tunica external typically blend into those of 
adjacent tissues, stabilizing and anchoring the blood vessel. 
Arteries may be divided into elastic and muscular arteries; the first, which include the 
pulmonary trunk, aorta, and their major arterial branches, transport large volume of the blood 
away from the heart; the second group, also known as medium-size arteries, distribute blood 
to the body's skeletal muscle and internal organ, and it includes the carotid, brachial, 
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mesenteric, and femoral arteries. The tunica media of the muscular arteries contains scattered 
smooth muscle cells, although they do not form a proper layer, and the contraction or 
relaxation of this muscle can produce a great changes in the diameters of the lumen. Since 
resistance to blood flow depends in part on this diameter, the activity of smooth muscle cells 
is very important on blood pressure regulation. 
Capillaries, that show a singular thin layer of endothelial cells, are the only responsible of 
the exchange between the blood and the surrounding extracellular fluid. There are two major 
types of capillaries: continuous and fenestrated. Continuous capillaries allow the diffusion of 
water, small solutes and lipid-soluble material, and avoid the passage of blood cells and 
peptide. Fenestrated capillaries, as the name implies, are not completely attached each other, 
but show some fenestration that allow the passage of small peptide. Capillaries do not 
function as individual units but as part of an interconnected network called capillary bed, or 
capillary plexus, which is characterized by a lot of connections between capillaries and 
venules. 
Veins transport de-oxygenated blood from periphery to the heart with a blood flows at very 
low pressure. Veins are classified on the basis of their size in three different types: venules, 
medium-size veins and large veins. Venules, which collect blood from capillary beds, are the 
smallest venous vessels and show three layers: an inner endothelium composed by endothelial 
cells, a middle layer of muscle and elastic tissue and an outer layers of fibrous connective 
tissue. Medium-size veins, comparable in size to the muscular arteries, characterized by a thin 
tunica media containing relatively few smooth muscle cells, and a thick layer, the tunica 
external, which contains longitudinal bundles of elastic and collagen fibres. The blood 
pressure in venules and medium-size veins is so low that it cannot oppose the force of gravity. 
Large veins include superior and inferior venae cavae. One of the most important 
characteristic of the large veins is the presence of valves, at more or less regular intervals, that 
prevents the retrograde flow of blood. These valves act like the valves of the heart, allowing 
blood flow in only one direction. In particular, when the individuals is in the standing 
position, these valves are closed, and only the compression of deeper veins, by contractions of 
the skeletal muscle, allows to the blood to open these valves, which in turn will be closed by 
the flowing back of blood itself. This force, called muscle pumping, works through the 
thoracic force giving to blood the needed energy to overcome the force of gravity. 
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1.2 Nervous system and its role in the blood pressure modulation  
 
It has been well established over the years that modification of one of aforementioned 
parameters, heart rate, peripheral vascular resistance, volemia, directly modulates the 
arteriolar blood pressure. For this reason, blood pressure regulation, likes other parameters of 
our body, is strictly settled by numerous and complex mechanisms such as endocrine and 
autonomic nervous system (ANS), which often work synergically.  
ANS is constituted by sympathetic and parasympathetic pathways, which have opposite 
activities on the same organs and tissues, and use two different types of neurotransmitter 
activating several receptors. The most abundant sympathetic fibres use noradrenaline (NA) 
as neurotransmitter and are named adrenergic or noradrenergic fibres while parasympathetic 
fibres use acetylcholine (Ach) thus called cholinergic. NA and ACh neurotransmitters are 
able to exert different activities and evocate different responses thanks to the activation of 
several receptors. Among the cholinergic receptors it is possible to distinguish two families: 
muscarinic receptors (M), M1, M2, M3, and nicotinic (N) receptors, Nn, Nm. Noradrenergic 
receptors are divided in alpha (α) and beta (β), which in turn are classified in α1 and α2, and 
β1, β2, and β3. To date, it is well understood the localization and the mechanism by which 
these receptors are activated and the effects that their activation lead to. Muscarinic and β 
adrenergic receptors are G-protein-coupled-receptor, and their different action depends on the 
sub-type of G-protein with which they are coupled. It is well known that G-protein can exist 
as a Gs (stimulatory), Gi (inhibitory) and Gq proteins, that work activating or inhibiting 
respectively an important effector, adenylate cyclase, that converts ATP in cAMP, which in 
turn stimulates a kinase cAMP-dependent such as PKC. Activation of Gq protein, leads to an 
increased activity of phospholipase C, that converts inositol-bisphosphate-membrane-
phospholipid (IP2) in inositol-triphosphate (IP3) and dyacilglycerole (DAG) increasing 
cytoplasmatic calcium (Ca
2+
) concentration. 
All β receptors, β1, β2, and β3 are associated with a Gs protein even if in some case β2 has 
been seen coupled with a Gi protein. Alpha receptors, α1 and α2, are coupled with a Gq and a 
Gi protein respectively. 
M1, M3 receptors are associated with a Gq protein while M2 is associated with an Gi protein. 
Nicotinic Nn and Nm receptors are classical potassium and sodium channels, with a 
pentameric structure, 2α, β, γ, δ subunits. These receptors are widely distributed, and the most 
part of organs and tissues receive sympathetic and parasympathetic fibres. Heart, vessels, 
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kidneys, endocrine glands, are the principal organs and tissues, strictly involved in the blood 
pressure regulation, that undergo sympathetic and parasympathetic modulation. 
Heart is modulated by autonomic nervous system; indeed, muscarinic and adrenergic 
receptors have been isolated from this organ. Pacemakers cells, whose role has been already 
described, show muscarinic M2 and adrenergic β1 receptors. M2 receptors, coupled to a Gi 
protein, once activated by ACh, vary ions flow, increasing the K
+
 conductance and reducing 
the Ca
2+
 inflow in both pacemaker and myocytes cells. The final effect of the M2 receptor 
activation is heart rate reduction and decreased electrical conductibility. Furthermore, there is 
a reduction of the contraction strength. All together these effects wok reducing the blood 
pressure regulation. Similarly, activation of adrenergic β1 receptors is associated with 
electrical and mechanical effects. It has been observed an increased Ca
2+
 flow across the cell 
membrane of pacemaker and myocytes, that leads to an increase in the discharge frequency as 
well as electrical conduction and ventricle strength contraction. These effects have 
hypertensive implication. 
The cardiovascular system maintains an adequate circulation of blood to all part of the body 
due to the blood vessels regulation, realized through the branches of the autonomic nervous 
system that reach almost 100% of them. Density and function of this innervation vary widely 
according to different types of vessels, modulating the vasculature tone. Vascular tone is the 
result of smooth muscle cells contraction, which may be modulated by different neuronal 
neurotransmitters, different receptors, cell-to-cell spread excitation, chemical events at the cell 
membrane. The vascular tone reflects directly the resistance to the blood flow of small 
vessels, in particular arterioles and pre-capillary arterioles. The increased vascular tone results 
in reduction of blood vessels diameter and consequently in blood flow, causing inadequate 
nourishment and oxygenation of the organ or tissue with a decreased activity. For all these 
reasons vascular tone or vascular resistance regulation is very important in the blood pressure 
control, and for this reason it is strictly controlled by autonomic nervous system. Vascular 
tone undergoes influences of adrenergic fibres, through NA release and β2 and α1 adrenergic 
receptors activation. β2 receptors, localized on top of the membrane of endothelial cells, are 
coupled with a Gs protein; its activation lead to an increased adenylate cyclase activity and 
cAMP production; raised cAMP concentration activates a cAMP kinase which in turn 
phosphorylates and activates a myosin light chain kinase, inducing relaxation of the 
endothelial cells. On the other hand, activation of adrenergic α1 receptors, coupled to a Gq 
protein, leads to an increased activity of phospholipase C, that up-regulates the IP3 and DAG 
production with a resulting increase of Ca
2+
 concentration. The Ca
2+
-calmoduline complex 
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activates myosin light chain kinase, which in turn phosphorylates the myosin light chain. It is 
this phosphorylation that promotes the interaction of myosin ATPase and actin and the cross-
bridge formation, leading to the initiation of a transient increase in vascular smooth muscle 
contraction. These effects mediate vasoconstriction and increase blood pressure. Muscarinic 
receptors that have been discovered across the membrane of endothelial cells are principally 
M3. Activation of these Gq-coupled receptors leads to an up-regulation of phospholipase C, 
which in turn, releasing DAG and IP3, increase the cytoplasmatic Ca
2+
 concentration. This 
effect seems to be important for activating the endothelial NO synthase (eNOS), that produces 
NO. This substance is able to spread easily in the smooth muscle cells, where activates the 
guanylyl cyclase increasing the conversion of GTP to cGMP; furthermore cGMP activates a 
cGMP-dependent protein kinase that most probably dephosphorylates the MLC, leading to a 
relaxation of these cells. Even if the relaxation effect of NO is well known, its mechanism to 
date is not completely clarified.  
It is well established that several substances of endothelial cells metabolism, such as CO2 
and O2 are involved in the vascular tone and in the blood pressure regulation. 
It has been seen that reduction of O2 concentration is associated with diminished 
contractility of vascular smooth muscle cells as well as increased CO2 concentration is 
associated with a vasodilatation. Similarly a wide number of substances with a vasoactive 
properties have been isolated and characterized, such as kallidin, bradykinin etc.... Some of 
these have important functions, like angiotensin-II (AG-II): which is an extremely powerful 
vasoconstrictor; another peptide is the vasopressin also called antidiuretic hormone, that 
besides the renal effects on Na
+
 and K
+
, has been shown to exert a cutaneous vasoconstriction 
in the renal vascular bed; histamine that is released from cells of the skin in response to injury 
or antibody-antigen reactions, not only dilates arterioles and venules but also increases their 
permeability; prostaglandins are a group of biologically active lipids that show a vasodilator 
effects. 
 
 
1.3 Kidney involvement in the blood pressure regulation 
 
Kidneys are the principal organs of regulation of the volume and solute composition of the 
body fluid by reabsorption and excretion of water and electrolytes. The composition of blood 
plasma varies only slightly from individual to individual in a healthy condition. In the table 
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below are reported the average normal values for the most important ions that come into play 
in the composition of these two compartments, blood plasma and cytoplasm.  
 
 
 
 
 
 
 
 
Table n.1 Electrolytes composition of blood plasma and cellular cytoplasm in a normal 
condition. 
 
Therefore, kidney exerts this important function but is not the only one, because other 
organs participate in this process, notably the lungs in respect to acid-base regulation, 
autonomic nervous system and endocrine glands. However, the kidney through its excretory 
activity, provides the major mechanism for maintaining homeostasis. In order to keep a 
constant internal and external environment the kidney must respond appropriately to 
variations in dietary intake and in extra-renal losses of solutes and water. It is well known that 
ion concentration, measured in terms of osmolarity, is one of the most important factor able to 
influence the volemia. In case of increased osmolarity our body through autonomic nervous 
system, endocrine and kidney systems induce a reabsorption of water in order to dilute these 
ions, increasing the volemia. Otherwise, if there is a wide loss of ions with a consequent 
decrease of osmolarity our kidneys eliminate the right volume of water to concentrate the 
solution within physiological range. All of this is possible because our systems always work 
trying to keep our body in a homeostasis condition. Since the structure and the function of the 
kidney are so closely related, it is necessary to have some knowledge of its structure before 
looking at its function. The basic unit of structure and function of the kidney is the nephron, 
that includes the glomerulus and its attached tubules; in succession there are: proximal 
convoluted tubule, loop of Henle and distal convoluted tubule and collecting duct. Glomerulus 
is completed surrounded by a Bowman's capsule, an anastomotic network of freely branching 
capillaries. These capillaries originate from an afferent arteriole, and leave the glomerulus as 
a single efferent arteriole. The afferent arteriole in turn breaks up to form peritubular 
Ions Blood plasma Cytoplasm 
Na
+
 145 mM 139 mM 
K
+
 4 mM 12 mM 
Ca
2+
 1-2 mM <0.0002 
Mg
2+
 1.5 mM 0.8 mM 
Cl
-
 116 mM 4 mM 
HCO
3-
 29 mM 12 mM 
Amino acids 9 mM 138 mM 
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capillaries surrounding the cortical tubules reaching also the deepest zone of the nephron, 
medulla, where they are called vasa recta. The presence of these blood vessels all around the 
renal tubules is very important because in this way water and electrolytes exchanges between 
them are possible. Our blood is filtered almost 26.7 times during the day and considering that 
the blood volume ranges between 5-7 L it results that total volume of 186 L is filtered for day. 
Of these 186 L of glomerular ultra-filtered liquid the 99% is reabsorbed and only the 1% is 
eliminated as urine, i.e. 1.8 L per day. 
The rate of filtration across the glomerular filtration membrane of the Bowman's space is 
determined by physical forces. The hydrostatic pressure in the glomerular capillaries (Pgc) is 
the driving force of the filtration; opposing filtration are the hydrostatic pressure in the 
Bowman's capsule (Pbs) and the colloid osmotic pressure (COP) exerted by the proteins of the 
capillary plasma. Because the filtrate in Bowman's space is protein free the COP may be 
considered negligible. The glomerular filtration rate (GFR) is directly proportional to the net 
balance of the these forces according to the mathematical equation:  
GFR = Kf [Pgc - (Pbs + COP)] 
Kf is considered constant and is defined as the product of the hydraulic conductivity and 
the surface area of glomerular capillaries. According to this definition, it's possible to say that 
at the Bowman's space the net difference between these forces is almost 8 mmHg, driving the 
ultra-filtered from the lumen of capillaries to the Bowman's capsule. Along all the distal tubes 
the difference between these forces becomes positive in the peritubular capillaries with a 
consequent reabsorption of the fluid that was lost before. 
Two thirds of the filtered volume is reabsorbed immediately in the proximal tube, while 
the remaining part starts to flow down along the descending trait of the Henle's loop. Along 
all the descending trait of Henle's loop there is a great reabsorption of water and the filtered 
solution reach a concentration of 1200mOsm, that is comparable with that of the external 
medulla zone; along the ascending trait of Henle's loop, ions such as Na
+
, K
+
 and Cl
-
 but not 
water, are widely reabsorbed reducing the concentration of filtered liquid. The filtered liquid, 
that is not yet called urine, continues its trip along the distal tubule, which similarly to the 
ascending trait is responsible of Na
+
 reabsorption but in the same time is impermeable to the 
water. The distal tube is the physiological target of an important hypertensive hormone, 
aldosterone, released from the glomerulosa cells of the adrenal gland (see chapter 2.0), 
responsible Na
+
 and consequently water reabsorption, increasing the volemia and the blood 
pressure. The last tube of nephron, the collecting duct, exerts an important function of 
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changing the urine concentration, regulating the water reabsorption. In this way, this tube is 
able to produce hypertonic urine in case of excess of ions that have to be eliminated or 
hypotonic urine in case of excess of water. This function is realized through specific channels 
called aquaporin, whose expression is under the control of a particular type of hormone, 
antidiuretic hormone (ADH) or vasopressin, released from anterior pituitary gland, whose 
activity is important for maintaining the osmolarity (see parag.1.4). Kidney is able to bring 
about these adaptive responses because of its interaction with the autonomic nervous system, 
which constantly receives informations about the ion content, volemia and blood pressure. 
The major level of regulation lies in a microscopic structure, juxtaglomerular apparatus 
(JGA), so-called for its proximity to the glomerulus. This apparatus is morphologically a 
highly specialized structure with both vascular and tubular components. It probably has an 
important role in a feedback mechanism controlling glomerular filtration rate and/or renal 
blood flow. It consists of several parts: granulated cells in the afferent and efferent arterioles, 
the macula densa, and the extra glomerular mesangium. It has been demonstrated only 
recently the presence of gap-junctions among these cells, whose role seems to be very 
important in the exchanges of informations. Some of the cells in the media of the afferent and 
probably the efferent arteriole close to the glomerulus are specialized myoepithelioid cells and 
contain granules that appear to be composed of the renin enzyme. The macula densa cells 
position is useful to monitor some aspect of distal tubular function possibly hydrostatic 
pressure and the concentration of one or more solutes especially Na
+
 concentration. In case of 
increased Na
+
 concentration in the filtered liquid that lies in the distal tubule, this cells start to 
work, releasing paracrine substances that seem to have double effects: on the one hand act on 
the afferent arteriole increasing the vascular tone and resistance while on the other hand 
transfer these informations to the epithelioid cells of juxtaglomerular apparatus, thereby 
regulating the release of renin. 
Renin is a protolithic enzyme that once released and entered in the systemic circulation 
converts the angiotensinogen, that is produced and released constitutively by the liver, to 
release the inactive decapeptide angiotensin-I. Angiotensin converting enzyme (ACE) 
synthesized by several tissues, split off the last two amino acids of the angiotensin I to form 
the octapeptide AG-II, which has important hypertensive activities. This mechanism 
represents the key response at the kidney level toward a Na
+
 reduction. However, other 
regulation mechanisms, as aforementioned, are involved in this complicated process. Afferent 
and efferent arterioles show particular type of receptors, called baroceotor, that are able to 
monitor constantly the pressure with which blood enters and leaves from the kidney, and in 
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case of reduced blood pressure these receptors through afferent fibres induce a sympathetic 
response. Furthermore, cellular membrane of juxtaglomerular cell has adrenergic β1 receptors 
that response to noradrenaline/adrenaline increasing the renin release.  
These observations show as the blood pressure regulation is a key mechanism realized in a 
cooperation manner between cardiovascular, autonomic nervous system, renal and endocrine 
glands. 
 
 
1.4 Endocrine involvement in the blood pressure regulation 
 
It is possible to imagine and assume that the connection point between the nervous and the 
endocrine system is represented by the hypothalamus through the pituitary gland or 
hypophysis. Hypothalamus is unique in this function and in the same time it is involved in 
several important processes. The hypothalamus is a relatively small area of the brain located 
beneath the thalamus nuclei and extends from the mesencephalon to the region of the optic 
chiasm and the pre-optic area. It has been well described the vascular organization of 
hypothalamus constituted by a series of capillaries that end in a capillary bed in the 
hypophysis, from which these vessels flow out with a singular vein into the systemic 
circulation.  
It is well known that hypothalamus receives different types of neuronal fibres, GABAergic, 
cholinergic and catecholaminergic; indeed, several transmitters, such as acetylcholine, gamma 
amynobutyric acid, dopamine, serotonin, substance P, adrenaline, histamine have been 
isolated from this area. 
It has become clear that the secretory activities of the cells of the anterior lobe of 
hypophysis are widely controlled by substances secreted in the hypothalamus and transported 
in the adenohypophysis by the portal vessel system. As stated previously, the hypothalamus 
integrates many functions and is involved in a series of reactions essential to the maintenance 
of homeostasis and to the initiation and control of many behavioural responses, such as 
reproduction, thirst and control of water balance, control of body weight, temperature 
regulation, reactions to stress, control of emotional reactions, sleep and arousal, control of 
somatic reactions.  
The hypothalamus exerts its control over body functions through endocrine, hypothalamic-
pituitary axis, and somatic neuronal efferent systems. It has a close relationship with the 
hypophysis and this hypothalamic-pituitary axis regulates the activity of nearly all endocrine 
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organs. Discussion of the role of the hypothalamus in the control of the body economy 
through the endocrine system can be divided in at least three parts: reproductive functions, 
water balance, and metabolic processes. The hypothalamus exerts its function through several 
peptides and biogenic amines, so-called releasing factors, which in turn lead to stimulation or 
inhibition of hormones secretion of pituitary gland. Among these substances we can recognize 
gonadotropins-releasing hormone (GnRH), thyrotropin-releasing hormone (TRH), 
corticotropin-releasing hormone (CRH), growth hormone release-inhibiting hormone or 
somatotropin (GHRH or STH), somatostatin-releasing hormone (SRIF). Each of these 
releasing factors secreted by the hypothalamus, reaches the anterior lobe of the pituitary gland 
and promotes or inhibits pituiry hormones release. Pituitary gland or hypophysis is divided in 
two parts: anterior lobe or adenohypophysis and posterior lobe or neurohypophysis. 
Histologically, the adenohypophysis consists of a large cells that contain secretory granules. 
As it has been already said, adenohypophysis is strictly related with the hypothalamus by a 
portal system of vessel, through which the releasing factors secreted into the hypothalamus 
reach this area and can exert their functions. The secretory cells of adenohypophysis show on 
the cellular membrane specific receptors with which the releasing factor interact leading to 
activation or inhibition of pituitary hormone secretion. The adenohypophysis secretes at least 
seven recognized hormones, four of which directly control the functioning of their particular 
target glands, the adrenals, thyroid, and gonads. These hormones are defined tropic or trophic. 
Unlike to the adenohypophysis the neurohypophysis contains no large epithelial cells full 
of secretory granules. Instead, it consists primarily of unmyelinated nerve fibres and modified 
glial cell, called pituicytes. Although it was thought for many years that the pituicytes were 
the source of the posterior pituitary hormones, it is now recognized that these hormones are 
neurosecretory products of the hypothalamus conducted to the neurohypophysis by carrier 
proteins (neurophysins) via neuronal axons and stored into secretory vesicles in the neuron 
terminal and released directly in the systemic circulation. While the adenohypophysis release, 
as aforementioned, several hormones under the hypothalamus stimulating factors, 
neurohypophysis is responsible of secretion of antidiuretic hormone or vasopressin (ADH) 
and oxytocin, which escape to the hypothalamus regulation. It seems to be likely that the role 
of neurohypophysis is just storage and release of these substances; indeed the posterior 
pituitary gland contains almost 15 unit of ADH, which is enough to maintain a man in 
maximum antidiuresis for more than 1 week. By contrast, the hypothalamus contains very 
little hormone less than 5% of the total amount stored in the posterior lobe of pituitary. While 
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the hypothalamus may be capable of meeting some demands for ADH, it may not be able to 
support intense and sustained antidiuresis.  
Pituitary hormones show a feedback mechanism of regulation, and in most cases it is a 
negative feedback; this means that releasing of these hormones is subjected to an auto-
limitation process and the hormone itself inhibits further secretion by the pituitary. 
Nevertheless, when the plasma concentration of the target gland hormone falls below under 
critical level, the negative feedback is relieved, and the trophic hormone is again secreted 
until the target gland produces enough hormone to shut off the pituitary. However, there are 
particular conditions during which this mechanism may be a positive feedback, leading to a 
continue releasing of the specific substance. Assumed that each of the pituitary hormones 
exert an important role in the regulation of several pathways involved in the maintenance of 
the homeostasis of our body, I want to focus only on the role of those hormones, whose 
activity is directly correlated with the blood volume, ions absorption or excretion and blood 
pressure regulation. Among all the hormones aforementioned, ADH, ACTH, TSH, have been 
demonstrated to work in synergism with nervous system to maintain blood pressure within a 
physiologic range. Currently it is well know the functional mechanism of TSH, released from 
the adenohypophysis under the stimulation of specific releasing factor, to stimulate the 
thyroid gland to produce Thyroxin (T4) and Triiodothyronine (T3) which stimulates the 
metabolism of almost every tissue in the body. Furthermore, thyroid gland is also involved in 
the secretion of a polypeptide hormone, calcitonin, also named thyrocalcitonin, whose role 
seems to be important for the Ca
2+
 regulation. Its activity is not completely clear but to date 
we can say that this hormone is involved in the reduction of Ca
2+
 circulating at a three 
different levels:  
 inhibition of Ca2+ absorption by the intestine 
 inhibition of osteoclast activity in bones  
 inhibition of renal tubular reabsorption of Ca2+ allowing it to be excreted in the urine 
 
Furthermore, calcitonin is also involved in the inhibition of phosphates reabsorption by the 
kidney. The role of this hormone is very important considering the key function of Ca
2+
 ions 
in the cellular responses. 
Similarly, the adrenocorticotropic hormone, ACTH, is secreted by the anterior lobe of the 
hypophysis in response to the CRH released by hypothalamus and exerts a key role not only 
in the metabolism but also in the blood pressure regulation. ACTH secretion is increased by 
reduced level of circulating cortisol and under conditions of stress such as fever, acute 
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hypoglycaemia, major surgery or by noxious stimuli; furthermore, its release resulted to be 
affected by the diurnal rhythm, increasing during the first few hours of sleep and reaching the 
peak at the time of awakening while it decrease during the evening. ACTH hormone, once 
released, by the systemic circulation reach the adrenal gland, that is the major target, where 
activates the first enzyme involved in the first step of synthesis of glucocorticoids and 
mineralocorticoid hormones (see chapter 2). Aldosterone is one of these, whose hypertensive 
role was completely clarified and will be deeper discussed in the next chapter. Furthermore, 
as an indirect consequence of its actions, ACTH, also maintains the size and blood flow of the 
adrenal cortex. Indeed, when present in excessive amounts, it causes enlargement of the two 
zones of the adrenal cortex, fasciculate and reticularis, while in its absence adrenal cortical 
atrophy occurs. Noteworthy is the aspect that ACTH has a lot of extracortical activities, 
modulating numerous organs and tissues.  
Antidiuretic hormone, ADH, or vasopressin is clearly involved in the urine production and 
especially in the regulation of the urine osmolarity and consequently is indirectly responsible 
of blood volemia and blood pressure regulation. As widely explained in the last paragraph, 
one of the essential functions of the kidney is control of the total body water content so that 
the total solute concentration of the body fluids in normal humans is maintained within a very 
narrow limits despite wide variations in the in fluid intake and extrarenal water losses. Thus, 
urine volume and osmolarity directly reflect changes in the same parameters of blood flow. 
The osmolarity of human urine can vary widely between 85 and 1400 mOsm/kg of water. 
These changes in osmolarity are realized mostly in the last part of distal tube and along the 
collecting duct where ADH exerts its activity. I have already explained the urine flow over the 
nephron; briefly here I want just to remember how the urine changes in volume and 
concentration. In the distal tube almost two third of the filtered liquid is reabsorbed in the 
proximal tube, and the liquid has the same concentration of the plasma of almost 
285mOsm/kg. Along the descending trait of the Henle's loop, only water is reabsorbed into 
the interstitial space, with a consequent increase of filtered liquid osmolarity that riches 
1200mOsm; at this point the fluid start to flow up along the ascending trait of Henle's loop, 
where Na+ and Cl- ions are reabsorbed and the fluid's osmolarity get off again to 285mOsm. 
In the last two traits, distal tube and collecting duct, urine osmolarity will be changed by ADH 
hormone, according to the body's needs, producing hypo or hyperosmotic urine. Plasma ADH 
levels, under normal condition, range approximately between 1 and 3µU/ml and plasma 
osmolarity is maintained around 285-290mOsm. When this value is changed as little as 2%, 
ADH output is significantly increased. ADH secretion is influenced by many neural and 
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humoral stimuli that excite or inhibit hypothalamic supraoptic nuclei, from which this 
hormone is released. Blood volume and pressure are constantly monitored by numerous 
receptors, osmoreceptor and baroreceptors, which afferent fibres reach the CNS, which in 
turn integrates the informations and send appropriate responses to the periphery. The location 
of the volume receptors and their afferents pathways are not known with certain. It seems to 
be like that atrial and ventricular stretch receptors, receptors located in the great veins of the 
chest and probably from the pulmonary circulation, may be involved in the blood pressure 
and osmolarity control. Furthermore, there are particular type of cells of the supraoptic nuclei 
of hypothalamus that have been recognized to be involved in this mechanism acting as 
osmoreceptor. ADH releasing undergoes the negative feedback regulation, similarly to others 
hormones. Thus, increased concentration of solute in the plasma evokes the release of ADH, 
which travels in the blood to the kidney, where it increases water reabsorption. The water thus 
reabsorbed dilutes the solutes in the plasma and thereby shuts off the signal for ADH 
secretion. When the solute concentration of plasma is too low, as might occur after drinking 
large volumes of water, ADH secretion is inhibited and free water is excreted until the solute 
concentration in plasma retains some optimal level that again initiates basal secretion of 
ADH. When the volume of blood decreases following haemorrhage, dehydration, or sodium 
depletion, signals originating from receptors that monitor either the central venous pressure or 
the arterial pressure are transmitted to the CNS and initiate the release of ADH. In addition, 
renin released from kidney may trigger increased ADH secretion through the intermediate 
AG-II. Increased water reabsorption reduces loss of volume in the urine, and in the presence 
of water intake increases plasma volume, thereby shutting off the signal for ADH secretion. 
The mechanism of action of ADH hormone is not completely understood, even if it seems to 
work activating its receptors V2 located over the basolateral membrane of epithelial cells in 
the last part of distal tube and collecting duct. These receptors are Gs-coupled proteins, whose 
activation lead to an increased level of cAMP, that stimulates the up-regulation of the gene 
expressing for the aquaporin channels and in the same time triggers their insertion by 
exocytosis mechanism.
5
 Thus ADH makes both tubules more permeable to water, that 
diffuses freely across the collecting duct epithelium into the medullary interstitium, and the 
urine equilibrates the interstitial concentration of 1200mOsm. The water reabsorbed from the 
cortical collecting ducts and distal convolution enters the peritubular capillaries of the cortex 
and is removed from the kidney. In the absence of ADH the epithelium of the distal 
convolution and collecting duct has a very low permeability to water, the tubular urine flows 
through the remainder of the tubule without achieving osmotic equilibrium with the 
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surrounding interstitial fluids (1200mOsm), and hypoosmotic urine is produced. It has been 
seen that ADH hormone exerts its hypertensive action activating also V1 receptors localized 
over the membrane of smooth muscle cells and leading to an increased vascular resistance.  
From these informations results quite clearly that alteration of mechanisms that lead to the 
ADH release are responsible of pathological conditions. Deficiency of ADH results in a 
continuous, copious flow of as much as 15L of dilute urine/day. This disease state is known as 
diabetes insipidus. It is accompanied by a profound thirst to compensate for the water loss in 
the urine. Otherwise, overproduction of ADH produces a disease state that is characterized by 
abnormal retention of water and dilution of plasma sodium. Renal compensation for the 
change in volume results in increased sodium loss, which aggravates the hyponatremia. 
 
 
1.5 Pharmacology of Hypertension 
 
As already said blood pressure regulation is realized by several integrated mechanism that 
involve heart functionality, vessels resistance modulation and water and ions reabsorption or 
excretion. Central and peripheral nervous systems, kidneys and endocrine systems work in a 
coordinated manner in order to keep blood pressure parameters within physiologic values 
ranging between 80/120 mmHg. Thus, the pharmacological therapies of hypertension can be 
realized at a different levels targeting one or more of these physiological mechanisms. Drugs 
currently available act either by decreasing CO or TPR. However, reduction of blood pressure 
by any of these mechanisms can trigger compensatory reflex responses that may prevent 
drug-induced decrease in blood pressure. 
Over the years it has been well clarified the complexity of hypertension and it has been 
described as a multifactorial pathology where others diseases such as dyslipidaemia, diabetes, 
renal dysfunction and endocrine alterations were included. Sometimes, antihypertensive 
therapies need an integrated treatment in order to reduce pathological risks and prevent 
cardiovascular complications too. Thus, the choice of therapy for a patient with hypertension 
depends on a variety of factors such as age, gender, race, body build, and lifestyle of patient; 
etiology of disease; other coexisting diseases; presence or absence of risk factors (smoking, 
alcohol consumption, obesity, etc...).  
In some cases patients show borderline blood pressure values for which a no 
pharmacological approach can be sufficient to restore them. Low sodium chloride diet, weight 
reduction, cessation of smoking, decrease in alcohol consumption, sports, etc... may be useful 
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to achieve this goal. Unfortunately, the most part of hypertensive patients need a 
pharmacological intervention because of their higher blood pressure values.  
Antihypertensive drugs can be divided into seven classes, based on mechanism of action; 
ACE inhibitors, α1 antagonists, β-blockers, angiotensin receptor-blockers, Ca2+-antagonists, 
central adrenergic inhibitor, diuretics, direct vasodilators and are summarized in the table n.2. 
 
 
Drug Advantages Disadvantages CO HR TPR 
Angiotensin-
Converting Enzyme 
(ACE) Inhibitors  
 
Captopril, 
Zofenopril, 
Benazepril, 
Enalapril, Lisinopril, 
Ramipril,  
Fosinopril 
Renoprotective in 
type 1 diabetics 
Profoundly 
antiproteinuric 
Decreased 
morbidity and 
mortality and 
symptomatic 
improvement in 
CHF patients 
Decreased 
ventricular 
remodeling and 
mortality post-MI 
Leftward shift of 
pressure-natriuresis 
curve 
Safely combined 
with other anti-
hypertensive, 
especially diuretics 
or calcium 
antagonists 
Cough (~9%) 
Rare angioedema 
(~3/1000) 
Rare hypokalemia 
Higher dose 
requirements in 
some African-
Americans 
BP lowering 
effect very 
sensitive to level 
of dietary sodium 
intake 
Reduced 
cardiac output 
by reducing 
blood volume 
These drugs 
have not 
effects on the 
heart rate 
 
Reduced 
vascular 
resistance 
Alpha1 Antagonists 
Non-selective: 
Phenoxybenzaminep
hentolamine, 
tolazoline,  
ergot-derivates; 
 
Selective: 
 prazosine, 
doxazosine, 
alfuzosine, 
terazosine, 
indoramine,  
uropidil 
Positive effect on 
all lipoprotein 
fractions 
Improved insulin 
sensitivity 
Unchanged to 
improved sexual 
function in men 
Blunts thiazide-
induced rise in 
cholesterol 
Improves maximal 
urine flow in men 
with BPH 
Orthostatic 
hypotension 
(particularly in the 
elderly, in 
combination with 
other vasodilators, 
in the setting of 
autonomic 
dysfunction, and 
in volume 
depleted patients) 
Slightly higher 
doses needed in 
African-
Americans 
Reduced 
cardiac output 
by reducing 
cardiac 
activity and 
lowering 
preload  
Not effect Marked 
reduction of 
vascular 
resistance 
28 
 
Angiotensin II (AT1) 
Receptor Antagonists 
or Sartan:  
Losartan, 
Telmisartan, 
Valsartan,  
Irbesartan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lesser peak BP 
lowering compared 
to ACEs 
Nearly complete 
blockade of A-II 
effect 
No effect on 
bradykinin, 
enkephalins, or 
substance P 
Uricosuric 
(losartan) 
Profoundly 
antiproteinuric 
Metabolically 
neutral 
Rare angioedema 
No cough 
Relatively flat BP 
dose-response 
curve 
 
No effect on 
bradykinin 
 
Limited data 
available in 
African-
Americans 
 
Absence of hard 
clinical end-point 
(i.e., CHF, MI, 
renal) data 
Rare 
hyperkalemia 
Reduced 
cardiac 
output, by 
inhibiting 
sympathetic 
outflow 
Not effect Reduced 
vascular 
resistance by 
inhibiting 
vascular AT2 
receptors 
β1-Blockers non-
selective: 
Propranolol,  
Pindolol,  
Bucindolol, 
Sotalol 
Timolol 
 
Selective:  
Atenolol  
Bisoprolol,  
Acetobutolol, 
Nebivolol 
Esmolol 
Betaxolol 
 
Differential cardiac 
and hemodynamic 
effects 
Proven to lower 
morbidity and 
mortality post-MI 
Selected agents 
useful in patients 
with migraine or 
angina 
Can worsen CHF; 
however, at low 
doses may 
improve CHF 
Low cardiac 
output symptoms 
Can worsen or 
precipitate 
depression 
Can aggravate 
PVD symptoms 
Lowers HDL and 
raises TGs 
Delays recovery 
from and masks 
symptoms of 
hypoglycemia 
Abrupt 
discontinuation 
can lead to 
rebound 
hypertension 
Reduced 
cardiac output 
by, reducing 
volemia, 
inhibiting 
central 
sympathetic 
outflow 
Inotropic, 
chronotropic 
and 
dromotropic 
negative 
effects 
Increased 
vascular 
resistance, 
mediated by 
inhibition of 
β2 receptors 
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β2-agonist 
short-cting: 
Salbutamol 
Terbutaline 
Metaproterenol 
Ritodrine 
Isoprenaline 
 
Long-acting: 
Salmeterol 
Clenbuterol 
 
 Loss of K+, 
alteration of 
cardiovascular 
electrical 
conductivity, 
sympathetic 
rebound 
Not effects  Not effect Reduced 
vascular 
resistance 
Calcium 
Antagonists: 
Nifedipine, 
Nicardipine, 
Isradipine, 
Verapamil,  
Diltiazem 
 
Unqualified 
efficacy profile 
(African-
Americans, 
diabetics, elderly) 
Heterogeneous 
electrophysiologic, 
inotropic, 
hemodynamic and 
SNS effects 
Useful in diastolic 
dysfunction 
Metabolically 
neutral 
Minimal erectile 
dysfunction in men 
BP lowering effect 
is robust in setting 
of high dietary 
sodium intake 
BP lowering effect 
not attenuated by 
NSAIDs 
Immediately post-
MI or during 
unstable angina 
(short-acting 
dihydropyridines) 
may increase 
CHD risk 
Rate-limiting 
CCBs can worsen 
CHF and increase 
mortality in 
patients with 
systolic heart 
failure 
Side effect profile 
varies 
(constipation- 
verapamil, pedal 
edema, and 
vasodilatory 
symptoms- 
dihydropyridines) 
Combination with 
beta blockers can 
result in profound 
bradycardia and 
depression of 
myocardial 
contractility 
Small effect Small effect Markedreducti
on of vascular 
resistance 
Central Adrenergic 
Inhibitors 
α2-agonist: 
Methildopa, 
Clonidine,  
Guanabenz 
 
Relatively cheap 
Useful in 
hypertensive 
urgencies 
(clonidine) 
Methyldopa is drug 
of choice for 
pregnant women 
Sedation 
Depression  
Orthostatic 
hypotension 
Decreased heart 
rate (clonidine) 
Rebound 
hypertension. 
 
Reduction of 
CO by 
inhibiting the 
sympathetic 
outflow 
Reduction of 
heart activity 
by inhibiting 
the 
sympathetic 
outflow 
Decrease of 
vascular 
resistance by 
inhibiting the 
sympathetic 
outflow 
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Direct Vasodilators 
NO-releasing: 
Nitroglycerin and 
nitrates, 
hydralazine, 
sodium nitroprusside, 
minoxidil 
(also activator of K+-
channel)  
 
Relatively cheap 
Effective in severe 
hypertension 
(minoxidil > 
hydralazine) 
Best suited for 
adjunctive therapy 
Salt and water 
retention 
necessitate use of 
loop diuretics 
Reflex 
tachycardia 
necessitates use of 
rate-limiting CCB 
or beta blocker 
Lupus-like 
syndrome (>200 
mg/d of 
hydralazine) 
Edema 
(minoxidil) 
Not effects Not effects Marked 
reduction of 
vascular 
resistance 
Diuretics 
Osmotic diuretics: 
Mannitol, Glycerol, 
Isosorbide. 
 
Carbonic anhydrase 
inhibitors: 
Acetazolamide, 
Methazolamide, 
Diclorophenamide 
 
Thiazide diuretics: 
Clorothiazide, 
Indapamide, 
Quinethazone, 
Hydrochlorthiazide, 
Chlorthalidone 
 
Loop diuretics: 
Furosemide, 
Bumetanide, 
Ethacrynic acid 
 
Potassium-sparing 
diuretics: 
Spironolactone, 
Canrenone, 
Triamterene, 
Amiloride 
Cheap acquisition 
cost 
Highly effective 
and lowers BP 
similarly in all 
demographic 
groups 
Proven to lower 
BP-related 
morbidity and 
mortality 
Enhances the BP 
lowering effect of 
all other BP drugs 
Thiazides and 
metolazone have 
relatively long half 
lives 
Thiazides 
ineffective when 
GFR <40 mL/min 
Dose-related 
hypokalemia 
Raises cholesterol 
and triglycerides 
Glucose 
intolerance 
especially in 
setting of 
K+depletion 
Increased uric 
acid 
Erectile 
dysfunction in 
men 
 
Reduction of 
CO 
Increase of 
heart rate 
Reduction of 
vascular 
resistance 
 
Table n.2 Most important antihypertensive drugs used in therapy, CO (cardiac output), HR 
(heart rate), TPR (total peripheral resistance)  
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2.0 Adrenal gland and hormones synthesis 
 
 
2.1 Physiology of the adrenal gland 
 
The adrenal glands are small, paired structures lying on either side of the midline of the 
abdominal cavity above the kidneys. Each gland consists of two major components: the outer 
cortical area and the inner medulla. The mature adrenal cortex consists of three 
morphologically distinct zones. These zones differ in enzymatic content, histologic and ultra-
structural morphology,
6,7
 mitotic rates, lipid distribution, and functional activity. The outer 
layer is the zona glomerulosa, the middle layer is the fasciculate and the inner layer is the 
zona reticularis. The adrenal gland may be considered as a double endocrine glands, because 
of different nature of released hormones. The medulla area secretes the water-soluble 
neurotransmitter, adrenaline, and receives innervation by preganglionic, cholinergic, 
sympathetic nerve fibres. The medullary cells, called chromaffin cells, are considered 
neuroendocrine cells because the two neurotransmitters adrenaline (80%) and noradrenaline 
(20%) are secreted directly into the systemic circulation, like other hormones, rather than act 
in the synaptic space and activate the post-synaptic adrenergic receptors. The adrenal cortex 
secretes substances moderately soluble in lipids of a chemical class known as steroids and is 
not controlled by secremotor nerves. Specifically, the zona fasciculate is responsible of 
glucorticoid hormones secretion, cortisol and corticostirone; the zona glomerulosa releases 
the most important mineralcorticoid hormone, aldosterone; and the reticularis leads to 
secretion of androgenic and estrogenic important precursor, androstenedione and 
dehydroepiandrosterone sulphate.
8
 Although, these hormones show some differences in 
structure and activity, they originate from the same substance, cholesterol. Cholesterol is 
stored in the adrenal cortex in both free and esterified form. Furthermore, cholesterol may be 
synthesized by the adrenal cortex from acetate and it can also be acquired from blood, where 
it appears from the dietary intake, or from the liver, in which cholesterol may be synthesized 
de novo. 
Synthesis and secretion of adrenal cortex hormones are stimulated by an important 
hormone, ACTH and the stimulation persist as long as it is present. As it was well explained 
in the previous chapter, ACTH is released by special neurons of the medial basal 
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hypothalamus that act as neuroendocrine transducers and signal integrators. These neurons 
receive and integrate neural inputs from other regions of the CNS and chemical inputs from 
blood and cerebrospinal fluid. The output of these neurons is the corticotropin-releasing 
hormone (CRH), which is carried from the hypothalamus, via the infundibular stalk, to the 
corticropic cells of adenohypophysis. After stimulation by CRH, corticotropic cells release 
ACTH, which then enters the general circulation and finally stimulates corticosteroidogenesis 
and increased glucocorticoid secretion at the adrenal cortex. It has been well established that 
ACTH exerts not only secretory effects but also trophic effects on the adrenocortical tissue; it 
is the major, but not the only, physiologic signal that determines the rates of glucocorticoid 
synthesis and release as well as trophic and secretory effects, including compensatory adrenal 
hypertrophy.
9,10
 However ACTH remains the most important stimulus in the glucocorticoid 
hormones secretion. The synthesis of adrenal hormones is realized by members of the 
CYP450 superfamily (steroid hydroxylase) and by steroid dehydrogenases. In the adrenal 
cortex of human five distinct steroids hydroxylases take place in the steroidogenic pathways 
leading to the production of the cortisol, corticostirone, androstenedione and 
dehydroepiandrosterone and aldosterone. Even though it was determined that the increase in 
the steroid hormones biosynthesis in response to ACTH/cAMP involves the delayed increase 
in steroidogenic gene transcription, it was also realized that ACTH/cAMP in the adrenal 
cortex contains two distinct components. Upon ACTH release from the anterior pituitary 
gland, the peptide hormone binds to its specific cell surface receptors on the adrenocortical 
cells. This interaction activates the adenylyl cyclase leading to increased cAMP concentration 
in the cytoplasm resulting in the activation of cAMP-dipendent protein kinase (PKA). Once 
PKA is activated there are two responses, acute and chronic, that occur to increase steroid 
hormones biosynthesis. During the acute response, an essential site of phosphorylation by 
PKA is cholesterol ester hydroxylase (CEH), which upon activation catalyses the conversion 
of cholesterol ester to free cholesterol.11 The acute response leads to mobilization of 
cholesterol, the initial substrate for all steroidogenic pathways, from cellular stores to the 
inner mitochondrial membrane where CYP45011A1 resides. This enzyme is in common 
between the three adrenal cortex areas, glomerulosa, reticularis and fasciculate. 
CYP45011A1 is the first enzyme of this pathway and converts cholesterol in pregnenolone, 
which in turn is converted in glucorticoid or mineralcorticoid hormones depending on the 
enzymes and cortical area. Glucocorticoid are lipid-soluble substances, thus, they reach the 
target organs and tissues flowing in the blood bound to plasmatic protein; albumin and 
globulin are the two main proteins that exert this role. Because of their lipophilic 
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characteristics glucorticoid hormones are able to cross the phospholipid double-layer of the 
cell membrane and enter into the cytoplasm where are localized their receptors. Upon 
interaction the resulting ligand-receptor complex leaves the cytoplasm and reaches the 
nucleus where modulates gene expression. These receptors have been seen in a large number 
of cells over the organs and tissues, leaving to imagine a widespread effects for these 
hormones: 
 inhibition of the inflammatory response 
 maintenance of normal arterial systemic blood pressure and volume 
 effects on metabolism including maintenance of blood sugar levels during starvation 
 support resistance to many noxious stimuli 
 
Amongst these effects, maintenance of blood pressure is of our interest and will be 
discussed below. Glucocorticoids are not usually thought to have any important effects of 
their own, except possibly in the kidney, where they increase the glomerular filtration rate by 
an unknown mechanism, but they are required for the vasoconstrictor action of 
norepinephrine. In the absence of glucorticoids the vasopressor action of catecholamine 
hormones is diminished or lost and blood pressure falls. It has been sought to explain this 
particular role of glucorticoids, analysing its inhibitory effects on the catecholamine-O-
methyl-transferase (COMT) enzyme that inactivates catecholamine hormones and 
transmitters. If this enzyme is not inhibited by corticosteroids, catecholamines are 
metabolized so rapidly that they cannot reach physiological level to exert vasoconstriction.12
 
 
It is well known the major role in the blood pressure regulation of the mineralocorticoid 
hormone, aldosterone, secreted by the outer section, zona glomerulosa, of the adrenal cortex. 
Aldosterone is defined a mineralocorticoid hormone, because it is involved in some 
pathways that have ions such as Na
+
, K
+
, and water as the major protagonists. This hormone 
controls salts balance and blood volume by binding to the mineralocorticoid receptors and 
activating genes involved in the Na
+
 reabsorption as well as K
+
 release from the kidney. The 
mineralocorticoid receptors are widely expressed in several organs and tissues, such as 
kidney, heart, brain, vascular smooth, and other tissues.13,14 Activation of the mineralocorticoid 
receptor by aldosterone in these tissues can trigger responses such as increased vascular 
resistance, increased volemia, increased cardiac output. Thus, all these effects lead to an 
hypertensive condition. Primary hypertension results from an overproduction of aldosterone 
that is independent of excess of renin-angiotensin stimulation and affects a significant portion 
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of patients.
15
 Furthermore, prolonged exposure to high level of aldosterone can result in an 
inflammatory responses, followed by damage to vascular and myocardial tissues and 
hypertensive effects. Thus, overproduction of aldosterone lead to deterioration of target 
organs.
16
 For all these reasons, aldosterone production is highly regulated by nervous, 
endocrine, physical integrated stimuli.  
 
 
2.2 Aldosterone synthesis mechanism 
 
Aldosterone synthesis takes place starting from the conversion of cholesterol to 
pregnenolone by CYP450 side-chain cleavage enzyme; pregnenolone by an isomerase 
enzyme is converted in progesterone, which in turn is converted in 11-deoxycorticostirone 
and corticostirone before to convert the latter in aldosterone. Aldosterone released into blood 
binds to plasma albumin and globulin. In this respect, its behaviour is similar to that of the 
glucorticoids, although the binding affinities are not as great for aldosterone as they are for 
glucorticoids. Under physiological conditions, approximately the half plasma aldosterone is 
bound to these proteins, whereas the other half is free. Just as in the case of the glucorticoids, 
there is no appreciable storage of aldosterone within the adrenal cortex, and the rate of 
synthesis is essentially equal to the rate of release, therefore its regulation involves signals 
that alter the rate of synthesis. 
Many hormonal and paracrine factors are involved in the regulation of aldosterone 
production; low and high concentration of circulating Na
+
 and K
+
 ions respectively, ACTH-
induced AG-II releasing, whereas it is inhibited acutely by circulating atrial natriuretic peptide 
and by locally produced dopamine and somatostatin.
17
 Considerable evidence supports the 
role of two key regulatory steps in the control of adrenal cell aldosterone synthesis. The first 
has been termed the early rate-limiting step. AG-II and K
+
 control this step through regulation 
of both protein expression and activities of the steroidogenic acute regulatory protein (StAR), 
which facilitates cholesterol transport from the outer to inner mitochondrial membrane where 
conversion to pregnenolone occurs.
18,19
 The second limiting reaction has been termed the late 
rate-limiting step, which represents the conversion of deoxycorticosterone to aldosterone by 
the mitochondrial enzyme aldosterone synthase, CYP11B2.
20,21
 CYP11B2 is expressed almost 
solely within the zona glomerulosa of the adrenal cortex. The main action of ACTH on 
glomerulosa cells is connected with the activation of transmembrane Gsα-coupled ACTH 
receptors and the generation of cAMP as a second messenger.
22,23
 Until the recent discovery 
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of a new family of cAMP binding protein, exchange protein directly activated by cAMP, that 
can directly activate small GTPase, RAP1 and RAP2, cAMP signalling was mainly linked to 
the activation of cAMP-dependent protein kinase and subsequently phosphorylation of target 
protein.
24
 Hydrolysis of cholesterol and activation of StAR, which are both critical steps in 
steroidogenesis, are regulated by PKA phosphorylation. Phosphorylation of CEH and StAR 
markedly decreases cholesterol ester levels and increase CEH activity. Although ACTH in 
zona glomerulosa cells acts primarily through cAMP, it has also been seen a stimulation of 
Ca
2+
 influx by activation of L-type Ca
2+
 channel.
25
 Increased Ca
2+
 concentration lead to an 
activation of Ca
2+
/calmoduline-dependent protein kinase.  
Similarly to the ACTH, also both agonists AG-II and K
+
 increase intracellular calcium 
levels and activate calmoduline and calmoduline kinase which leads to increased CYP11B2 
transcription.
26,27
 Adrenal glomerulosa cell stimulation occurs predominantly through AG-II; 
acute activity of AG-II is realized through activation of AG-II type 1 receptor (AT1R) via a q-
subunit of G-protein coupled receptors (Gq), whose activation increases the cAMP levels, 
which in turn activates a phospholipase C enzyme.
28
 This enzyme stimulates the hydrolysis of 
plasma membrane phosphoinositide inositol-1,4-bisphosphate with production of inositol-
1,4,5-trisphosphate (IP3) and DAG. IP3 increases cytoplasmatic Ca
2+
 concentration, activating 
calcium/calmoduline-dependent kinase, (CaMK)
29 
which, as already said, increases the gene 
expression of CYP11B2 and the aldosterone production.
30,31,32
 Chronically, AG-II acts to alter 
the expression of various genes,
33
 including CYP11A1, CYP11B2 and StAR protein.
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K
+
 ions concentration with AG-II represents the major signal for the aldosterone secretion. 
It has been well clarified over the years that alteration of circulating K
+
 ions concentration has 
a great influence on the zona glomerulosa cells, because of depolarizing shift in the K
+
 
equilibrium potential, that leads to a K
+
-induced membrane depolarization. Depolarization of 
the resting potential membrane of glomerulosa cells is the major stimulus for the voltage-
dependent Ca
2+
 channels opening, which together with the Ca
2+
 concentration gradient gives 
the driving force of Ca
2+
 transport inside the cell. Similarly for the other cases, the increase of 
Ca
2+
 concentration into the cytoplasm triggers the CAMK enzyme, whose activity results in 
the CYP11B2 expression. 
Thus, the three most important stimuli for aldosterone secretion, ACTH, AG-II, K
+
, and in 
particular the last two, although acting through different mechanism, trigger steroidogenesis 
by a process involving the calcium messenger system. It will be better clarified in the next 
paragraph the enormous importance of the resting membrane potential for aldosterone 
production.  
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2.3 Aldosterone activity 
 
Aldosterone regulates blood pressure through its activity on the kidney and cardiovascular 
system and it is a crucial component of Na
+
, K
+
 and H
+
 homeostasis. Aldosterone regulates 
the concentration of these important ions through activation of mineralcorticoid receptor 
(MR), which is widely distributed in epithelial cells of target tissues, such as kidney and 
colon,
35 
smooth muscle, endothelium, cardiomyocytes and hippocampal neurons.
36,37
 MR is 
activated not only by the steroid aldosterone but also by cortisol in cells that do not express 
the enzyme 11β-hydroxysteroid dehydrogenase type 2.  
It has been well clarified that the main activity of aldosterone on the blood pressure 
regulation is realized by activating this receptor in the aldosterone-sensitive distal nephron, 
comprising the distal convoluted tubule (DCT) and both principal cells and intercalated cells 
of the connecting tubule (CNT) and collecting duct (CD).
38
 In common with other steroid 
hormone receptors, MR operates as a ligand-dependent transcription factor, indeed, in the 
distal nephron the expression of aldosterone-epithelial Na
+
 channel (ENaC) is tightly 
regulated by aldosterone, which promotes the MR-dependent transcription of ENaC. MRs are 
localized inside the cell into the cytoplasm where the aldosterone easily enters because of its 
lipophilic nature. The binding of aldosterone stabilizes the interaction of MR with specific 
DNA sequence elements in the promoter regions of aldosterone-responsive genes to promote 
or suppress their expression through the recruitment of specific coactivators or corepressor.
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Aldosterone-bound MR links to the DNA regulatory elements that are also recognized by GR. 
The transcription effects stimulated by aldosterone through MR are augmented by the rapid 
activation of signal transduction cascades, which are most often initiated through the 
interaction of aldosterone with MR. Even though some of these rapid signalling responses 
have been known for some time, it is only recently that their relevance to the physiological 
effects of aldosterone has been characterized and their synergism with the transcriptional 
responses to aldosterone has been established.
40
 
The Aldosterone is able to increase the gene expression of ENaC in the apical membrane 
of the distal nephron cells increasing the Na
+
 flow from the tubular lumen to the cytoplasm of 
these cells raising the cytoplasmatic concentration of Na
+
. Thus, ENaC is a key regulator of 
aldosterone-mediated Na
+
 conservation by the kidney. These channels continually cycle 
between the cell membrane and a sub-apical, intracellular pool.
41
 Thus, equilibrium exists 
between the various processes that contribute to ENaC subunit transcriptional regulation, 
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subcellular trafficking, and expressed protein stability to achieve a steady state in ENaC 
surface expression. It has also been seen that aldosterone exerts its activity also increasing the 
expression and the functionality of the Na
+
/K
+
 ATPase pump on the baso-lateral membrane 
supporting the Na
+
 reabsorption and K
+
 excretion. The activity of Na
+
/K
+
 ATPase provides a 
favourable electrochemical driving force for aldosterone-induced apical Na
+
 reabsorption 
through ENaC.
42
 This provides a favourable electrochemical gradient for K
+
 transported into 
the cytoplasm to be secreted across the apical membrane into the ultrafiltrate through K
+
 
channels, or alternatively recycled back into the blood through basolateral K
+
 channels. The 
increased level of Na
+
 ions into the systemic blood circulation leads to an increase of 
osmolarity, which in turn stimulates ADH release and activity which is responsible of water 
reabsorption from the collecting duct in order to restore the osmolarity within a physiological 
range. A consequence of this process is a marked increase of volemia and blood pressure. 
Because aldosterone has an opposite effect on the Na
+
 and K
+
 excretion, the urinary Na
+
/K
+
 
concentration ratio falls when aldosterone acts. Changes in this parameter are often used as an 
indication that the hormone's level has changed. 
Alterations of aldosterone secretion, low production or high production, have very 
important pathological implications because of its role over the organs and tissues. On one 
hand removal of aldosterone by adrenalectomy leads to an overall reduction of Na
+
 
reabsorption and a powerful and uncontrolled loss of extracellular fluid volume. This marked 
loss of liquid leads the subject to an hypovolemic shock condition, which is a frequent cause 
of death in adrenally insufficient animals. On the other hand, hypersecretion of aldosterone 
leads to a very complicated pathological conditions that often do not respond to the classical 
antihypertensive therapy.  
 
 
2.4 Resting potential membrane of zona glomerulosa cell and its role in the aldosterone 
secretion 
 
The mechanisms that control aldosterone secretion are not fully understood, although the 
negative membrane potential of adrenal ZG cells seems to be pivotal. Membrane 
depolarization has long been hypothesized to be an important component of the cellular 
mechanism mediating AG-II and K
+
 stimulation of aldosterone secretion from the 
glomerulosa cells. This mechanism has been extensively studied in an in vitro model 
constituted by isolated human glomerulosa cells (H295R), rat and bovine glomerulosa cells, 
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by patch-clamp technique. These studies demonstrated that both elevated extracellular K
+
 ions 
and AG-II depolarize the resting potential membrane (Vm), supporting the hypothesis that 
Ca
2+
 influx through voltage-gated channel plays a primary role in stimulation of secretion. 
Several lines of evidence have demonstrated that stimulation of Ca
2+
 influx is necessary to 
sustain AG-II and K
+
 induced secretion,
43,44
 and several Ca
2+
 influx pathways have been 
identified in glomerulosa cells, T and L-types voltage-gated channels, capacitative Ca
2+
 
channels,
45
 Ca
2+
 permeant nonselective cation channels and Na
+
/Ca
2+
 exchange.
46
 In this 
regard, potential membrane (Vm) is a critical determinant of Ca
2+
 influx trough these 
pathways by virtue of its role in control of channel gating and its contribution to ionic 
electrochemical gradients. Pharmacological studies have led to the hypothesis that T-channels 
are the primary Ca
2+
 influx pathways leading to stimulation of aldosterone secretion.
47
 
However, L-type Ca
2+
 channels doesn't seem to be involved in the Ca
2+
 flow in the same cells.  
As already said above, AG-II and K
+
 ions trigger the calcium messenger system and raise 
cytosolic free Ca
2+
 concentration, although through very different mechanisms. It has well 
demonstrated by several in vitro experiments that AG-II is able to decrease the resting 
membrane potential of the zona glomerulosa cells and increase the Ca
2+
 concentration in the 
cytoplasm of these cells. AG-II induces phosphoinositide breakdown through activation of a 
specific phospholipase C. This leads to the formation of DAG and IP3, which in turn 
mobilizes Ca
2+
 from intracellular storage organelles. Increased Ca
2+
 concentration is 
responsible of membrane depolarization which in turn can start a positive feedback, opening 
voltage-dependent Ca
2+
 channels on the cell membrane. In the same time, AG-II contributes 
to the membrane depolarization through inhibition of both leak and voltage-gated K
+
 
conductance.
48
 Pharmacological inhibition of leak K
+
 conductance was reported to be 
sufficient to depolarize glomerulosa cells and induce Ca
2+
-dependent stimulation of 
aldosterone secretion.
49
 Most probably other channels may also contribute to AG-II-induced 
depolarization. Indeed, Lotshaw et al. reported that AG-II activates Ca
2+
-permeant 
nonselective cation channels, which may contribute to membrane depolarization.  
K
+
 involvement in the steroidogenesis has been demonstrated too. The ZG cell membrane 
is selectively permeable to K
+
 giving it the characteristics of a K
+
 electrode over a wide range 
of extracellular K
+
 concentrations. The K
+
 flow from the outer to the inner of glomerulosa 
cells causes an increase of the resting potential membrane, that leads to a secondary rise in 
intracellular Ca
2+
 through T-type Ca
2+
 channels, which is thought to be the primary stimulus 
for increased production and release of aldosterone.
50
 Whereas after AG-II stimulation the 
source of Ca
2+
 is both the intracellular store and the extracellular space, the Ca
2+
 signal 
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evoked by K
+
 flow depends exclusively on the Ca
2+
 influx. A distinctive feature of adrenal 
zona glomerulosa cells is the high resting K
+
 conductance, responsible for the negative 
membrane potential (-80mV) that closely follow the K
+
 equilibrium potential. At a this value 
of membrane potential two families of K
+
 channels may give rise to K
+
 conductance: inward-
rectifying-potassium channel and two pores domain K
+
 channel TASK-1 and TASK-3. 
TASK1 and TASK3 are encoded by KCNK3 and KCNK9 genes respectively and highly 
expressed in the adrenal cortex.
51,52
 It has been seen in the human adrenal cortical cell line 
H295R that inhibition of these two-pores K
+
 channels with antisense oligonucleotides, 
decreases the K
+
 current and consequently the resting potential membrane, resulting in 
increased intracellular Ca
2+
 levels, CYP11B2 expression and aldosterone secretion, consistent 
with their role in regulating aldosterone production. Furthermore, it is noteworthy to 
emphasize that AG-II, under physiological conditions, binding with its receptors AT1, is able 
to close TASK K
+
 channels. This closure in turn causes the depolarization of the plasma 
membrane, the activation of voltage-gated Ca
2+
 channels, and an elevation of cytoplasmatic 
Ca
2+
 levels that promotes CYP11B2 transcription and aldosterone production. 
53,54 
 
 
 
 
Fig. 3 Schematic representation of KCNJ5 channel activity across the membrane of H295R cells in a 
resting condition (figure on the left of the panel) and in a presence of AG-II (figure on the right of the 
panel). It has been proposed this mechanism: in the absence of AG-II KCNJ5 channels seem to be 
opened with an outflow of K
+
 from the inner to the outer of cells and a consequent membrane 
hyperpolarization; when AG-II is present activates its G-coupled ATIIR1 receptor and the two 
subunits α and γβ are released with the second one responsible of KCNJ5 interaction and inhibition. 
KCNJ5 inhibition leads to a loss of K+ outflow with a consequent resting membrane depolarization 
Physiological condition Angiotensin II presence 
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and a consequent opening of voltage-dependent Ca2+ channels, increased cytoplasmatic Ca
2+
 
concentration and CYP11B2 up-regulation. 
 
 
2.5 KCNJ3/KCNJ5 (Kir3.1, Kir3.4 or GIRK1 and GIRK4) implication on resting potential 
membrane and aldosterone production 
 
The inward-rectifying potassium channel KCNJ5, also called Kir.3.4 or GIRK4, is a G 
protein-coupled inwardly rectifying potassium channel, belonging to the seven Kir channel 
subfamilies denoted as Kir1 to Kir7. Kir3.x is gated by ligand-stimulated G protein-coupled 
receptors and activated by a large number of neurotransmitters, including acetylcholine, 
adenosine, ATP, dopamine, serotonin and somatostatin. The Kir3 gene family has four 
members including Kir3.1 to Kir3.4, with a widespread distribution at the plasma membrane 
in various different tissues, including heart,
55
 central and peripheral neurons,
56
 various 
endocrine tissues, as well as no excitable cells, such as platelets.
57
 These genes are highly 
conserved between species with Kir3.1 and Kir3.3 subunits having 98 and 99% of homology 
and Kir3.4 with 94% of sequence identity (Fig. 4). 
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Fig. 4 KCNJ5 gene homology over several species, from ; both Kir3.1 and Kir3.4 show an 
amino acid sequence equality ranging from 94 to 99%, demonstrating their importance in the 
cell functionality and viability.  
 
 
The ATP-dependent Kir channel and the classical Kir channel were isolated for the first 
time in 1993 from the outer medulla of rat kidney and a mouse macrophage cell line. These 
channels were structurally characterized and it has been seen that their primary structure is 
constituted by two putative membrane-spanning domains, TM1 and TM2, linked by an 
extracellular pore-forming region (H5) and cytoplasmatic amino (-NH2) and carboxyl (-
COOH) terminals domains.
58 
This structure seems to be common to all types of Kir channels 
(Fig. 5) 
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Fig. 5 Primary structure of Kir channel; it shows two transmembrane domains TM1 and TM2 linked 
by a pore-forming H5 loop and cytosolic amino and carboxyl terminals (left image). On the right it is 
showed the structure of voltage-gated potassium channel which is constituted by six transmembrane 
domains, two of which, TM5 and TM6 are linked by a H5 loop, similarly to the previous one. 
 
The H5 region it is likely to be the most important structure of the Kir channel, because it 
seems to act as a "ion-selectivity filter" and shares with other K
+
 -selective ions channels the 
signature sequence Gly-Tyr-Gly, highly conserved over the species. This filter of selectivity 
allows the only K
+
 flow across the membrane in or out the cytoplasm.
59
. Another important 
characteristic of the Kir channel is the absence of the S4 region, conserved in voltage-gated 
Na
+
, Ca
2+
 and K
+
 channels. As a result, Kir channels are insensitive to membrane voltage and, 
when activating stimuli are absent, this channel would be opened to the membrane potential 
(Em). The architecture of the transmembrane domain of Kir channels has been elucidated only 
after the crystal structure resolution. Protein structure of these four Kir channels show a 36% 
sequence identity, that reaches the 80-90% in the transmembrane and pore regions, 
demonstrating their importance in the channel activity. The Kir3.1 is the most abundant 
subunit and in the same time is also the most divergent of the four since it shares only 44% 
sequence identity with the other three channels. Kir3.2, Kir3.3 and Kir3.4 are more closely 
related and share 62% of amino acid structure.
60,61
 It is well known that the primary structure 
of Kir channel made up by two transmembrane domains is insufficient to form a complete and 
functional channel, whereas it becomes active in a tetrameric structure. Heterodimerization 
generally occurs between members of the same family as for example Kir3.4 forms 
heteromeric complex with Kir3.1. It has been seen that the tetrameric structure is organized 
with the two TM2 domains opposite one another in order to form the channel pore, while the 
others two TM1 are localized to the side of each TM2. The ion conduction pore can be 
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divided in three distinct zones that consist of the selectivity filter, the water-filled central 
cavity and the internal face of the pore made up of the internal bases of the four inner (TM2) 
helices. Analysis conducted to explain the mechanism underlying the activation of several 
potassium channels has provided clear evidence for mobility of the TM2 helices contributing 
to Kir channel gating.
62
 
Inwardly rectifying potassium channels (Kir) transport potassium ions into and out of cells, 
and play a key role in a cell’s ability to generate and transmit electrical signals. In general, Kir 
channels tend to hyperpolarize the membrane potential in excitable cells such as neurons and 
cardiac myocytes, whereas they carry outward current in no excitable cells such as those in 
the anterior pituitary gland.
63
 The most important biological fingerprint of Kir3.x channel is 
their characteristic inward rectification which depends critically on positively charged 
polyamines that reside into the cytoplasmic side of the cell.
64,65
 This characteristic is totally 
different from the voltage-gated K
+
 channel current; instead, their relationships with 
membrane voltage don't follow Hodgkin-Huxley kinetics but their behaviour seems to be 
depended more on the electrochemical gradient for K
+ 
(membrane potential (Em) minus 
equilibrium potential of K
+
 (EK)). Therefore, under physiological conditions, Kir channels 
show a large K
+
 conductance flow at potential negative to Ek but permit less current flow at a 
depolarized potential. This limited potassium flow at a depolarized potential is due to the 
blockade by intracellular magnesium (Mg
2+
) and polyamines. Thus, the inward rectification 
turns out not to be an intrinsic function of the channel protein but a result of the block of 
outward K
+
 flux by Mg
2+
 and polyamines. Cells that show a large Kir conductance are 
expected to show the resting membrane potential (Eres) close to Ek and no spontaneous 
electrical activity. This and their essential voltage independence, permits Kir channels to play 
a key roles in the maintenance of Eres and in regulation of the action potential duration in 
electrically excitable cells.
66 
The G protein-coupled receptor rectifying potassium channel KCNJ5 is, similarly to other 
members of the KCNJ family, a ligand activated inward rectifier, although the ligand for a 
KCNJ5 channel does not bind to the ion channel itself. Indeed, activation of Gi/o protein-
coupled receptor (GPCR) lead to releasing of two G-protein subunits, Gα and Gγβ, which in 
turn binds to and activates the KCNJ-type channel itself, whereas in the absence of the ligand 
the Kir channels are closed. Upon interaction of Gγβ subunit with the internal face of the Kir 
channel there are great conformation changes in the channel structure allowing its closing and 
a consequently blockade of K
+
 ions outflow.
67
 It has well established that KCNJ5 potassium 
channel is associated with several GPCR over different tissues and organs of our body. While 
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its activity in mediating the modulation of acetylcholine (Ach) in the heart and dopamine in 
the pituitary gland is almost completely understood the same cannot be said for KCNJ5's role 
in adrenal gland. It has been seen that the inhibitory effect of Ach on the rate, frequency, and 
strength of contractility of the heart is negatively modulated by M2 receptor and furthermore 
by muscarinic-gated potassium channel IKAch. Ach interacts with its muscarinic receptor M2, 
G protein-coupled receptor, whose activation release the two subunits Gα and Gγβ. The latter 
subunit activates in turn the IKAch channel contributing to the negative inotropic and 
chronotropic effects of Ach.
68
 Cardiac IKAch is comprised of two related protein GIRK1 and 
GIRK4, whose presence is necessary to form a functional IKAch.
69
 It has been seen that 
activation of IKAch in KCNJ5 knock out (KO) mice demonstrated the pivotal role that this 
channel has in heart rate regulation. These mice exhibited resting tachycardia, incapacity to 
respond to parasympathetic stimuli and a long ventricular effective refractory period 
compared with wild type (WT) animals. Moreover, in KCNJ5 KO mice, IKAch was shown to 
play a central part in the generation of atrial fibrillation.  
It has well established by several experimental activities, such as in situ hybridization, 
semi quantitative PCR, molecular cloning, immunocytochemistry and coimmunoprecipitation, 
an abundant presence of inward-rectifying-potassium channels GIRK1 and GIRK4 in the 
pituitary gland. Indeed, it has been seen that dopaminergic D2 receptors are coupled with 
inward rectifying potassium channel (IRK), whose activation seems to mediate dopamine's 
activity in the prolactin (PRL) release. Dopamine is a physiological regulator of PRL 
secretion from the pituitary gland, exerting a tonic inhibitory control.
70
 However, the 
dissociation of DA from its D2 receptors seems to be another important physiological stimulus 
for the PRL secretion.
71
 In addition, subnanomolar concentrations of DA have been reported 
to directly induce a PRL release.
72,73
 Molecular characterization of the G protein-gated IRKs 
in pituitary tissue is a necessary step in elucidating the physiological role of the DA-activated 
K
+
 channels in the regulation of PRL secretion. Firstly, DA is able to inhibit PRL secretion by 
directly activating pituitary dopaminergic D2 receptor, that is coupled to a Gi protein, whose 
activation releases the two G protein subunits, Gα and Gγβ.  
From in vivo studies it has been demonstrated that a DA-activated K
+
 conductance plays a 
critical role in the PRL secretion and it has been seen that this K
+
 conductance is voltage and 
calcium concentration independent, but can be activate at a normal resting potential 
membrane. K
+
 conductance can also be positively modulated by Gγβ complex, which interacts 
with the cytoplasmatic chain of IRK channel and induces a IRK opening and K
+
 flow from 
the inner to the outer of the cells with a consequent hyperpolarization of the resting potential 
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membrane. Furthermore, it has been seen that in some systems KCN-family channels can also 
be activated by dopaminergic D4 receptors. As it has been anticipated below, the role of 
KCNJ5 in the glomerulosa cell is not completely understood; it has been hypothesized these 
potassium channels can act as a dopamine-activated GIRK because of the presence of high 
quantity of DA in the adrenal gland area. To date, not too much is known about the 
physiological role of inward-rectifying potassium channels in the adrenal gland, even if a role 
in maintaining a hyperpolarized potential membrane may be hypothesized.  
Jin et al. demonstrated that there are several amino acid residues over the TM2 domains of 
KCNJ5 that exert a crucial role in the channel activation and in the same time they 
demonstrated that substitutions of these residues would change TM2 helix flexibility and form 
constitutively active channel. Similarly, mutations in the carboxyl and amino-terminals lead 
to a loss of capacity of Gγβ to interact and activate this channel. Several studies conducted 
over the last decade on KCNJ5 potassium channel demonstrated a strong association of this 
mutated channel with several cases of hypertension. Indeed, was reported that mutations in or 
around the selectivity filter of KCNJ5 lead to a marked loss of K
+
 ions selectivity in the 
glomerulosa adrenal cells with a consequent inflow of Na
+
 ions from the outside to inside of 
the cell and an increase of resting membrane potential. Membrane depolarization opens 
voltage-gated Ca
2+
 channels leading to a marked increase of Ca
2+
 ions into the cells, which in 
turn activates the Ca
2+
 dependent pathways, one of which leads to a great production of 
aldosterone. In this circumstance the synthesis of aldosterone doesn't undergo the normal 
physiological control mechanisms but it is only regulated by membrane depolarization and 
increased cytoplasmatic calcium levels. A such condition is fully elucidated in the most 
common secondary form of hypertension, primary aldosteronism.  
 
 
2.6 Hyperaldosteronism 
 
Primary aldosteronism is the most common cause of secondary hypertension, with a 
prevalence of 5-15% depending on the severity of blood pressure levels. The most important 
feature of primary aldosteronism is the hypersecretion of the mineralocorticoid hormone 
aldosterone in a manner that is fairly autonomous of the renin-angiotensin system. The 
hypokalaemia that was once considered a prerequisite for primary aldosteronism suspicion is 
in fact only present in a minority of affected patients.
74 
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Primary aldosteronism is a heterogeneous group of disorders that may be divided in two 
main groups: 
 
 Familial primary aldosteronism 
 Sporadic primary aldosteronism 
 
The two most common subtypes of sporadic forms are bilateral adrenal hyperplasia 
(BAH) and Aldosterone-Producing Adenoma (APA), which together accounts for over 
90% of all cases of primary aldosteronism, which in turn show a 60% and 30% of frequency 
respectively. Although the majority of primary aldosteronism is sporadic, there are 
monogenic familial forms of the condition, familial form type-I (FH-I), type-II (FH-II) and 
type-III (FH-III) that account for almost 10% of all cases. The diagnosis of primary 
aldosteronism and subsequent subtype identification is imperative because it enables the use 
of a targeted therapy, either the surgical removal of APAs or the pharmacological treatment of 
BAH. Furthermore, the relevance of primary aldosteronism diagnosis is consolidated by 
observations that patients with primary aldosteronism are prone to cardiovascular and 
cerebrovascular complications and to metabolic syndrome in comparison with patients with 
essential hypertension that have similar cardiovascular risk profiles.
75,76
 Several guidelines 
and algorithms for the diagnosis and treatment of primary aldosteronism have been developed 
and proposed over the last 4 years.
77
 The diagnostic steps include: 
 
 case detection testing  
 confirmatory testing  
 subtype classification  
 localization 
 
Patients with a positive detection test are recommended to undergo confirmatory testing to 
either confirm or exclude the diagnosis of primary aldosteronism. The Endocrine Society’s 
clinical practice guidelines recommend the use of any of four confirmatory testing procedures, 
oral sodium loading test, saline infusion test (SIT), fludrocortisone suppression test, and 
captopril challenge test (CCT). Finally, subtype differentiation should be undertaken to 
establish the site of aldosterone hyperproduction in the adrenal glands. Subtype differentiation 
is performed by adrenal computed tomography scanning (CT) and adrenal venous sampling, 
which is the only reliable method to distinguish unilateral from bilateral primary 
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aldosteronism in the differentiation of primary aldosteronism. It is the method of choice 
because enables identification of the source of increased secretion of aldosterone. This is an 
important aspect because the detection of adrenocortical adenoma secreting the excess of 
aldosterone is an indication for surgical treatment, whereas bilateral adrenal hyperplasia is an 
indication for conservative treatment.
77
 In the last ten years, significant progresses in 
understanding the genetic background of primary aldosteronism has been observed, adding 
new informations that helped to characterize the different forms of primary aldosteronism. 
Familial hyperaldosteronism type-I also called glucocorticoid-remediable aldosteronism, 
described for the first time in 1966 by Sutherland et al., is an autosomal dominant monogenic 
form of primary aldosteronism that accounts for <1% of all cases of primary aldosteronism
78
 
and characterized by early onset hypertension, elevated ACTH-dependent aldosterone 
concentrations, suppresses plasma renin concentrations and increased urinary excretion of the 
hybrid steroids, 18-hydroxicortisol and 18-oxocortisol. Despite the elevated aldosterone level, 
hypokalaemia is uncommon.
79,80
 The molecular basis of the condition is attributed to an 
unequal crossover between the genes CYP11B1 (which encodes steroid 11β-hydroxylase) and 
CYP11B2 (which encodes aldosterone synthase). The resulting hybrid gene encodes an 
enzyme chimera with aldosterone synthase activity that is expressed in the adrenal zona 
fasciculata under control of ACTH hormone instead ofAG-II.
79
 Therefore, in patients with 
FH-I, aldosterone concentrations are persistently suppressed by glucocorticoid administration. 
Most affected individuals develop severe hypertension in early life and are prone to 
cerebrovascular events, although patients with mild hypertension or blood pressure within the 
normal range have been described in many families.
81
 The phenotype of the disease can vary 
not only between affected families but even within the same family.
82
 Diagnosis of FH-I is 
usually made through use of a long PCR technique. As recommended by the Endocrine 
Society Guidelines, genetic testing for FH-I should be considered in patients with 
hypertension and a family history of early onset hypertension or a cerebrovascular accident at 
a young age.
83
 Familial hyperaldosteronism type-II is a non-glucorticoid-remediable form of 
primary aldosteronism that is clinically and biochemically indistinguishable from sporadic 
forms. The prevalence of FH-II was reported to be as high as 6%. The pattern of transmission 
is autosomal dominant in some families, but this cannot be determined in all cases because of 
the small number of affected family members.
78
 The molecular basis of FH-II is still 
unknown, but genetic analyses of five cohorts from Australia, Italy and South Africa have 
demonstrated a linkage of FH-II with chromosome 7p22;
84
 however, this linkage has not been 
demonstrated in other families, thus indicating that FH-II could be a heterogeneous disease. 
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The first family affected by FH-III was described by Geller et al. in 2008 as an early-onset 
and particularly severe form of primary aldosteronism with distinctive clinical and 
biochemical features. Affected patients displayed marked aldosteronism, hypokalaemia and 
severe hypertension that was resistant to medical therapy, necessitating bilateral 
adrenalectomy. Furthermore, FH-III shows marked bilateral adrenal hyperplasia, high levels 
of 18-oxocortisol. The molecular genetics features of FH-III and some cases of FH-II have 
been only recently resolved with the discovery of a germline mutations in the KCNJ5 gene, 
which is located on chromosome 11q24 and encodes the G-protein-activated inward rectifier 
K
+
 channel 4.
85
 The first mutation that was described in this family by Choi et al. was an 
inherited Thr158Ala mutation in the GIRK4 and, succeeding this original finding, an 
additional six families with FH-III caused by KCNJ5 mutations were rapidly discovered.
86
 
Two families of these showed a Gly151Glu mutation and a milder phenotype, treatable with 
medical therapy and with a normal appearance of the adrenals at CT scanning. Others two 
families showed a Gly151Arg mutation and one family a Ile157Ser mutation. These families, 
in contrast to the previous described, display marked bilateral hyperplasia and require 
bilateral adrenalectomy to treat hypertension.
87,88
 The clinical features of families carrying the 
Gly151Glu mutation indicate that they show a milder phenotype compared with the other 
mutations. These mutations that lie in or near the highly conserved selectivity filter of KCNJ5 
potassium channel lead to a loss of selectivity for K
+
 ions and increase Na
+
 conductance with 
a consequent membrane depolarization, voltage-gated Ca
2+
 channels opening, increase of 
cytoplasmatic levels of Ca
2+
, that is the normal signal for aldosterone production and maybe 
cell proliferation in adrenal cortex. Gly151Glu alters the K
+
 selectivity and the Na
+
 
permeability in a similar way to Thr158Ala. It seems to be likely that these characteristics of 
Gly151Glu mutation may be responsible of osmotic shock and cell death in adrenal cells. This 
finding potentially explain the lack of adrenal hyperplasia and the paradoxically milder 
phenotypes of families carrying the Gly151Glu mutation.
88
 The FH-III Thr158Ala mutation 
carriers display massive production of hybrid steroids, atypical responses of aldosterone and 
cortisol to dexamethasone, and reduced androgen production in contrast to the milder FH-III 
Gly151Glu phenotype. This extreme phenotype of T158A could be the mutation itself or an 
unidentified alteration that was not seen in Gly151Glu family.  
As it has been said previously, the most common form of PA is the sporadic forms APA 
and BAH which account for the 90% of all cases; amongst the all cases of APA a 40% was 
affected by KCNJ5 mutation. It has been seen that in patients with APA, the KCNJ5 
mutations are remarkably more prevalent in female than in male individuals (>70%) and the 
49 
 
mutation carriers are significantly younger compared with non-carriers (age 42 years vs 48 
years).
89
 
As well as for the familial form also for the first description of APA Choi et al., reported 
somatic mutation of KCNJ5, Gly151Arg and Leu168Arg, in 8 of 22 APAs in a group of 
Swedish patients with apparently non-familial PA85 Another mutation deletion Ile157del has 
been identified in Cambridge, from an Australian pedigree and it has been well 
characterized.
90,91
 Subsequently Mulatero et al. reported a new germline mutation, G151E, in 
two affected members mother and daughter, in one of 21 investigated families. Both showed 
an early-onset hypertension and moderately sever biochemical primary aldosteronism, but, 
unlike the family studied by Geller et al., the adrenals appeared normal and hybrid steroid 
level were only slightly higher than those for apparently non-familial primary aldosteronism 
patients. This new mutation showed like others loss of Na
+
/K
+
 selectivity.
92
 Scholl et al., 
showed other two families with the same germline G151E mutation with an early-onset 
primary aldosteronism.
93
 Furthermore, another G151R mutation has been undertaken from 
two different pedigrees and they showed a much more severe phenotype, characterized by a 
very early-onset and severe primary aldosteronism that was poorly responsive to 
spironolactone. 
To date, it is possible to say that mutation of selectivity filter of KCNJ5 potassium channel is 
a key player in sporadic as well as the much rarer syndromic forms of PA, since up to 40% of 
APAs. It seems to be one of the most important genetic cause of ions flow alteration, 
membrane depolarization and aldosterone production. 
 
 
3.0 Lipid metabolism 
 
3.1 Lipid metabolism 
 
Lipids are a group of natural molecules that include fats, waxes, sterols, of which the most 
important is cholesterol, soluble vitamins (such as A, D, E and K), monoglycerides, 
diglycerides, triglycerides, phospholipids. Dietary lipids of physiological and especially 
pathological importance include triglycerides, which account for 90% of dietary lipid, 
cholesterol esters, phospholipids and the fat soluble vitamins. Lipids represent the most 
concentrated source of calories in the diet, yielding more than twice as many calories per 
gram as either carbohydrate or protein and requires less than half the amount of intracellular 
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water for storage (Ex. 9 calories/gr as compared to 4 calories/gr of carbohydrates). Both 
properties depend on its long chain fatty acid constituents.  
It is well know that the human diets contain variable amount of triglyceride and cholesterol 
provided by diet. Typical Western diets provide as much as 40% of the total calories in the 
form of triglyceride, but, on a worldwide scale, this type of diet is geographically and 
historically unusual. Most dietary triglyceride is absorbed in the duodenum and proximal 
jejunum after undergoing partial hydrolysis in the gut lumen. Triglycerides are mechanically 
mixed with the aqueous secretions of gastrointestinal tract to form large fat droplets. Then a 
smaller emulsion of smaller fat droplets is formed as bile acids, and phospholipids from the 
diet and bile become associated with the droplet surface. These substances are amphophilic, 
i.e., partly hydrophilic and partly hydrophobic, and thus promote the formation of a stable oil-
water interface.
94
 These fat droplets are continuously exposed to the enzymatic activity of 
lipases, including the lingual lipase that begins to act in the stomach and a lipase in pancreatic 
liquid that acts within the intestinal lumen. This enzymatic activity releases monoglycerides 
and free fatty acid (FFAs). At the same time, action of a pancreatic phospholipase on the 
phospholipid associated with the droplet surface leads to the formation of lysophospholipids 
and FFAs. The hydrolytic products leave the droplet surface and, in association with the bile 
acids, form aggregates termed micelles. The micelles are small enough to be absorbed 
through spaces present between the microvilli of intestinal epithelial cells, and once released 
monoglycerides and FFAs will be able to cross the cell membranes. Within the cells the FFAs 
and the monoglycerides and the small amounts of free glycerol that are formed during 
digestion are reconverted into triglyceride, reacting with ATP and coenzyme A (CoA) to form 
fatty acyl-CoA, which in turn can react with lysophosphatidilcholine to form 
phosphatidilcoline or with cholesterol to form cholesteryl esters. All these lipids will be 
packaged with proteins to form large particles called chylomicrons and then secreted into 
lymph. The FFAs and monoglycerides that are converted back to triglycerides are those that 
have chains at least 14 carbon atoms long. Shorter chain fatty acid largely pass through the 
epithelial cells and are transported via the portal vein to the liver.
95,96
 Once reached the 
bloodstream, chylomicrons are hydrolysed by lipoprotein lipase (LPL) releasing triglycerides, 
which in turn will be absorbed to the luminal surface of capillaries. Most of FFAs released in 
this way are taken up by adipose cells, and stored as adipose tissue triglyceride. Over the 
passages chylomicrons change in composition; they lose phospholipid and apo-lipoproteins 
AI, AII and AIV and take up cholesterol and apo-lipoproteins CI, CII, CIII and apo E. Apo 
CII it is known to be particularly important because it affects the clearance of chylomicron 
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triglyceride from the plasma, by activating LPL. Thus, patients with a familial apo CII 
deficiency develop hypertriglyceridemia and hyperlipidaemia when they ingest fat because 
chylomicrons accumulate in the plasma.
97,98 
The other lipid particularly important by a physiological and pathological point of view is a 
sterol, named cholesterol, which is a key component of cell membrane and lipoproteins and a 
precursor of bile acids and steroid hormones. Its role in the membrane composition and 
architecture seems to be due apparently to its amphophilic character and its unique, rigid 
structure, that allows it to intercalate between membrane phospholipids. This intercalation 
markedly decreases the permeability of membranes to water-soluble molecules and also 
decreases membrane fluidity.
99
 Although a dietary requirement for cholesterol doesn't exist, 
cholesterol introduced with diet significantly participates to a pool of cholesterol and its bile 
acid products that circulate several times each day between the intestine and the liver. 
Cholesterol introduced daily by diet can range up to 0.5/1.0 g/day and most part of this 
cholesterol is in the form of cholesteryl ester and probably is not directly absorbed; but 
pancreatic fluid contains a cholesteryl ester hydrolase that in the presence of certain bile acids 
catalyses the hydrolysis of cholesteryl esters in the intestinal lumen to release FFAs and 
unesterified cholesterol, which is ready to be absorbed. The process of absorption is not 
completely clear, even if it seems to be likely a passive rather than an active mechanism. 
Likely to triglyceride absorption also cholesterol is taken up by micelles of bile acid and 
FFAs, monoglycerides and phospholipid; as a component of these micelles, cholesterol enters 
the spaces between the microvilli of the mucosal cells and becomes available for net transfer 
into the cell. If net transfer of cholesterol into mucosal cells does not occur but FFAs, 
monoglycerides, or lysophospholipids are taken up, the micelles are disrupted and cholesterol 
precipitates, no longer capable of being absorbed. Overall, cholesterol absorption is 
incomplete and only 30-60% seems to enter body pools.
100
 It seems to be likely that 
cholesterol absorption is realized by soluble, lipid-carrier protein that bring it from the 
microvillus membrane to the intracellular site of lipoprotein synthesis. The cholesterol 
absorbed, once within the epithelial cells, mixes with the intracellular pool of cholesterol, is 
esterified again with fatty acid and enters the chylomicrons, which also contain small amount 
of free cholesterol. After the chylomicrons enter the plasma and are attacked by LPL, much of 
this cholesterol, particularly the cholesterol ester, becomes associated with chylomicron 
remnants. The remainder of the cholesterol and also the remaining phospholipid apparently 
become associated with high density lipoprotein (HDL). Chylomicron remnants contain apo-
E, which interacts with its receptors localized on the surface of hepatocytes, and thanks to this 
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interaction chylomicrons are rapidly removed from plasma into hepatocytes.
101
 The ingested 
particles are hydrolysed within secondary lysosomes to yield amino acids, FFAs, and 
unesterified cholesterol. One effect of the influx of chylomicron remnant cholesterol into the 
liver is the decreased synthesis of endogenous cholesterol because of reduced hydroxyl-
methylglutaryl-CoA reductase (HMGCoA reductase) activity. This is the rate-limiting 
enzyme of cholesterol biosynthesis and catalyses the conversion of HMG CoA to mevalonic 
acid, the first committed metabolite in the biosynthesis of cholesterol. It is subject to 
multivalent feedback suppression by sterols and by non-sterol products of mevalonic acid,
102
 
as well as to phosphorylation and dephosphorylation.
103
 Down-regulation and inactivation of 
HMG-CoA reductase by these mechanisms leads to diminished formation of hepatic 
cholesterol, which limits the tendency of dietary cholesterol to increase hepatic cholesterol 
levels. The most part of cholesterol synthesised ex novo by the liver or introduced with the 
diet is either converted into bile acids or secreted directly into bile.
104
 It is well known that 
bile acids come into play during the fat digestion and absorption along the intestinal tract and 
in the same time it is well known as our body is not able to increase bile acid production in 
response to a dietary cholesterol. Furthermore, each component of these substances are 
subjected to an enterohepatic circulation, i.e., they are efficiently absorbed by an active 
mechanism in the distal ileum and return to the liver complexed to the albumin of the portal 
blood. Nevertheless, a small portion of the bile acids and a larger portion of the bile 
cholesterol escape reabsorption during each recirculation of the bile, that in adding to the loss 
of cholesterol by desquamation of skin and intestinal mucosa counterpoises the amount of 
cholesterol that is daily synthesized and absorbed. Furthermore, the liver exerts an important 
function in maintaining the pool size by synthesizing new bile salts to replace those that are 
lost. This synthetic capacity of liver is limited so that the bile salt pool in the jejunum falls 
below the critical concentration, with resultant impairment of lipid absorption.  
It is known that most peripheral cells can synthesize cholesterol but few cells can even 
partially degrade it, thus, special mechanism are required to keep cholesterol balance in 
peripheral tissues. The liver contributes to these mechanism secreting at least two lipoproteins 
and one plasma enzyme that together contribute to the cholesterol transport to and from 
peripheral cells. One type of lipoprotein secreted is very low density lipoprotein (VLDL), also 
involved in the triglyceride transport; indeed, VLDL of hepatic origin consists of a core of 
triglyceride stabilized by a thin film of phospholipid, unesterified cholesterol, apo-
lipoproteins B100, C, and E. Into the peripheral tissue VLDLs are metabolized by LPL, that 
catalyses the partial hydrolysis of the triglyceride, producing remnant lipoproteins. These 
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cholesterol-rich remnants may be taken up directly by the liver or may continue to circulate in 
the plasma and be gradually converted into small lipoproteins known as low-density 
lipoproteins (LDLs) that delivery cholesterol to peripheral cells. LDL show a diameter that is 
one fourth to one third of the diameter of the parent VLDL, and show a core that is made 
chiefly by cholesteryl ester surrounded by phospholipid, unesterified cholesterol, and apo-B. 
The net effect is the formation of a cholesterol-rich lipoprotein that is small enough to be 
transported across the endothelial cells of peripheral capillaries. The conversion of VLDL to 
LDL usually requires about 12 h, after which LDLs are gradually cleared from the 
bloodstream, principally by two mechanisms, one receptor-dependent, and another 
nonspecific mechanism such as pinocytosis. The best understood mechanism is that mediated 
by LDL receptor, which bind lipoproteins that contain apo-B and/or apo-E with a high 
affinity. Once interaction between receptor and lipoprotein is realized, complex is internalized 
by adsorptive endocytosis. Vesicles formed by this process subsequently fuse with lysosomes, 
whereupon the lipoproteins are degraded by lysosomal hydrolases and unesterified cholesterol 
is released into the cytosol. As cytosolic cholesterol accumulates, it is esterified by an 
intracellular acyl CoA-cholesterol acyltransferase (ACAT) or used to form membranes. At the 
same time, increased cytoplasmatic cholesterol levels, activates feedback mechanisms that 
reduce intracellular HMG-CoA reductase activity and down-regulate the LDL receptor. These 
feedback mechanisms clearly limit both the intracellular synthesis of cholesterol from acetyl 
CoA and the uptake of excessive amounts of LDL cholesterol. In the LDL clearance process 
an important role is played by LDL-receptor and apo-B and E, whose importance is 
emphasized by the strikingly high concentrations of LDL that are typically found in the 
plasma of patients affected by familial hypercholesterolemia.
105
 Familial 
hypercholesterolemia may be caused by incapacity of our body to form functional apo-B and 
E receptors and/or inability to internalize lipoproteins. Cells that normally show LDL 
receptors include fibroblast, smooth muscle cells, adrenocortical cells, luteal cells from the 
ovary. Thus, these receptors are widely distributed over tissues and organs, accounting for 
about two thirds of the removal of LDL particles from plasma.
105
 The LDL receptors are 
usually localized into cytoplasmatic vesicles and are subject to a recycling process, according 
to the intracellular requirements for cholesterol. For example, since LDL it has been seen to 
play a key role in delivering cholesterol to endocrine cells that synthesise steroid hormones, 
under corticotropin stimulation the LDL receptor number increases highly.
106 
In addition to secreting VLDL, the liver secretes lipoproteins referred to as nascent high 
density lipoprotein (HDL), a heterogeneous class of lipoproteins, which have in common a 
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high density (>1.063 g/mL) and a small size. These lipoproteins contain phosphatidilcoline, 
unesterified cholesterol, and apo-AI or E. Mature HDL3 and HDL2 are synthesised from 
lipid-free apo-AI or lipid-poor pre-β1-HDL as the precursor. These precursors are released 
from lipolysed VLDL and chylomicrons or are produced as a nascent HDL by the liver or 
intestine. After being secreted into plasma, nascent HDLs interact with a plasma enzyme that 
also is synthesised and secreted by the liver. This enzyme, lecithin-cholesterol acyltransferase 
(LCAT), forms cholesteryl esters in plasma by transferring fatty acids from HDL 
phosphatidilcoline to HDL unesterified cholesterol. The LCAT enzyme is activated by apo-
lipoproteins, in particular by apo-AI, that is the principal apo-lipoprotein component of 
mature, circulating HDL. Differences in the quantitative and qualitative content of lipids, apo-
lipoproteins, enzymes, and lipid transfer proteins result in the presence of various HDL 
subclasses, which are characterized by differences in shape, density, size, charge, and 
antigenicity.
107
 Lipoproteins not only deliver cholesterol to cells but apparently also 
contribute to reverse cholesterol transport (RCT). Cholesterol in peripheral cells in the form 
of cholesteryl ester is hydrolysed by an intracellular cholesteryl ester hydrolase.
108
 Then, on 
interaction of cells with HDL that is transiently bound to HDL receptors on the cell surface,
109 
the liberated unesterified cholesterol transfers to the plasma membrane and becomes 
associated with the HDL. RCT describes the metabolism and an important anti-atherogenic 
activity of HDL, namely, the HDL-mediated efflux of free cholesterol from non-hepatic cells 
and its subsequent delivery to the liver and steroidogenic organs, in which cholesterol is used 
as a precursor for the synthesis of lipoproteins, bile acids, vitamin D, and steroid 
hormones.
110,111
 Approximately 9 mg cholesterol per kg body weight is synthesized by 
peripheral tissues every day and must be moved to liver for effective catabolism.
112 
Alteration 
of RCT can lead to a deposition of free cholesterol (FC) within the arterial wall and thereby 
contributes to the development of arteriosclerosis. Evidence that HDLs contribute importantly 
to reverse cholesterol transport is provided by the abnormalities that accompany Tangier 
disease. This inborn error of metabolism is characterized by abnormally low level of HDL in 
the plasma and by the presence of cholesteryl ester-rich foam cells (macrophages) in 
peripheral lymph nodes.  
Several lines of evidence suggest that cholesterol efflux may be realized by three different 
mechanisms: aqueous diffusion, SR-BI-mediated FC efflux, and ABCA1-mediated efflux. 
Cholesterol molecules are sufficiently water-soluble to transfer from cell membrane to an 
acceptor by the aqueous diffusion mechanism.
113
 This process involves desorption of 
cholesterol molecules from the donor lipid-water interface and diffusion of these molecules 
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through the intervening aqueous phase until they collide with and are absorbed by an 
acceptor. The aqueous diffusion mechanism involves a simple diffusion process, and, as such, 
cholesterol transfer is passive and driven by the cholesterol concentration gradient. In this 
mechanism process, the unstirred water layer surrounding cells creates a significant diffusion 
barrier.
113
 The other mechanism of cholesterol efflux is based on the interaction between 
acceptor and SR-BI receptors of donor. These receptors are members of the CD36 family of 
proteins and share about 30% sequence homology with the other members of this 
family.
114,115
 Besides stimulating the efflux of free cholesterol, expression of SR-BI also 
facilitates the influx of free cholesterol, thus, the movement of free cholesterol is bidirectional 
and the net movement depend on the cholesterol concentration gradient, like to the aqueous 
diffusion. Furthermore, besides mediating the bidirectional flux of free cholesterol, SR-BI is 
able to induce a selective uptake of other lipoprotein lipids, including cholesteryl ester, 
phospholipid, and triglyceride.
116
 This movement is unidirectional, and by promoting the net 
flux of HDL cholesteryl ester and triglyceride, SR-BI induces depletion of HDL core lipids. 
SR-BI receptors interact with a wide range of acceptors, including HDL, LDL, oxidized LDL, 
acetylated LDL, and small unilamellar vesicles.
117
 The last mechanism of free cholesterol 
efflux is mediated by ABCA1. This receptor is a member of a large family of ATP-binding 
cassette transporters that have common structural motif and use ATP as an energy source to 
transport a variety of substrate, including ions, lipid, and cytotoxins. In contrast to SR-BI, the 
preferred cholesterol-acceptors for ABCA1 is a lipid-poor apo-lipoproteins. All of 
exchangeable apo-lipoproteins, such as apo AI, apo AII, apo AIV, apo E, and apo C can act as 
phospholipid and cholesterol acceptors for ABCA1.
118,119
 ABCA1 promotes the unidirectional 
efflux of cholesterol and phospholipids to lipid-free or lipid-poor apo-lipoprotein, and is also 
involved in the lipidation of apo-lipoprotein AI in the formation of nascent HDL. It has been 
demonstrated by several studies that a direct interaction between cholesterol transporter and 
apo-lipoprotein play an important role in ABCA1-mediated efflux. ABCA1 has been seen to 
cross-link with the apo-AI, indicating a very specific association between them. These results 
are confirmed by recent studies conducted by Fitzgerald et al., that show as four different 
mutant ABCA1 transporters with missense mutation exhibited little or no apo-AI-induced 
efflux or cross-linking to apo-AI. This result suggest that a direct interaction between apo-AI 
and ABCA1 is necessary for efflux. 
Plasma lipoprotein can also be removed by less specific mechanisms. Macrophages and 
endothelial cells possess a scavenger receptor that recognizes modified LDL (i.e. oxidized 
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LDL). The uptake of modified lipoproteins by this scavenger pathway has been hypothesized 
to contribute to the deposition of cholesterol in atherosclerotic plaques.
120 
 
 
3.2 Disorders of lipid metabolism 
 
Hyperlipidaemia is characterized by an accumulation of one or more of the major lipids 
transported in plasma and is a manifestation of one or more abnormalities of lipid metabolism 
or transport. Speaking of hyperlipidaemia or dyslipidaemia, we are referring to 
hypercholesterolemia, hypertriglyceridemia or both. These hyperlipidaemias may be primary 
or secondary. Secondary hyperlipoproteinaemias are the complication of underlying, 
metabolic disturbances, drug-induced effects, or the result of dietary excesses. Otherwise, 
primary hyperlipoproteinaemias are genetically determined and may be classified by 
lipoprotein phenotype or genotype. Furthermore, the genetic classification may be subdivided 
into monogenic (caused by single-gene inheritance) and polygenic-multifactorial (caused by 
multiple subtle genetic factors that act together or in combination with environmental 
factors).
121
 The biochemical parameters of primary and secondary hyperlipoproteinaemias are 
very similar, thus, their differentiation is sometimes difficult and represent the cornerstone of 
successful therapy, because the secondary form may be corrected simply through changes in 
lifestyle. Primary hyperlipidaemia has been classified into six types, based on the specific 
patterns of the various lipoproteins in plasma.(Table n.3) 
 
 
 
Table n.3 Primary Hyperlipidaemia classification based on lipoprotein phenotype 
 
However, these types of pattern are not specific, and the plasma lipoprotein pattern may 
change with the time in any individual.  
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Abundant evidence supports the importance of abnormal lipoprotein metabolism in 
atherosclerotic disease and more in general in cardiovascular disease. Several epidemiological 
studies have documented that diets reach of saturated fats and cholesterol accelerate 
atherogenesis. The prominent alterations that are consistently related to atherogenesis include 
hypercholesterolemia (reflecting increased concentration of LDL), hypertriglyceridemia 
(reflecting increased concentration of VLDL and/or remnants and triglyceride enrichment of 
LDL and HDL), increased apo-B levels, and reduced levels of HDL and its apo-AI.
122
 
Hypercholesterolemia is the major risk factor associated with the increased incidence of 
atherosclerosis in the United States and in Europe. Although many atherosclerotic lesions are 
fibrous and contain relatively little lipid, the effects of lipid on the endothelium, monocytes, 
and smooth muscle, and the accumulation of lipid in the lesion of hypercholesterolemic 
individuals, are critical components of the process of atherogenesis. Since different animals 
are able to form lesion of atherosclerosis similar to human when they develop 
hypercholesterolemia, it has been possible to understand the cellular changes that come into 
play in the atherosclerotic plaque formation. Faggiotto et al. focused on this particular issue 
adding new important informations.
123
 These data show that the first and most striking event 
occurs after 7 to 14 days of diet-induced hypercholesterolemia. This consists of the 
attachment of large number of leukocytes, principally monocytes, to the surface of the arterial 
endothelium. The monocytes attach to the endothelial cells in clusters that appear to be 
located throughout the arterial tree in all large and medium-sized arteries. These monocytes 
then migrate over the surface of the endothelium and use the junctional site to slip between 
the cells and localize in the sub-endothelial space. In the sub-endothelial intima space, 
monocytes become converted into macrophages, so that within 1 month large number of foam 
cells, or lipid-filled macrophages, are found beneath an intact endothelium. These cells 
continue to enlarge as they fill with lipid. Such accumulation of foam cells represent the 
establishment of the first and ubiquitous lesion of atherosclerosis, the fatty streak. The fatty 
streaks continue to grow, and because of this process the surface of the artery becomes highly 
irregular and convoluted. Over the time, small numbers of smooth muscle cells begin to 
appear beneath the accumulated macrophages within the intima and also begin to accumulate 
deposits of lipid and take on the appearance of foam cells. After approximately 6 to 12 
months at the very high cholesterol and LDL levels, changes occurred at branches and 
bifurcation of the main arteries. These changes consist of retraction of the endothelial cells 
covering some of the fatty streaks caused by endothelial cell-cell detachment. Endothelial 
retraction exposes the numerous lipid-filled macrophages to the blood flow and permits them 
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to remove the lipid they have ingested from the lesion by taking it with them into the 
circulation to the spleen and to lymph nodes. In this way, the macrophages play a role in the 
lesions of atherosclerosis similar to their role at site of injury, where they are the principal 
scavenger cells. Thus, in very real sense, the progressing lesions of atherosclerosis represent a 
special kind of inflammatory response in which macrophages (and perhaps T-lymphocytes) 
attempt initially to protect the tissues. With the continuing insult (hypercholesterolemia, 
diabetes, and so on), the response becomes excessive, and the resultant fibro-proliferative 
events themselves become the disease process. When macrophages become exposed to the 
circulation they can act as a deposit site for platelets, which start to form a fibrotic cap that 
overlay areas of extensive proliferation of smooth muscle cells intermixed with lipid-filled 
macrophages, beneath which were found cell debris, lipid accumulation, and sometimes 
calcification.  
Thus, in keeping with these informations and The Lipid Research Clinical Trials results it 
seems quite clear as lowering of plasma LDL levels would be extremely beneficial. 
Furthermore, it has been seen either in animal models either in human patients aggressively 
treated with lipid-lowering regimens a regression of atherosclerotic plaque, fatty streaks, 
significant reduction in the size of the smooth muscle proliferative lesions, with a consequent 
benefits in atherosclerosis, myocardial infarction, and coronary artery disease. 
Brown and colleagues have demonstrated a statistically significant regression of semi-
occlusive lesions of human coronary atherosclerosis in association with decreases in plasma 
cholesterol and LDL levels.
124
 These results provide clear evidence of pathological role of 
cholesterol and more in general of lipids. 
 
 
3.3 Kinesin like protein 6 role in the lipid pathway  
 
Three major superfamilies’ of microtubule motor proteins have been identified, kinesin, 
myosin, and dynein. Kinesin is a wide superfamily constituted by 45 members expressed in 
mammalian cells, which share analogies in the motor domain but differ considerably in their 
cargo-binding tail domain.
125
 Although KIFs are conserved between species, many different 
types exist within a single organism, suggesting that KIFs might have diverged through 
molecular evolution to mediate different cellular functions. Conventional kinesin, also known 
kinesin-1, and most of the other vesicles motors in the kinesin superfamily move 
unidirectionally toward the plus end of the microtubule.
126
 Thus, kinesins are likely to be 
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involved in the in trafficking events directed toward the cell periphery, such as motility from 
the Golgi to the plasma membrane. However, other minus end-directed kinesins also 
contribute to intracellular trafficking events, such as the minus end-directed transport of early 
endosomes.
127
 The intracellular transport is essential for appropriate cellular morphology and 
function. Kinesin proteins have been seen to transport organelles, protein complexes, and 
mRNA to specific site along the microtubule while hydrolysing ATP for energy. Kif6 is a 
member of the kinesin 9 family but the precise molecular function of kif6 is still not known, 
and in particular its association with the circulating cholesterol level is not understood. It is 
likely to play a role in the cellular transport of proteins along microtubules and could be 
involved in cellular transport in the cardiovascular system.
128
 To date, all studies have focused 
on investigating polymorphism in the KIF6 gene within the context of coronary artery disease 
even if its molecular pathway needs to be clarified. Indeed, there has been considerable debate 
regarding the role of KIF6 in coronary artery disease. Several lines of evidence that used a 
candidate gene based approach in several atherosclerosis population cohorts have observed an 
increased risk of adverse coronary events in carriers of the rs20455 C variant in the KIF6 gene 
which lead to a Trp719Arg substitution in the Kif6 protein.
129,130
 However, these results were 
refuted by a large part of Genome-Wide-Association-studies metanylisis using 19 case-
control studies where cases were defined either by a history of prior myocardial infarction 
and/or the presence of coronary artery disease at angiography.
128
 Furthermore, no association 
between the KIF6 variant and this pathological condition has been found in the most recent 
large meta-analysis.
131
 Nevertheless, evidence from international randomized controlled trials 
with statins associated carriage of Tpr719Arg genotype with a greater clinical response to 
statin therapy.132,133 Another study, JUPITER trial, has been realized on a wide population of 
patients, men and women, without prior cardiovascular disease or diabetes, were randomly 
allocated to rosuvastatin 20 mg/day or to placebo and followed for first major vascular events 
and for all causes of mortality. The effects of Tpr719Arg polymorphism have been evaluated. 
Outcomes obtained from this study didn’t show any correlation between genotype and major 
cardiovascular risk factors, as well as no clinically meaningful differences in pharmacological 
response have been seen between carriers and non-carriers. 
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3.4 Pharmacology of lipid metabolism 
 
As it has been mentioned above, several lines of evidence from epidemiological and 
biochemical studies have demonstrated the importance of reducing to physiological level 
lipids concentration and in particular total cholesterol and LDL concentration. Indeed, it has 
been well demonstrated over the years that a linear relationship between LDL-C levels and 
relative risk for CHD exists, as showed in Fig. 6 below: 
 
 
 
Fig.6 Linear correlation existing between LDL-C and Relative Risk for CHD demonstrates 
the high importance to keep total cholesterol level and LDL within a physiological range 
suggested from the international guidelines for cholesterol level (Grundy et al. Circulation 
2004; 110(2):227-239). 
 
According to the World Health Organization (WHO), LDL cholesterol level ranging from 
100-130 is considered optimal, >160 high, >190 very high; Total Cholesterol is considered 
desired <200, borderline between 200-239, and high ≥240; HDL cholesterol <40 is believed 
low, ≥60 high (Table n.3).  
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LDL Cholesterol level (mg/dl) Acceptance Degree 
<100 Optimal 
100-129 Near optimal/above optimal 
130-159 Borderline high 
160-189 High 
≥190 Very high 
Total Cholesterol  
<200 Desirable 
200-239 Borderline high 
≥240 High 
HDL Cholesterol  
<40 Low 
≥60 High 
 
Table n.4 Classification of lipids level in the blood and acceptance risk according to the 
international guidelines. 
 
Risk factors such as diet, smoking, physical inactivity, obesity, high blood pressure, lipids 
(high LDL and low HDL cholesterol and raised triglycerides), diabetes, family history of 
coronary heart disease are responsible of a huge number of cases of coronary heart disease. 
The World Health Organization (WHO) believes that 60% of coronary heart disease and 40% 
of strokes are due to elevated LDL cholesterol levels. Reducing LDL-C has long been the 
primary target of cholesterol policy and this remains the case today. The two major 
approaches of LDL-lowering therapy are therapeutic lifestyle changes (TLC) and drug 
therapy. Dietary therapy should be the first approach in all form of lipid disorders. Although 
there is a great variation in individual response to a low-fat, low-cholesterol diet, changes of 
alimentary habits can be expected to play a significant role in improving most lipid profile. 
The minimal goals of dietary therapy should be to reduce LDL cholesterol to under 160 mg/dl 
and lower the total cholesterol to under 240 mg/dl in patients without CAD or two additional 
risk factors and to less than 130 mg/dl if any of these conditions apply. In the same time, if 
the patient result to be also overweight, the dietary approach should provide also a total 
caloric intake, as well as the intake of saturated fat and cholesterol.  
Drug treatment of lipid disorders should not be used until a precise diagnosis is firmly 
established and the presence of treatable of secondary causes has been ruled out. Before to 
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start the drug lipid-lowering therapy, maximum dietary effort should be done. To date, there 
are several classes of lipid-lowering drugs which act at a different levels of cholesterol 
biosynthesis, such as bile acid sequestrants (Cholestyramine, Cholestipol), Nicotinic acid, 
Fibric acid derivatives (Gemfibrozil, Clofibrate), HMGCoA-reductase inhibitors (Statins). 
Cholestyramine and Cholestipol are quaternary ammonium salts that act as anion-exchange 
resins, binding bile salts in the intestine tract. This sequestration leads to a reduction of 
reabsorption of bile salts and consequently to a decrease of their enterohepatic recycling; in 
the same time there is an increase of bile salts excretion in the stool. The positive effects on 
lipid-lowering of this class of drugs is represented by the fact that cholesterol will be used for 
an ex-novo synthesis of bile salts rather than be used for LDL or VLDL synthesis. 
Cholestyramine and Cholestipol are considered first line agents and are highly effective in 
decreasing LDL cholesterol.
134
 The bile acid sequestrants are difficult to be used because of 
their side effects, related to nausea, abdominal pain, constipation, and indigestion. Because of 
their site of action, intestine, these drugs have been seen to interfere with the 
pharmacokinetics of other drugs such as digitalis, phenobarbital, thiazides, etc..., reducing 
their intestinal absorption.  
The B vitamin nicotinic acid or niacin is able to reduce the LDL levels by about 25% and 
VLDL levels by about 75%. The mechanism with which this drug acts is complex and most 
probably related to a decreased cholesterol and VLDL hepatic synthesis. Nicotinic acid has 
been also seen to decrease the release of free fatty acid from adipose tissues and thus 
decreases the level of substrate involved in the triglycerides synthesis. Furthermore, this drug 
is able to increase the HDL levels by 20 to 40%. Similarly to bile acid resins, nicotinic acid’s 
activity, is accompanied by frequent side effects, that include cutaneous flushing and 
gastrointestinal (GI) symptoms.  
Gemfibrozil and clofibrate are the fibric-acid derivatives widely used in USA; in Europe, 
fenofibrate, benzafibrate, and ciprofibrate are also used. The fibric-acid derivatives are used in 
VLDL and triglycerides lowering. Their mechanism of action is not completely clarified, even 
if they seem to act by increasing lipoprotein lipase activity via peroxisome proliferator 
activated receptors-α; this action leads to an increase of VLDL clearance.135 In the same time, 
fibric acid derivatives also increase the cholesterol secretion into the bile. Fibric-acid 
derivatives usually are well tolerated, with nausea and GI discomfort the major side effects.  
The last class, not for importance, of lipid-lowering drug is represented by 3-hydroxyl-3-
methyl-glutaryl-CoA-reductase inhibitors, the so-called statins: atorvastatin, pravastatin, 
lovastatin, rosuvastatin, and simvastatin. This class of drugs is the most extensively used in 
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the treatment of hypercholesterolemia. The efficacy, safety, and benefits of statins make them 
the drugs of choice. Statin are able to lower the serum low-density lipoprotein and 
triglycerides levels, and in the same time they increase the HDL levels. Furthermore, it has 
been seen that statins offer an important contribution to the reduction of the risk for the major 
cardiovascular events, such as MI and death for CVD in selected population. Side effect of 
statins are principally muscle-related (such as muscle weakness) and in general mild in nature. 
More serious side effects, such as myopathy and fatal rhabdomyolysis are rare and often can 
be seen when statins are used in combination with other medicines that affect statin 
pharmacokinetics.
136
 Usually statins are used singularly, even if there are several cases in 
which statins are used in combination with other lipid-lowering drugs. However, doubts about 
the benefits of statins, alone or in combination with other lipid-lowering drugs, remain. In 
patients with a very high LDL levels or mixed dyslipidaemia that fail to reach the desired 
lipids levels on statin monotherapy, other classes of drugs are often added in order to improve 
clinical outcomes. Besides the co-administration, another aspect of statin therapy that remains 
difficult for prescribers is the ability to predict individual patient’s response to therapy, in 
terms of efficacy and genetic predisposition to possible adverse effects.
137
 Plasma 
concentration of statins as well as the pharmacological efficacy can vary widely amongst 
patients that receive the same dose of the same statin. Recent results obtained from 
pharmacogenomics and pharmacogenetics studies have demonstrated a wide number of 
candidate genes (40 gene) that are involved in the modulation of statin pharmacokinetics and 
pharmacodynamics. Doubtless, the most important is the gene expressing for the HMGCoA 
reductase enzyme. Statins act binding to the catalytic domain of HMGCoA-reductase enzyme 
that, as above said, catalyses the rate-limiting step of cholesterol biosynthesis. All statins 
share rigid, hydrophobic groups that are covalently linked to the HMG-like moiety. All statins 
are competitive inhibitor of the natural substrate HMGR, and it has been seen that they act 
occupying the HMG-binding pocket and part of the binding surface for CoA, thus sterically 
preventing substrate from binding. Comparing the complex obtained between the natural 
substrate and the enzyme or between a statin and the enzyme, a clear rearrangement of the 
substrate-binding pocket has been seen after the statin interaction. The strong efficacy of 
statin’s interaction with the catalytic site of HMGCoA-reductase is probably due to the large 
number of van der Waals interaction, which in turn reflects the importance of each amino acid 
that takes part in the catalytic site's constitution. Several studies have shown as structural 
changes of catalytic site of HMGCoA-reductase, principally caused by genetic alteration, lead 
to a loss of statin treatment efficacy. 
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4.0 Genetic background 
 
4.1 Pharmacogenetics, pharmacogenomics, and individualized therapy 
 
Individual variability in drug efficacy and drug safety is one of the most important 
challenge in current clinical practice of this century and the personalized therapy seems not to 
be a dream anymore.  
In a large patient population, a medication that is demonstrated efficacious and safe in 
many patients, it is proven to be inefficacious and sometimes lethal in some other peoples. 
Although large individual variability in drug efficacy and safety has been well documented 
amongst peoples since the beginning of the medicine, its understanding still represents an 
unmet need. The demonstration of individual variation in drug response has proven difficult, 
even if the demand to overcome such variation has received more attention and become the 
goal of modern medicine. It is well known that large variability of drug efficacy and adverse 
drug responses in patients is a major determinant of the clinical use, regulation, and 
withdrawal from the market of clinical drugs. Drug response is influenced by several factors, 
some of which involve important aspects that are intrinsic to the biology itself.  
Genetic variation in humans was recognized as the most important determinant of 
individual variability of drug response from clinical observations in late 1950s.
138,139
 From 
these studies it has been observed amongst a certain population differences in plasma 
concentration of specific drugs and in the similar way also differences of metabolites 
concentration in urine, demonstrating that variances in pharmacodynamics and 
pharmacokinetics are present and exert a very important role. It has been seen that in some 
patients a very low or a very high concentration could be present and the biochemical traits 
leading to the variation of drug concentration were found inherited. These clinical findings 
fostered the formation of pharmacogenetics. Differences of drug response and behaviour 
reflect sequence variations of specific genes coding for drug targets, such as proteins, drug-
metabolizing enzymes, receptors, drug-transporters.
140,141
 Starting from these outcomes, the 
availability of the complete human genome sequence has made it possible to analyse the 
impact of variations of human genome sequence on the pathogenesis of important diseases 
and the response to drug therapy. The amount of knowledges and informations acquired over 
the years on genome-disease and genome-drug interaction has brought to a new area so-called 
pharmacogenomics starting from the previous pharmacogenetics. This goal provided a 
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rationale for the hope that the personalized medicine can be achieved in the near future. Both 
pharmacogenomics and individualized drug therapy are increasingly influencing medicine, 
biomedical research, in many areas, including clinical medicine, drug development, drug 
regulation, pharmacology, toxicology.  
As already said drug efficacy and adverse drug reactions dose-dependently determine the 
clinical outcome of clinical therapy. To date, it is well known as these parameters change 
widely over the cohort and the personalized therapy, based firstly on a genetic screening and 
then on using of the right drug and concentration, may represent the only possible way to 
avoid to use an inefficacious drug and increase adverse drug reactions. We know that a higher 
dose boosts drug therapeutic effect but in the same time it increases the possibility to have 
undesirable side effects. The difference between the drug therapeutic effect and its side effects 
defines the so-called therapeutic window (Fig. 7) 
 
 
 
Fig.7 Representation of dose-response curve. Panel A shows the therapeutic window, that is 
the difference between the efficacy and the toxicity. This window may vary from patient to 
patient, B and C, requiring dose-adjustment (Qiang Ma and Anthony Y. H. Lu, 
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine, Pharmacol Rev 
63:437–459, 2011). 
For many drugs, the optimum dose required for effective and safe therapy varies 
significantly from patient to patient, because the minimum therapeutic dose can be too low or 
too high. Such a situation can be characterized by an atypical therapeutic window, dose-
response curve, and toxicity resulting in unexpected and undesirable outcomes.
142
 Genetic and 
nongenetic factors affect individual variability of a drug response by modulating the dose-
response curves of drug efficacy and drug toxicity of patients. Clinical outcome is altered if 
drug dose is not adjusted accordingly. 
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4.2 Single nucleotide polymorphisms (SNPs), important genetic variation  
 
Inherited differences in DNA sequence contribute to phenotypic variation, influencing an 
individual’s anthropometric characteristics, risk of disease, and response to the environment. 
A central goal of genetics is to localize the DNA variants that contribute most significantly to 
population variation in each trait.
143 
The idea that genes control some drug responses was suggested for the first time in the 
1950 thanks to a correlation between inheritance or ethnicity and aberrant drug responses. 
This idea was strengthened by family and twin studies in 1960s 1970s, extended by 
biochemical studies in 1980s, and solidified by molecular genetics in the 1990s.
144,145,146
 
Cloning and characterization of the first human gene containing DNA sequence variations, 
singular nucleotide polymorphisms, that influence drug pharmacodynamics and 
pharmacokinetics did not take place until the end of 1980s.
147
 Although there are a number of 
different types of polymorphic markers, most attention recently has focused on single 
nucleotide polymorphism (SNPs, pronounced snips), and the potential for using these to 
determine the individual drug response profile. Polymorphisms are genetic variations of 
human genome that occur at a frequency of 1% or greater in the population. These variations 
can appear as insertion or deletion of short fragments of nucleotide, even if the most common 
variations are SNPs. A SNP is a DNA sequence variation characterized by a singular 
nucleotide substitution among members of the same species or between chromosomes in an 
individual. SNPs are the most abundant genetic variants in mammalian genomes and 
specifically in the human genome they account for 3.2 million and are responsible for the 
90% of genetic human differences.
148
 SNPs are classified in three different groups depending 
on where they are located in the genome:  
 
1. c-SNPs, variations located in coding region, exons, whose presence could modify or not 
the amino acid sequence in the protein structure, defined as synonymous and non-
synonymous respectively 
2. p-SNPs are located in perigenic region, i.e., in regulatory regions such as promoter, 
enhancer, etc… Such polymorphism can modulate both the expression level and the 
stability of the protein, by influencing the mRNA stability.  
3. r-SNPs, random SNPs that are located in the intergenic region, i.e., in those regions that do 
not show genes but that constitute the 98% of our genome. These variations are not able to 
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influence the genetic expression. However they may alter the DNA structure by 
influencing the tertiary structure of DNA, and its capacity of interaction with chromatin or 
with enzymes such as topoisomerase. For these reasons, to date, we cannot exclude their 
implication in the pharmacogenetics.  
 
Currently there is a growing list of polymorphisms found in genes encoding of drug 
transporters and targets, drug-metabolizing enzymes, as well as disease-modifying genes, that 
have been linked to drug effects in humans. Pharmacogenetics has indeed proven to be a 
potential source of biomarkers able to predict drug response and adverse drug reaction. For 
this reason, during the last decade a rapid development of techniques in the area of genome 
analysis has been seen and recognized as needful for the identification of new 
pharmacogenomics biomarkers. Such biomarkers mainly originate from genes encoding drug-
metabolizing enzymes, drug transporters, and drug targets. Some of these are now integrated 
by the USA Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) into drug label inserts.
149 
Although the numerous potential benefits of pharmagenomics and pharmacogenetics have 
been announced and sometimes also demonstrated, to date, this innovative area of research is 
so rarely used in clinical practice. This seems to be a particularly relevant question that in the 
next year needs to be answered. It seems that the failure to use of this type of approach in the 
clinical practice is related not only to scientific issues but also to cultural limits. For example, 
individualizing dosages, even based on easily assessed patients characteristics, such as sex, 
age, renal functionality, has not embraced by medical or pharmaceutical communities. 
Furthermore, there is a strong resistance to relying on tests for every medical decision. Not 
only does pharmacogenomics require a laboratory test, it also requires an interpretation of 
genotypes, which will probably require clinicians to receive further training in molecular 
biology or genetics. Lastly, it also difficult to demonstrate that individualization of drug 
therpy on the basis of genetics improves clinical outcomes, given the multi-genic nature of 
most drug effects. These represent just some of limits that can hinder the clinical use of this 
discipline.  
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4.3 An overview on the genetic variations 
 
The replication of genome before cell division is a remarkably precise process. 
Nevertheless, some errors during DNA replication can happen and lead to a new mutations. It 
is well known that genetic errors can occur at different levels of cellular growing. If they 
occur during mitosis, after conception, for instance, and during life, they are defined somatic 
mutations. Somatic mutations can happen at any time, and they usually lie in non-coding 
regions. For all these reasons they are said to be phenotypically silent. Because they do not 
occur in cells that give rise to gametes, the mutation is not passed along to offspring. Somatic 
mutations are thought to be the cause of most sporadic cancers, that are not inherited. In 
cancer there are usually somatic mutations of important genes like Ras, involved in the cell 
proliferation and survival, as well as other genes p53, etc… These mutations are restricted to 
an individual cell and any daughter cells that may have been produced (when the cell divides). 
Thus, the mutation can be seen only in the tumour tissue but not in the healthy tissue of the 
same patient.  
If the mutation occurs during meiosis, in producing the egg or sperm, they are referred to 
as germ line mutation. If the mutant sex cell participates in fertilization, then the mutation will 
be passed to the next generation. An individual of perfectly normal phenotype and of normal 
ancestry can harbour undetected mutant sex cell. The mutation will be detectable only if it 
participates to the zygote formation.  
The point mutation is the simplest type of mutation, which is characterized by the 
substitution of a singular nucleotide, addition or deletion of a small number of nucleotides 
Amongst the point mutations we can recognize, besides singular nucleotide polymorphism, 
other mutations that are here listed: missense mutation, non-sense mutation, deletion, 
insertion or addition mutation.. Depending on where the mutation occurs and which base is 
changed we can divide these mutations in missense or non-synonymous and sense or 
synonymous mutation.  
With 61 codons for 20 amino acids, many of the codons are synonyms, coding for the same 
amino acid. This means that each amino acid can be expressed by several codons, up to six in 
the case of leucine, while methionine and tryptophan have two codons. In most cases it has 
been seen that synonyms differ by only one base, so it’s quite plausible that a point mutation 
can lead to a new codon that encodes for the same amino acid. This type of mutation is called 
synonymous, silent mutation or sense-mutation. Missense mutation happens when a single 
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base substitution leads to a new codon that encodes for a different amino acid; for this reason 
is defined also non-synonymous because of a different product. This substitution may have a 
different degree of influence on protein structure and its functionality, according to the 
chemical nature of the new amino acid and the position where the substitution occurs in the 
protein structure. In case the amino acid shows the same chemical and physical properties, its 
influence on the protein structure and above all on the activity can be considered negligible, 
but whether the new protein has different characteristics we can obtain a non-functional 
protein or a protein with a reduced activity with a consequent health problems.  
A non-sense mutation (UAG, UGA, UAA) is obtained when a point mutation substitution 
leads to the formation of one of the three stop-codons, which are known to be important 
because of their role in the peptide chain elongation, signalling the end of the process. If a 
point mutation changes a normal coding triplet in a stop-codon, the resulting protein will be 
cut off early and consequently will result to be incomplete and plausible not working. This 
has health implication, as it happens in the cystic fibrosis, a non-sense mutation caused 
pathology.  
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5.0 Aim of the study 
 
This study was realized focusing our attention on three different diseases such as 
hypertension, hypercholesterolemia and hyperaldosteronism, trying to add new informations 
on their etiology. To date, hypertension is the most studied pathology worldwide because of 
its epidemiology. Recent reports indicate that 1 billion of peoples in 2000 had hypertension, 
and this number is predicted to increase to 1.56 billion by 2025. New reports also suggest that 
hypertension prevalence is increasing in the developing countries and is becoming to be one 
of the leading causes of death and disability. It is well know that hypertension is a 
multifactorial disease where several risk factors such as diet, smoking, alcohol consumption, 
cholesterol levels, aging, and the presence of other pathological conditions come into play. 
Nevertheless, this huge amount of information is not enough to justify the numerous cases of 
ictus, heart attack, and cardiovascular diseases in an non-negligible percentage of patients. 
Thus, to date there is an urgent need to identify new metabolic and above all genetic markers 
that can be used in the predictive medicine. Starting from genetic characterization of each 
patient, predictive medicine may be able to quantify the risk of particular subject to develop 
hypertension or another cardiovascular disease, and in this way it may personalize the therapy 
and low the annual worldwide cost of hypertension treatment quantified in $370 billion. 
Despite of the widespread availability of antihypertensive drugs, the blood pressure of many 
patients remains high and uncontrolled. This represents a very important issue especially in 
reference to the billions of dollar spent annually. Amongst all the causes that may be 
responsible of uncontrolled blood pressure, such as non-adherence to the therapy, diet, 
lifestyle, interfering medications, or underlying diseases, genetic variations have a 
determinant role.  
The first part of the study takes in consideration a pathological condition, known as 
hyperaldosteronism, characterized by a dysregulation of aldosterone secretion by adrenal 
glomerulosa cells. It is well demonstrated that up to 10% of peoples with hypertension have 
abnormal aldosterone levels (primary aldosteronism, PA) and in a significant minority of 
these it arises from aldosterone-producing-adenomas (APA) in the adrenal cortex. Several 
potassium channels are expressed in the glomerulosa cells, even if we paid our attention on a 
specific inward-rectifying-potassium channel, KCNJ5, located across the membrane. This 
channel shows a specific characteristic, i.e. is extremely selective toward K
+
 ions, giving them 
the possibility to flow across the membrane in both directions. It is well known that the ZG 
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cell membrane is selectively permeable to K
+
 giving it the characteristics of a K
+
 electrode 
over a wide range of extracellular K
+
 concentrations. Depolarization causes a secondary (and 
transient) rise in intracellular Ca
2+
 through a T-type calcium channel, which is the primary 
stimulus for increased production and release of aldosterone. It has been recently reported that 
mutations of the selectivity filter of KCNJ5, showed either in familial form of PA either in 
much rarer syndromic form of PA, APA, allow other ions to flow across the membrane 
changing the electrolytic composition of cytoplasm. Because of selectivity loss, Na
+
 ions, 
driven by their electrochemical gradient, start to flow from outside to inside depolarizing the 
potential membrane. The aim of this study is to understand the molecular mechanisms by 
which wild type (WT) and mutated forms of KCNJ5 can modulate the resting membrane 
potential, leading to an overproduction of aldosterone.  
Starting from the awareness that genetics plays an important role in the development of 
several diseases, including hypertension, we moved our attention on investigating the role that 
singular nucleotide polymorphisms of important genes have in the blood pressure modulation 
and cholesterol biosynthesis in a rural unselected population. We focused our attention on 
several genes of the hypertensive pathway, such as angiotensing-converting-enzyme (ACE), 
angiotensinogen, beta-1 and beta-2 adrenergic receptors, angiotensin-II receptor-1 (ATII-R1), 
and aldosterone synthase (CYP11B2); further we analysed other two genes, hydroxyl-methyl-
glutaryl-CoA-reductase (HMGCoA-reductase) which catalyses the first step of the 
endogenous biosynthesis of cholesterol, and Kinesin-like-protein 6, which seems to be 
involved in the intracellular transport of organelles. Selected polymorphisms of these genes 
were analysed firstly by using Real-Time PCR and Real Time RFLP techniques for the 
genetic discrimination and then by using an informatics approach with the aim to find a 
statistically significant correlation between genotype and hypertensive phenotype for each 
subject. 
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6.0 Material and methods 
 
6.1 Genomic DNA extraction and sequencing 
 
Peripheral venous blood samples were collected from each patient and genomic DNA was 
extracted using standard method from fresh whole blood. In brief, we collected blood in either 
a heparin or EDTA-containing Vacutainer by venepuncture. The blood extracted was stored 
at room temperature and DNA was extracted within the same working day. We firstly from 
whole blood prepared a leucocytes pellet placing 3mL of blood in a 15 mL falcon tube and 
added 7mL of reagent A and mixed by inversion for 5 minutes. The lysis was considered 
completed when the solution had a clearish red colour. Subsequently, we centrifuged at 3000g 
for 5 minutes at room temperature (RT) and then we sucked the supernatant from the white 
pellet present on the bottom of the tube and added 1mL of reagent A and mixed to make the 
pellet completely dispersed. In the last step, we added 6mL of reagent A, mixed by inversion 
and centrifuged again at 3000g for 5 minutes at RT; we discarded the supernatant into waste 
container to get a clear/white/purer pellet. 500μL of 5 M sodium perchlorate were added and a 
1000uL pipette was used to mix the pellet by drawing it up and down until it was fully 
dispersed. We added 2mL of reagent B and briefly inverted to mix; tubes were placed in 
water bath at 65°C for 2 hrs. We allowed the tubes to cool to RT and added 2mL of ice-cold 
chloroform and then mixed on rotating mixer for 30 to 60 minutes. The solution was 
centrifuged at 3000g for 10’ and then 1.5/2.0 mL of aqueous layer were carefully removed 
into a new, clean microfuge tube. 3mL of ice-cold 100% ethanol were added; the solution was 
mixed by inversion to precipitate the DNA. Supernatant was discarded and DNA was washed 
with 2 mL of ice-cold 70% ethanol. Ethanol was then removed and DNA was left to air-dry. 
200 μL of TE buffer were added to resuspend our DNA, which was stored at –20 °C to –80 °C 
for long term. Concentration and purity of DNA extracted were checked spectroscopically 
using a NanoDrop instrument.  
The entire coding sequence (exon 2-3) and flanking regions of KCNJ5 were resequenced 
by using polymerase chain reaction technique in order to look for rare variants that might be 
important for the pathophysiology of sporadic primary aldosteronism. PCR was performed on 
25ng of gDNA in a final volume of 30μl containing 1.5mM MgCl2, 0.2mM of each primer 
forward (F) and reverse (R) (Table n.5), 0.2 deoxynucleotide triphosphate and 1.0 unit of Taq 
DNA polymerase ( Life technologies corporation, Australia).  
73 
 
  
KCNJ5_1F GTGGCCTTCCATCTTGTGTT 
KCNJ5_1R GAGGGTCTCCGCTCTCTTCT 
KCNJ5_2F CCATTGAGACCGAAACAACC 
KCNJ5_2R GGCACAGACCTGCATCTTCT 
KCNJ5_3F ATTGATGGATGAATGGATGAATG 
KCNJ5_3R AGCCCCCAAACAGCACACTC 
 
Table. n.5 PCR primers used to amplify the coding and flanking regions of human KCNJ5  
 
 
6.2 Mutagenesis site specific and X-Gold cells transformation 
 
To reproduce and study the same mutations that have been previously identified by 
resequencing of coding and flanking regions of human KCNJ5 gene, we used an in vitro 
approach based on the site-specific mutagenesis technique. We used pCMV6-AC-GFP 
plasmid as a vector (Origen) (Fig. 8) 
WT KCNJ5 cDNA and pCMV6-AC-GFP vector were undergone to the activity of the 
same restriction enzymes to produce in both sticky ends that are complementary each other. A 
subsequent reaction was catalysed by a ligase enzyme which is able to promote the formation 
of a phosphodiester bond between juxtaposed 5' phosphate and 3' hydroxyl termini in duplex 
DNA or RNA. The plasmid used expresses for green fluorescent protein (GFP), which gives 
the advantage to monitor the expression of our cDNA, and also it expresses for an ampicillin 
resistance gene, giving us the possibility to select only bacteria and/or cells that have been 
actually transfected. 
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Fig.8 Organization of pCMV6-AC-GFP plasmid used as a vector for our KCNJ5 cDNA 
 
Once WT KCNJ5 cDNA was added to the plasmid vector, the next step was to produce a 
site-mutated cDNA. This was done with a commercial kit QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies). Several approaches to this technique have been 
published, but these methods generally require single-stranded DNA (ssDNA) as the template 
and are labor intensive or technically difficult. QuikChange II XL Site-Directed Mutagenesis 
Kit shows many advantages comparing with others kit; indeed, it is specifically optimized for 
large, difficult constructs and allows site-specific mutation in virtually any double-stranded 
plasmid DNA (dsDNA) and it eliminates the need for sub-cloning and for ssDNA rescue. 
Furthermore the QuikChange II XL site-directed mutagenesis kit does not require specialized 
vectors, unique restriction sites, multiple transformations or in vitro methylation treatment 
steps. The rapid three-step procedures generate mutants with greater than 80% efficiency.  
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Fig.9 Overview of the site-directed mutagenesis protocol: there are 3 different steps through 
which it is possible to produce a specific mutation, such as insertion/deletion, and point 
mutation. 
 
Site-directed mutagenesis approach is based on the use of supercoiled double strands DNA 
(dsDNA) vector with an insert of interest and two synthetic oligonucleotide primers, both 
containing the desired mutation. The oligonucleotide primers, each complementary to 
opposite strand of the vector, are extended during temperature cycling by PfuUltra HF DNA 
polymerase. Extension of the oligonucleotide primers generates a mutated plasmid containing 
staggered nicks. In last cycles, products are treated with Dpn I endonuclease, which is specific 
for methylated and hemi-methylated DNA, that will be digested. 
For our mutagenesis reactions, we prepared a sample reaction solution constituted by a 5uL 
(10x) of reaction buffer, 1μL of dsDNA template (5-50ng set up tests), 1.25μL of primers mix 
(125ng), 1μL of dNTP, 1μL of polymerase, and water up to 50μL. Each sample reaction 
solution was undergone to PCR technique. The first step of this reaction is the denaturation of 
the double strands that is realized at 95 °C for 1 minute; during the annealing phase during 
which our primers interact with the DNA template temperature was maintained to 95 °C for 
another minute and then was lowered to 60 °C for 50’’, and increased again up to 68 °C for 8 
minutes (1min/kb). The reaction was continued for 18 cycles at the end of which the 
temperature was maintained at 68°C for 7’ and then lowered to 4 °C to cool the reaction 
solution. Once the mutagenesis and the amplification were stopped, in each reaction solution 
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1μL of Dpn I endonuclease was added and left at 37 °C for 1h to digest the DNA template in 
order to leave the only site-mutated DNA.  
The nicked vector DNA, incorporating the desired mutation is then transformed into X-
Gold ultracompetent cells. These cells were thawed on ice and 30-50μL per reaction were 
aliquoted into pre-chilled 15mL tubes; 1μL of site-mutated DNA was added to cells and 
incubated on ice for 30’. Cells were then immediately incubated in a pre-warmed bath at 42°C 
for 45’’ and on ice again for 2’. At the end of this incubation 250μL of lysogeny broth (LB), 
better known as LB medium, were added to the reaction cell solution and incubated at 37°C 
for 1h:30’ with shaking 250rpm. 40-50μL of the medium containing cell were spread 
according the dilution method onto LB ampicillin agar dishes and cultured at 37°C overnight 
until colonies appeared (Fig. 10). 
 
 
 
Fig.10 Colonies of X-Gold ultracompetent cells transformed with site-mutated KCNJ5 cDNA, 
growth and selected onto LB ampicillin agar  
 
A single colony from each dish, as shown in Fig.10, was picked up and grown overnight in 
4mL of LB medium containing ampicillin (stock solution 1mg/mL) diluted 1:1000μL at 37 °C 
and 250rpm (so called miniPrep). The plasmid DNA was then collected using the Roche mini 
prep kit and this DNA was sequenced to determine if the mutation was actually present, and 
to ensure that the rest of the KCNJ5 cDNA was not mutated by accident.  
DNA sequencing was done starting from a reaction solution constituted by 300-400ng 
DNA, 1.5uL of primer, 2uL master mix, 2uL of diluent, H2O to 20uL. This solution was 
undergone to a PCR reaction (95 °C 30s, 50 °C 30s, 60 °C 4min for a 35 cycles) and the DNA 
amplified was then precipitated adding 1uL Glycogen, 2uL 3M Sodium Acetate, and 1uL 
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0.1M EDTA, followed by 60uL of cold 95% ethanol. The solution was mixed and transferred 
to a PCR 96 well plate, that was centrifuged (1100 rcf) at 4°C for 30’. The supernatant was 
discarded by inverting the plate onto the tissue paper and 200uL of cold 70% ethanol were 
added; these steps were repeated two times changing only the duration of centrifuge that was 
lowered to 10’. Plate was left to air dry at a room temperature for 10-15’and then filled with 
40uL of loading buffer (formamide) and a drop of mineral oil to the top of each sample. Plate 
was so loaded in a sequencing machine.  
Once the sequencing reaction was finished and mutation was ascertained, a large bacteria 
culture, so called maxiprep, was prepared. We added 100μL of miniprep solution in 100mL of 
LB medium (+ampicillin) and left overnight at 37 °C. In the next day bacteria were collected 
by centrifugation at 4000g at 4°C for 30’. The supernatant was threw away and pellet used for 
DNA extraction with a Qiagen Plasmid Maxi kit. Purity and concentration of DNA were 
checked spectroscopically using a NanoDrop instrument. The DNA extracted was in part used 
to make the bacterial stab by adding pure glycerol and stored at -80°C; and the remaining part 
was used for our experiment.  
 
 
6.3 RNA synthesis  
 
cRNAs of KCNJ5 and KCNJ3 constructs were created using the Ambion mMESSAGE 
mMACHINE T7 kit according to the manufacturers (life technologies). This commercial kit is 
indicated for the routine synthesis of capped RNA for oocytes microinjection, and in vivo/in 
vitro transfection. Constructs of human KCNJ5 and KCNJ3 under the T7 promoter in the 
pGEM vector (Fig. 11) were a generous gift from Dr. Nicole Schmitt (Danish Arrhythmia 
Research Centre). 
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Fig.11 pGEM vector structure used to run the cRNA transcription  
 
The pGEM constructs were linearized using the restriction enzyme NotI. 1 µg of purified, 
linearized DNA was used as starting material and all further steps were carried out following 
the manufacturer's instructions. The incubation period at 37 °C was increased from one hour 
to two hours to ensure maximum yield. The RNA was then purified using the RNeasy Mini 
kit (Qiagen) before it was analysed and quantified by UV spectrophotometry and gel 
electrophoresis in reducing conditions. 
 
 
6.4 Oocytes preparation  
 
Female Xenopus laevis frogs were anaesthetized with 3-aminobenzoic acid ethyl ester and 
the ovaries were removed through a midline abdominal incision. The oocytes were then 
placed into a Petri-dish with ND96 solution (96 mM NaCl, 2.0 mM KCl, 1.0 mM, MgCl2 and 
5.0 mM HEPES buffer, pH 7.4 without CaCl2) containing 1 mg/ml collagenase (from 
Clostridium histolyticum, Sigma) and placed on a rocker for 45–60 minutes at RT. After the 
removal of collagenase by washing the oocytes 3 times in ND96, stage V and VI oocytes 
(sharp border between animal and vegetal poles, diameter 1–1.2 mm) were selected and 
manually defolliculated using ultra-fine forceps. The defolliculated oocytes were stored in 
ND96 overnight at 17 °C. Microinjection needles were pulled from 0.53 mm diameter glass 
capillaries (Drummond Scientific) using the Narishige PC-10 micropipette puller heated to 
58.1° C. The needle tips were broken off manually by tapping them gently on a metal rod. 
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The size of the tip was assessed by the Narishige MF-900 microscope (tip diameter 15–25 
µm). cRNA injections were performed using the Drummond Nanoinject automatic injector. 
Prior to loading the microinjection needle with the cRNA, it was backfilled with non-
fluorescent mineral oil (Sigma) to seal the pipette from air. 2 µl cRNA was then loaded into 
the needle by suction and oocytes were placed onto a Plexiglas well under a microscope 
(Narishige). Each oocyte was injected with 10–20 ng of KCNJ3 + KCNJ5 wild type or mutant 
cRNA (injection volume 50nl). Coinjection is necessary because it has been seen that KCNJ5 
heteroetramerizes with KCNJ3 to form a functional channel. Water-injected oocytes were 
used as a control. After injection, oocytes were incubated at 17 °C in HEPES-buffered ND96 
containing 2 mmol/L sodium pyruvate and 0.1 mg/mL gentamicin at 18°C for 2 to 3 days 
before use. The ND96 solution was changed every two days and damaged oocytes removed. 
After 3–5 days, protein expression was assessed using confocal microscopy and the oocytes 
were used in two-electrode voltage clamp experiments. 
 
 
6.5 Two electrode voltage clamp  
 
Two-electrode voltage clamp technique was used for the electrophysiological studies. The 
instrument presents microelectrodes that were filled with 3 M KCl (1 to 2 MΩ) for voltage 
sensing and current passing. External voltage and current electrodes consisted of fine, 
chloride coated silver wires. Oocytes were held in a small chamber and perfused continuously 
with ND96 (2 ml/min) at room temperature (18 to 20°C). Current–voltage (I-V) plots were 
obtained from voltage step protocols ranging from −140 to +100 mV in 20 mV increments. 
Oocytes were held at each voltage step for 500 ms, with 100-ms intervals between the voltage 
steps. For the I-V plots, the steady state current at each voltage step was used. Oocytes were 
perfused continuously with the high-Na
+
 ND96 (2 mL/min) at room temperature (18°C–
20°C). To study selectivity, the voltage step protocol was performed first in the high-Na
+
 
ND96 (92 mmol/L Na and 2 mmol/L K) solution before the perfusing solution was switched 
to high-K
+
 (45 mmol/L K) and the I-V plots recaptured. The high-K
+
 bath was finally 
changed to high-K
+
 containing 2 mmol/L BaCl2, and a second set of I-V plots was obtained. 
The KCNJ5 current was the difference between these 2 curves. In experiments where the 
specific channel blocker tertiapin-Q was used (Ascent Scientific), currents were measured in 
high-K
+
 in the presence and absence of the blocker (10 nmol/L). The clamp potential of the 
two-electrode voltage clamp amplifier (OC-725C amplifier; Warner Instruments, Hamden, 
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CT) was controlled using the program Pulse and Pulsefit (HEKA Electronic, Lambrecht, 
Germany) in conjunction with an ITC-16 interface (Computer Interface Instrutech Corp., 
Long Island, NY). Data were filtered at 1 kHz 
 
 
6.6 H295R cell culture 
 
Human adrenocortical carcinoma cell line, NCI-H295R, obtained from the American Type 
Culture Collection (ATCC), was used for in vitro studies. The cells were grown in a 1:1 
mixture of Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F12 Medium (Sigma). 
For routine maintenance the medium was supplemented with 5% of fetal bovine serum (FBS), 
1% of insulin/transferrin/selenite mixture (1.0 mg/ml recombinant human insulin, 0.55 mg/ml 
human transferrin (substantially iron-free), and 0.5μg/ml sodium selenite, stock solution 
100x), 1% of penicillin/streptomycin solution (100 units/ml penicillin, and 100 µg/ml 
streptomycin), 1x of L-glutamine ( stock solution 100x). Cells were grown at a 37 °C in a 
humidified atmosphere of 95% O2 and 5% CO2.  
Cells were grown in a 75cm
2
 flask up to a 65-70% of confluence, after that cells were 
splitted in a new flask. For splitting, the medium was threw away and cells were washed two 
times with 5mL of Phosphate Saline Buffer (PBS). After washing, 2 mL of 1x Trypsin-EDTA 
solution (0.025%) were added and incubated for 5’ into the incubator at 37 °C. Because of 
trypsin toxicity, after incubation a double volume of medium was added to the flask and cells 
were collected in a 15mL falcon tube and then centrifuged at 1000g for 5’. The supernatant 
was discarded and cells were resuspended into a complete medium and splitted according to 
the need in new flasks.  
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Fig.12 H295R human adenocarcinoma cell line used for in vitro studies in two different state 
of confluence; low confluence (left panel) and high confluence (right panel). ATCC company. 
 
 
6.6.1 Cell counting  
 
Cell counting was done whenever we needed to know the exact number of cells to seed in 
a 24-well plate. Cells were detached according to the protocol above mentioned. In brief, cells 
were washed two times with a PBS solution and then incubated for 5’ at 37°C with 2mL of 
trypsin solution. After incubation ,cells were collected with normal medium, and centrifuged 
at 1000g for 5’; finally, cellular pellet was resuspended into 1mL of complete medium. Of the 
cellular solution 10μL were diluted in 90μl, and of this solution 10μl were taken and mixed 
with an equal volume of Trypan Blue solution, pipetting up and down. 10μL of this solution 
was loaded into a Neubauer chamber and cell number was counted under an inverted 
microscope (focus 10x).  
 
 
6.6.2 H295R transfection 
 
The plasmid constructs were transiently expressed in H295R cells by electroporation using 
the Nucleofector device and reagents from the Nucleofector kit R according to manufacturer 
instructions (Lonza). 
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The day of transfection NCI-H295R cells (60-70% of confluence) were counted as 
aforementioned and 2x10
6 
cells/well were aliquoted in a 1.5mL tube. Cells were centrifuged 
at 90g for 15 minutes. The supernatant was gently discarded and cellular pellet was carefully 
resuspended up and down with 100μL of pre-warmed nucleofection solution, to which 3μg of 
the plasmid KCNJ5 DNA (WT or mutated) were added. Transfection solution was then 
transferred into an Amaxa cuvette for the electroporation. The electroporeted solution was 
then resuspended with a volume of pre-warmed RPMI up to reach 500μL and incubated at 37 
°C for 15’; this solution was seeded gently in the right well. Cells were incubated for 12hrs at 
37 °C, after that the transfection solution was replaced with 500μL of fresh medium. 
Transfected cells were monitored to the fluorescence microscope and the transfection 
efficacy, typically 80% to 90% (Fig. 13) was assessed using the green EGFP fluorescence 
signal measured by fluorescence-activated cell sorting (FACS Calibur machine, 
bdbiosciences). The percentage of transfected cells (GFP-positive cells) was then used to 
normalize aldosterone release values from each well.  
 
 
 
Fig.13 Fluorescence microscope image of H295R transfected cells with a WT KCNJ5. The 
same picture was acquired with a fluorescence filter turned off (left panel), and turn on (right 
panel). Transfected cells are well characterized by the green fluorescent colour. 
 
 
6.6.3 Aldosterone release and radioimmunoassay technique  
 
As aforementioned cells were transfected by electroporation and incubated for 24h at 37 
°C before to replace the transfection solution with the normal medium. For the aldosterone 
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release experiment the electroporation solution was substituted with a complete medium 
without antibiotics and FBS, and they were grown on either in the presence or absence of 
ATII (10 nmol/L) for a further 24 hours. The supernatants were then collected for aldosterone 
assay using 200μL aliquots of the culture supernatant and the commercial Coat-A-Count 
[
125
I]-aldosterone radioimmunoassay. 
Once the aldosterone powder was dissolved with the right volume of deionized or distilled 
water, a serial dilutions (12.5, 25, 50, 100, 200, 600, 1200 pg) were done in normal plastic 
tubes and 200μL of stock solution were then transfered in the standard curve polypropylene 
tubes coated with antibodies (in duplicate). Furthermore, we prepared for each sample two 
tubes, where we transferred 200μL of the supernatant medium previously collected from the 
24-well plate. Lastly, we added 1 mL of iodinated radioactive aldosterone solution (
125
I 
Aldosterone) in each standard and sample tubes plus 2 blank and 2 total tubes. Our samples 
were incubated for 18h at RT, and at the end of the incubation period the radioactive solution 
was removed from each tube of standard curve, samples, and blank, except from total. The 
radioactivity was quantified through the beta-counter machine.  
 
 
6.6.4 Cell viability and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay 
 
The MTT (3,(4,5-dimethylthiazol-2)2,5-difeniltetrazolium bromide) assay is a standard 
colorimetric assay used to measure the vitality of the cells or a cytotoxicity of a 
drug/substance on your cell line. This assay is based on the capability of a particular enzyme, 
succinate dehydrogenase, located into the mitochondrial compartment and active only in the 
alive cells. This enzyme split the thiazolyl tetrazolium in a formazan salt, insoluble in 
hydrophilic solvent but soluble in DMSO or in HCl-isopropanol solution, obtaining a violet 
solution. The intensity of the solution is directly proportional to the concentration of the 
formazan salt, which in turn is an expression of cell vitality. Cell viability was measured 
using an MTT kit (http://www.millipore.com) according to manufacturer instructions. In 
brief, H295R cells (300.000 cells/well electroporeted with different KCNJ5 mutant forms as 
above) were seeded into 96 well-plates and incubated at 37°C. The medium was changed after 
24 hours and grown on either in the presence or absence of ATII (10 nmol/L) for a further 24 
hours before adding the MTT reagent solution. Medium was replaced with 100μL of MTT 
solution (1x) and cells incubated for 2hrs at 37 °C. At the end of incubation, 96-well plate was 
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centrifuged at 4 °C for 30minuts at 2500g to precipitate the formazan salts. Once the supernatant was 
carefully removed paying attention to no remove formazan salts, 100μL of DMSO were added to 
solubilize them. Absorbance was immediately read with the ELISA plate reader at 540nm. 
Results have been obtained as optical density OD. 
 
 
6.6.5 Statistical analysis  
 
All data are presented as mean±SEM. Comparisons between groups was by ANOVA with 
post hoc testing using GraphPad/Prism5 for Windows software. Statistical significance was 
set at P < 0.05. 
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6.7 Brisighella population recruitment  
 
Brisighella Heart study is a prospective population-based study, started in 1972, involving 
2939 randomly selected individuals, free of cardiovascular disease at enrolment, all resident 
in the northern Italian rural town of Brisighella. Brisighella was chosen as a typical example 
of a rural community in the process of industrialization, with a very low rate of 
immigration/emigration and above all with homogeneity of lifestyle habits. Participants were 
cyclically evaluated, every 4 years following enrolment, during which lifestyle informations, 
and physical and biochemical data were obtained and recorded into a database. Inclusion and 
exclusion criteria were used to select the population:  
 being of historical population of Brisighella study,  
 aging from 30-70 years old  
were used as inclusion criteria, while  
 peoples of different race from Caucasian, 
  peoples with secondary hypertension or affected by severe diseases  
were excluded from the study. 
 Brisighella heart study protocol was approved by the Ethical Committee of the Bologna’s 
University, and from each patient we obtained the informal consent.  
 
 
6.7.1 Brisighella blood samples collection 
 
Blood samples were collected in the morning after a fasting period of 12h (overnight) in 
heparin-enriched tubes. DNA was extracted in the same date of collecting samples or after a 
short storage at -80 °C. Blood samples were used for biochemical and physical analysis, such 
as LDL, HDL, total cholesterol level (TC), triglyceride, APO-A1, APO-B quantification. 
Furthermore, anthropometrics parameters such as systolic and diastolic blood pressure, heart 
rate, breath rate, metabolic syndrome diagnosis, non-alcoholic fatty liver disease, were 
checked. Cholesterol level was defined high in case of TC > 200mg/dL, or lipid lowering 
therapy. Three blood pressure (BP) readings were recorded, and hypertension was defined as 
systolic BP ≥ 130 mmHg and diastolic BP ≥ 85 mmHg, or use of antihypertensive medication. 
Genomic DNA was isolated from 200μl EDTA-anticoagulated whole blood using the 
QIAamp DNA Blood kit (Qiagen, Hilden, Germany) according to manufacturer. In brief, after 
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treatment with lysis buffer, the kit provides proteinase K, commonly used to digest proteins, 
to remove contamination and inhibits nucleases that might degrade DNA. The lysate 
buffering conditions are adjusted to allow optimal binding of the DNA to the silica membrane 
of the QIAamp spin column. To improve the purity of DNA eluted, column was washed two 
times with two different wash buffers (Buffer AW1 and Buffer AW2). Purified DNA was 
lastly eluted from the membrane with 100μl of elution buffer (AE). Concentration and purity 
of DNA extracted, were checked spectroscopically using a NanoDrop instrument at a 
wavelength. of 260nm and DNA was stored at -20 °C. 
 
 
6.7.2 Genotyping analysis, PCR restriction fragment length polymorphism (RFLP) and 
Real time PCR methods.  
 
DNA samples were diluted with a DNAase free water in 96-well plate in a concentration of 
10ng/μl and stored at -20 °C. Genotypes were determined by RFLP and/or the Real-Time 
PCR approaches according to published methods or as recommended by manufacturer. The 
genotype results were confirmed by repetition of 70-80% of the samples. Negative controls 
were included in each reaction as quality control.  
The principle components to perform a PCR are primers, containing sequences 
complementary to the target region, DNA polymerase, which is necessary to enzymatically 
assemble a new strand of DNA, deoxynucleoside triphosphates (dNTPs), the building blocks 
from which the DNA polymerase synthesize a new DNA strand, buffer solution and usually 
divalent cation that helps the reaction (i.e. MgCl2).  
 
 
 
 
Components Final concentration 
Water 0.52X 
10x Buffer 1X 
MgCl2 solution 2.00 mM 
dNTPs 0.15mM 
Forward primer 0.13mM 
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Reverse primer 0.13mM 
Taq Polymerase 0.03 U/μl 
 
Table n.6 Reagent used to make a Real time RFLP master mix  
 
DNA was added at this mixture and the thermal cycling program was performed. The 
DNA is replicated in every cycles and the amount increased exponentially. After the 
amplification of the sequence of interest, the appropriate restriction enzyme was used to 
recognize the SNP, if present, and cut the DNA strand at this level, creating DNA fragments. 
The DNA restriction fragments, obtained after an overnight incubation at RT, were then 
separated electrophoretically at 200 Volt (V) for 30’, on home-made or pre-cast 
polyacrylamide gel 10% TBE (Bio Rad, Hercules, CA, USA). The DNA band was then 
visualized by using ethidium bromide, an intercalating agent commonly used as a fluorescent 
tag. When exposed to the UV ray, its fluorescence is 20-fold higher after binding DNA. The 
image of the gel was acquired using a digital photo camera connected to VERSADOC-4000 
(BIO RAD) and visualized with Quantity ONE software.  
There are three different situations that can emerge from the analysis: homozygosis for the 
WT, homozygosis for the SNP, and heterozygosis in which only one of the two alleles shows 
the SNP while the other allele is WT. 
Real time PCR or quantitative PCR (qRT-PCR) is a variation of the standard PCR 
technique used to quantify DNA or mRNA in a sample. Using sequence specific primers, the 
relative number of copies of a particular DNA or RNA sequence can be determined. 
Quantification of amplified product is obtained using fluorescent probes and specialized 
machines that measure the fluorescence while performing temperature changes needed for the 
PCR cycles. More specifically for our use, an allelic discrimination assay was used to detect 
variants of a single nucleic acid sequence. The presence of two primer/probe pairs in each 
reaction allows genotyping of the two possible variants of a polymorphism site in a target 
template sequence. One fluorescent dye detector is a perfect match to the WT (allele 1) and 
the other fluorescent dye detector is a perfect match with the SNP (allele 2). The allelic 
discrimination assay classifies unknown samples as: 1) homozygotes (sample having only 
allele 1 or 2) and 2) heterozygotes (sample having both allele 1 and 2). The allelic 
discrimination assay measures the change in the fluorescence of the dyes associated with the 
Taqman probes VIC
(R)
 and FAM
TM
 (Applied Biosystem, Foster City, CA), that selectively 
bind wt or SNP allele. The reaction was prepared using 10ng DNA, 20X or 40X Taqman 
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genotyping assay mix, 2X Taqman
(R)
 Universal Master Mix, No AmpErase
(R)
UNG and water 
RNAase free, for a total volume of 25μl. Each reaction was run in presence of a negative 
control, no template control (NTC). The analysis was performed using Real Time PCR 
System 7300 (Applied Biosystem). 
The allelic discrimination is characterized by three different steps: a) a pre-read run, using 
an allelic discrimination plate that measures the fluorescence at the baseline; b) an 
amplification run, using a standard curve plate document to generate Real-Time PCR data that 
consist in 95 °C for 10 min, 40 cycles at 92 °C for 15 sec, and 60 °C for 1 min; c) finally, an 
allelic discrimination run (post-read run), using the allelic discrimination plate to analyse the 
data and discriminate the genotype, after removing the baseline fluorescence. Allelic 
discrimination assays use the fluorogenic 5’ nuclease chemistry: fluorogenic probes, reporter 
(R), are used to detect specific PCR product as it accumulates during the PCR cycles. 
Additionally, the two probes at the 3’ end bind the quencher (Q) and a minor groove binder 
(MGB) to improve the probe affinity for the target DNA.  
The process could be described in 4 passages: a) polymerization: R and Q are attached to 
the 5’ and 3’ end of a probe; b) strand displacement, when both dyes are attached to the probe, 
R dye emission is quenched; c) cleavage, during each extension cycle: the DNA polymerase 
system cleaves the R dye from the probe; d) completion of polymerization: the R dye emits its 
characteristic fluorescence (Fig. 14). The signal is extremely specific because the probes do 
not interfere and the fluorescence signal is present only when the binding between probes and 
target DNA is correct. 
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Fig.14 Molecular basis for Taq-man based allelic discrimination processes: a) 
polymerization, b) strand displacement, c) cleavage, d) completion of polymerization. 
 
In the table below are reported the most important informations about the genes involved 
in the blood pressure regulation and lipid metabolism regulation, that we have analyzed in our 
population study. 
 
Table n.7 In this table are summarized the most important informations of our genes of 
interest: name of gene analyzed, singular nucleotide polymorphism variation, type of 
mutation (synonymous, and non-synonymous, etc…), primers ID, and the technique used to 
make the analysis.  
 
Name of Gene Primer assay SNP Mutation 
Method of 
analysis 
HMGCoA rs3846662 C/T  Real-Time PCR 
 rs3761740 A/C  Real-Time PCR 
KIF6 rs20455 C/T 
Missense 
Arg>Trp 
Real-Time PCR 
 rs9471077 A/G  Real-Time PCR 
 rs9462535 A/C  Real-Time PCR 
AGT rs699 C/T 
Missense  
Thr>Met 
Real-Time PCR 
AGTR1 rs5186 A/C  Real-Time PCR 
ACE 1r/1f 2r/2f  Inser/Del PCR RFLP 
CYP11B2 rs1799998 C/T  Real-Time PCR 
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6.7.3 Statistical analysis  
 
To assess the association between genetics characteristics and blood pressure, odds ratios 
(HR) with a 95% confidence interval (95% CI) were estimated by using a multivariate logistic 
regression analysis. Gender, age, cholesterolemia, body mass index, and waist circumference 
were used as covariates in addition to the genotype. 
The distribution of genotypes was tested for Hardy-Weinberg equilibrium (HWE), and 
qualitative data were analyzed using a X
2 
test. Similarly, allele and genotype frequencies in 
different groups were compared by X
2 
analysis. P-value was calculated between two 
subgroups of patients, hypertensive and not hypertensive, and alleles: no hypertension (allele 
2) vs hypertension (allele 0). The level of significance was set at P <0.05.  
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7.0 Results and discussion  
 
7.1 KCNJ5 resequencing  
 
To realize this study we started from an accurate selection of population patients affected 
by PA. Our cohort is constituted by 251 white patients, recruited between 1999 and 2006 at 
either the Greenslopes or the Princess Alexandra Hospitals in Brisbane, Australia. Peoples 
were accurately investigated for PA phenotype, indeed, several biochemical and physical 
parameters were measured. Patients were identified on baseline hypokalaemia, a basal upright 
renin of <4 mU/L and an aldosterone:renin ratio (ARR) of >150. The genetic study was 
approved by the Ethics Committee of University of Queensland, and informed consent for 
DNA collection and the genetic study was obtained from all participants. 
The entire coding and the flanking regions of KCNJ5 gene were resequenced in all patients 
and we identified 3 heterozygous missense mutations (Fig. 15), one of which (E246K) was 
novel. The other 2 are present on the dbSNP database (R52H, rs144062083; G247R, 
rs200170681) but were not validated. 
 
a.                      b.                        c. 
 
 
Fig.15 Sequence chromatograms for the 3 heterozygous missense mutations identified in the 
cohort. A) It is showed the missense mutation 155G>A that leads to an Arginine (R) – 
Histidine (H) substitution at the position 52 of peptide chain; B) it is showed the 736 G>A 
that leads to a Glutamate (E) – Lysine (K) substitution at the position 247; C) in the last panel 
is represented the substitution 739 G>A, responsible of Glycine (G) – (Arginine) substitution 
at the position 247 in the protein structure.  
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Mutations that we have identified are not present in the selectivity filter but in the immediate 
neighbouring parts as it is possible to see from the fig. 16 below. 
 
 
 
Fig.16 KCNJ5 potassium channel structure: all the mutations characterized in our 251 
population patient, R52H, E246K, Q282E, are not localized in the selectivity filter but in 
neighbouring region.  
 
Both mutations R52H and G247R resulted to be very rare, appearing just once (1/4296) in 
the National Heart and Lung Institute ESP6500, and G247R once (1/661) in the Clin-Seq-
SNP cohorts, respectively. Another 12 subjects in the cohort were identified as carriers for the 
rare non-synonymous SNP (population frequency of 2% [22/1075] in the 1000 genomes 
cohort), rs7102584 (C/G), which causes a charge-changing amino acidic substitution E282Q 
(Glutamate/Glutamine) in KCNJ5. The phenotype of the rs7102584 heterozygous carriers 
was similar to non-carriers (Table 8), although the values of their aldosterone:renin ratios 
clustered at the lower end of the distribution for the cohort. The subjects with the missense 
mutations were noticeably younger (Table 8). 
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Missense 
mutation 
Sex 
(F/M) 
Age at 
diagnosis 
Aldo 
(pmol/l) 
Renin 
(mU/L) 
ARR Diagnosis* 
(APA/BAH) 
R52H M 46 835 5.3 157 BAH 
E246K F 37 365 1.3 290 BAH 
G247R F 38 863 1.5 575 BAH 
    
    rs7102584 genotype 
GC  N=12 7/5 55.5±11 476±244 4.3±5.3 134±67 3/9 
GG N=239 132/107 56.0±9.4 688±446 4.9±4.7 273±321 54/185 
 
 
Table n.8 Clinical phenotype of the PA cohort by mutation and rs7102584 genotype 
 
 
 
7.2 Expression of WT and mutant form of KCNJ5 in Xenopus laevis, and its effect on the 
resting membrane potential  
 
The wild type and mutant forms of KCNJ5 potassium channel were expressed in Xenopus 
laevis oocytes to investigate their influence on the resting membrane potential. Before to 
analyse the mutant channel behaviour on aldosterone release the electrophysiological activity 
of these mutations has been previously studied. Two electrode voltage clamp was realized as 
above in two most important solution, high Na
+
 and low K
+
 and vice versa.  
From the electrophysiological studies resulted that two of three missense mutations, R52H 
and E246K , and the coding SNP variant, E282Q, widely depolarized the resting membrane 
potential of oocytes in a high Na
+
 bathing solution. Furthermore, it has been seen that the 
other missense mutation, G247R, did not modify the resting membrane potential, indeed its 
effect is completely comparable with that of the WT channel, as you can see in fig. 17 below. 
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Fig.17 Different activity of KCNJ5 WT and mutant forms on the resting membrane potential 
variation in Xenopus laevis oocytes. Great difference has been observed between EK, RH, EQ 
and WT form (mean±SEM; n=6). It has also been seen that the missense mutation G247R did 
not exert any effects on this parameter. *Significantly different from WT, P<0.01. 
 
The steady-state current–voltage curves were generated with high-Na+ and low K+ (92 
mmol/L Na
+
; 2 mmol/L K
+
) with then high- K
+
 (45 mmol/L K
+
; 0 mmol/L Na
+
) in the bath 
solutions to look for evidence of altered Na
+
 permeability. 
As you can see from the Fig. 17 WT KCNJ5 shows typical inward-rectification in the high 
extracellular K
+
 concentration, while changing the bathing solution with a high Na
+
 
concentration it was not possible to measure any passage of current. Also as expected, the WT 
Ba-sensitive K
+
 current was almost completely blocked by the specific Kir channel inhibitor 
tertiapin-Q (Fig. 18). A different result has been obtained with the missense mutations 
E246K, R52H, and the SNP E282Q. Indeed, the R52H channel showed no clear rectification, 
and the I-V curve was broadly unchanged by switching to a high extracellular Na
+
 solution 
confirming a substantial loss of K
+
 selectivity in this channel. Furthermore, R52H and E246K 
KCNJ5 mutant forms were not blocked by the specific inhibitor tertiapin-Q, unlike the WT 
channel, demonstrating that amino acidic substitution may induce a conformational change of 
the structure reducing the interaction between antagonist and its site.  
The E246K mutation behaved similarly to R52H. However, the G247R mutation behaved 
like the WT channel with clear rectification, and almost no detectable current in the high-Na
+
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bathing solution (Figure 17). The E282Q channel behaved like the WT channel in the high 
extracellular K
+
; however, switching to the high-Na
+
 solution left the I-V essentially 
unchanged again, suggesting a substantial loss of K+ selectivity. 
 
 
High extracellular K
+
 concentration             High extracellular Na
+ 
concentration 
 
 
 
 
Fig.18 Current-voltage curves of WT and mutant forms of KCNJ5 potassium channel 
obtained from clamped Xenopus laevis oocytes in two different bathing solution: high K+ and 
low Na
+
( right) and low K
+
 and high Na
+
 concentration. The absence or presence of KCNJ5 
antagonist, tertiapin-Q (50nM), are indicated respectively by ● and ○ (mean±SEM; n=6-8).  
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7.3 Aldosterone release from transiently transfected H295R cells  
 
Once missense mutations and SNP were identified, they were electrophysiologically 
characterized in the Xenopus oocytes. Furthermore, human adrenocortical cells, H295R, were 
transiently transfected with KCNJ5 plasmid cDNA opportunely site-mutated with the aim of 
studying how these genetic variations could affect basal and AG-II-stimulated aldosterone 
release. Human H295R cell line releases aldosterone either in basal either under AG-II 
stimulation condition and currently provides the most robust in vitro model for the human 
zona glomerulosa study.  
H295R cells were transfected with pCMV6-AC-GFP empty vector as a negative control, 
and with the previously identified mutation, deletion del157, as a positive control. 
Unstimulated H295R cells transiently expressing the variant channels showed an upward 
trend in basal aldosterone release; however, this was only significant for E246K and the 
delI157 (Figure 19). In contrast, all the variants significantly increased ATII-induced 
aldosterone release. The E282Q variant produced a modest ≈1.5-fold increase, whereas the 
missense mutations produced a larger increase (2–3-fold) similar to the delI157 KCNJ5 
control.  
 
 
 
 
Fig.19 Aldosterone release from H295R transiently transfected cells with empty vector or one 
of the KCNJ5 mutant forms. In the panel A are reported results of aldosterone release under 
basal condition; panel B shows the AT-II (10nM)-stimulated aldosterone secretion; panel C 
shows the difference between AT-II stimulated and basal aldosterone release. These results 
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are reported as mean±SEM; n=6. *P<0.05 and #P<0.01 vs empty vector control.  
 
In contrast to the other mutations, the G247R missense mutation that behaved 
indistinguishably from the WT channel in the oocytes did not affect basal or ATII-induced 
aldosterone release from H295R cells (Fig. 20). 
 
 
 
Fig.20 Aldosterone release from H295R cells transfected with empty vector (negative 
control), del157 (positive control) and the missense mutation G247R. This missense mutation 
behaves similar to the negative control, empty vector, and do not produce any alteration in 
terms of membrane depolarization and aldosterone secretion. * P<0.01 versus control. 
 
 
7.4 KCNJ5 mutations and their effects on cellular viability  
 
To add more information about the pathophysiological role of KCNJ5 potassium channel 
wt and mutant forms, we transfected the H295R cells as above and checked their viability 48h 
after transfection. To date, it is quite clear as alterations in ions composition in both 
intracellular and extracellular environment may be cause of cellular death. It was observed 
that all of the mutant forms were electrophysiologically active, and reduced cellular viability.  
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Fig.21 Viability of H295R cells transfected with WT and electrophysiologically active mutant 
forms of KCNJ5 potassium channel. Cell viability has been evaluated 48h after transfection; 
results are indicated as fold changes of optical density (OD) versus control (WT or Empty 
vector). Results are an average of 4 different experiments. *P<0.05 versus WT or empty 
vector control. 
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7.5 Allelic frequency and genotype distribution in the Brisighella population 
 
Genetic analysis started with the evaluation of the allele frequency of each singular SNPs 
investigated in our cohort (Table 9). The frequency was considered in both hypertensive and 
not hypertensive groups for a total number of 1566 patients.  
 
Table n.9 Allele frequency of polymorphisms in hypertensive and not hypertensive patients 
within the Brisighella population; P<0.05 no Hypertension (allele 2) vs Hypertension (allele 
0);OR was calculated with a confidence interval of 95%. 
 
Genotypes number % number (%) P-value OR (95%CI) * 
 Hypertension 
No 
Hypertension 
  
AGT rs699 
0 
2 
 
511 (47.1) 
575 (52.9) 
 
907 (44.3) 
1139 (55.7) 
 
0.004 
 
1.294 (1.087-1.541) 
1 
AGTR1 rs5186 
0 
2 
 
737 (68) 
347 (32) 
 
1442 (70.5) 
604 (29.5) 
 
0.052 
 
0.831 (0.689-1.002) 
1 
CYP11B2 rs1799998 
0 
2 
 
644 (59.3) 
442 (40.7) 
 
1108 (54.1) 
940 (45.9) 
 
0.001 
 
1.331 (1.117-1.586) 
KIF6 rs20455 
0 
2 
 
687 (63.3 
399 (36.7) 
 
1302 (63.6) 
746 (36.4) 
 
0.333 
 
0.915 (0.765-1.095) 
1 
KIF6 rs9471077 
0 
2 
 
425 (39.1) 
661 (60.9) 
 
785 (38.3) 
1265 (61.7) 
 
0.524 
 
1.059 (0.887-1.265) 
1 
KIF rs9462535 
0 
2 
 
418 (38.5) 
668 (61.5) 
 
784 (38.2) 
1266 (61.8) 
 
0.636 
 
1.044 (0.874-1.247) 
1 
HMGCoA 
rs3761740 
0 
2 
 
983 (90.5) 
103 (9.5) 
 
1849 (90.2) 
201 (9.8) 
 
0.567 
 
1.089 (0.812-1.461) 
1 
HMGCoA rs384662 
0 
2 
 
592 (54.4) 
496 (45.6) 
 
1107 (54) 
941 (46) 
 
0.340 
 
1.088 (0.915-1.294) 
1 
* Odds ratio (OR) age and gender adjusted 
 
Allele frequency is one of the most important genetic parameters to be considered. Each 
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singular gene has a different distribution frequency among the same population and several 
human populations. Thus, individual can show different combinations of the variants with a 
different frequency. These levels of variation in DNA sequence has important implications for 
the individual medicine practice, for public health aspects of medicine, and for research 
design and data interpretation. The allele frequency can be considered as a measure of 
susceptibility to develop a pathology. In this regard, scientific communities need to know not 
only about the existence of DNA sequence variants but also the frequencies of those variants 
within several populations.  
 
 
7.5.1 Distribution of our polymorphism in hypertensive and non-hypertensive individuals 
 
For the genotype study we firstly started with the Hardy-Weinberg equilibrium evaluation, 
and its relative P-value was reported in the table below (Table 11). As it is possible to see, 
deviation from the HWE was observed for AGT, KIF6 (rs9471077), and for KIF6 (9462535). 
Because the genotypes of the 90% of duplicate samples included in the sample set agreed with 
each other, genotyping errors could be excluded. Deviation from the HWE leads to suppose 
that the statistically significant values found in the polymorphism distribution analysis are 
purely due to the case. Indeed, the allele frequency in a small population like our can be 
radically altered by random events; thus, the final results, even if significant, might be 
considered with particular attention. However, in this case the X
2
 probability test seems to 
confirm the accuracy of our results, since its values are not small enough to reject the 
hypothesis.  
 
Table n.10 Comparison of Hardy-Weinberg P value between hypertensive and not 
hypertensive patients. P-value of HWE is reported and considered significant if <0.05. 
Accuracy of results was checked with the X
2
 test. Deviation from the HWE can be seen for the 
only genes AGT and KIF6 rs9471077, and KIF6 rs9462535, whose P-values are 0.03, 0.005 
and 0.006 respectively. 
 
Genotypes 
% n 
distribution 
HWE  
P-value 
% n distribution 
HWE  
P-value 
 Hypertension  No Hypertension  
AGT rs699 
0 
 
122 (22.4) 
0.759 
 
184 (18) 
0.03 
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1 
2 
 
267 (49.2) 
154 (28.4) 
 
539 (52.7) 
300 (29.3) 
 
AGTR1 rs5186 
0 
1 
2 
 
 
256 (47.3) 
225 (41.5) 
61 (11.2) 
 
0.281 
 
497 (48.6) 
448 (43.8) 
78 (7.6) 
 
0.094 
CYP11B2 
rs1799998 
0 
1 
2 
 
 
 
194 (35.8) 
256 (47.1) 
93 (17.1) 
 
0.587 
 
 
297(29) 
514 (50.2) 
213 (20.8) 
 
0.732 
KIF6 rs20455 
0 
1 
2 
 
 
220 (40.5) 
247 (45.5) 
76 (14) 
 
0.618 
 
402 (39.3) 
498 (48.6) 
124 (12.1) 
 
0.109 
KIF6 
rs9471077 
0 
1 
2 
 
 
90 (16.6) 
245 (45.1) 
208 (38.3) 
 
0.218 
 
129 (12.6) 
527 (51.4) 
369 (36) 
 
0.005 
KIF rs9462535 
0 
1 
2 
 
 
87 (16) 
244 (45) 
212 (39) 
0.235 
 
129 (12.6) 
526 (51.3) 
370 (36.1) 
0.006 
HMGCoA 
rs3761740 
0 
1 
2 
 
 
444 (81.8) 
95 (17.5) 
4 (0.7) 
 
 
0.6584 
 
 
833 (81.3) 
183 (17.8) 
9 (0.9) 
 
 
0.763 
HMGCoA 
rs384662 
0 
1 
2 
 
 
 
157 (28.9) 
278 (51.1) 
109 (20) 
 
 
 
0.483 
 
 
312 (30.4) 
483 (47.2) 
229 (22.4) 
 
 
0.107 
 
Besides the allele frequency, polymorphic distribution of each singular SNPs has been also 
evaluated in our population (Table 10). The polymorphic distribution gives an idea of how 
much diffused is a gene, within a population, as homozygous WT, heterozygous, or 
homozygous SNP, that we conventionally named 0, 1, and 2 respectively. Amongst the three 
different combinations, homozygous WT, heterozygous, and homozygous SNP, WT is 
considered the negative control. 
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Table n.11 Distribution of SNPs within our cohort, divided in two groups, hypertensive and 
non-hypertensive. Through a statistical approach, a correlation between SNP and the 
hypertensive phenotype was evaluated, and results were considered significant for a P<0.05.  
 
Genotypes 
% n 
distribution 
% n 
distribution 
P-value OR (95%CI) * 
 
Hypertension 
No 
Hypertension 
  
AGT rs699 
0 
1 
2 
 
0 
1+2 
 
122 (22.4) 
267 (49.2) 
154 (28.4) 
 
122 (22.4) 
421 (77.6) 
 
184 (18) 
539 (52.7) 
300 (29.3) 
 
184 (18) 
839 (82) 
 
 
0.006 
0.002 
 
 
0.002 
 
1 
0.633 (0.458-0.877) 
0.562 (0.392-0.806) 
 
1 
0.607 (0.446-0.827) 
AGTR1 rs5186 
0 
1 
2 
 
0 
1+2 
 
256 (47.3) 
225 (41.5) 
61 (11.2) 
 
256 (47.3) 
286 (52.7) 
 
497 (48.6) 
448 (43.8) 
78 (7.6) 
 
497 (48.6) 
526 (51.4) 
 
 
0.305 
0.053 
 
 
0.129 
 
1 
1.145 (0.884-1.485) 
1.526 (0.995-2.342) 
 
1 
1.210 (0.946-1.547) 
CYP11B2 
rs1799998 
0 
1 
2 
 
0 
1+2 
 
 
194 (35.8) 
256 (47.1) 
93 (17.1) 
 
194 (35.8) 
349 (64.2) 
 
 
297(29) 
514 (50.2) 
213 (20.8) 
 
297(29) 
727 (71) 
 
 
 
0.028 
0.002 
 
 
0.004 
 
 
1 
0.732 (0.554-0.967) 
0.574 (0.403-0.819) 
 
1 
0.683 (0.526-0.888) 
KIF6 rs20455 
0 
1 
2 
 
0 
1+2 
 
220 (40.5) 
247 (45.5) 
76 (14) 
 
220 (40.5) 
323 (59.5) 
 
402 (39.3) 
498 (48.6) 
124 (12.1) 
 
402 (39.3) 
622 (60.7) 
 
 
0.769 
0.163 
 
 
0.812 
 
1 
0.961 (0.738-1.251) 
1.316 (0.895-1.937) 
 
1 
1.031 (0.803-1.322) 
KIF6 rs9471077 
0 
1 
2 
 
0 
1+2 
 
90 (16.6) 
245 (45.1) 
208 (38.3) 
 
90 (16.6) 
453 (83.4) 
 
129 (12.6) 
527 (51.4) 
369 (36) 
 
129 (12.6) 
896 (87.4) 
 
 
0.022 
0.186 
 
 
0.047 
 
1 
0.655 (0.456-0.940) 
0.778 (0.536-1.129) 
 
1 
0.707 (0.502-0.995) 
KIF rs9462535 
0 
1 
2 
 
0 
1+2 
 
87 (16) 
244 (45) 
212 (39) 
 
87 (16) 
456 (84) 
 
129 (12.6) 
526 (51.3) 
370 (36.1) 
 
129 (12.6) 
896 (87.4) 
 
 
0.036 
0.254 
 
 
0.075 
 
1 
0.677 (0.470-0.975) 
0.805 (0.554-1.169) 
 
1 
0.732 (0.519-1.032) 
HMGCoA 
rs3761740 
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0 
1 
2 
 
0 
1+2 
444 (34.8) 
95 (34.2) 
4 (0.7) 
 
444 (34.8) 
99 (65.2) 
833 (81.3) 
183 (17.8) 
9 (0.9) 
 
833 (81.3) 
192 (18.7) 
 
0.604 
0.785 
 
 
0.577 
1 
0.918 (0.665-1.268) 
0.831 (0.221-3.130) 
 
1 
0.914 (0.666-1.254) 
HMGCoA 
rs384662 
0 
1 
2 
 
0 
1+2 
 
 
157 (28.9) 
278 (51.1) 
109 (20) 
 
157 (28.9) 
387 (71.1) 
 
 
312 (30.4) 
483 (47.2) 
229 (22.4) 
 
312 (30.4) 
712 (69.6) 
 
 
 
0.781 
0.326 
 
 
0.552 
 
 
1 
0.960 (0.722-1.277) 
0.840 (0.593-1.190) 
 
1 
0.922 (0.705-1.205) 
* Odds ratio (OR) age and gender adjusted 
With regard to the analysis of genetic polymorphism distribution, comparing the presence of 
at least one variant allele (heterozygous or homozygous for the SNP) in both non-
hypertensive and hypertensive groups, we observed a statistically significant difference in 
AGT, CYP11B2 (rs1799998) and KIF6 (rs9471077) (Table 10).  
Afterwards, we moved our attention on the hypertensive group of individuals, and we 
recognized a limited group of subjects (470 individuals) undergoing antihypertensive therapy. 
We further divided this group in two subgroups, i.e. responder and non-responder, and then, 
we tried to find a correlation between the pharmacological response and the genetic 
characteristics. Pharmacological response was corrected for the age, sex, body mass index 
(BMI) and cholesterolemia.  
 
Table n.12 In this table is reported the SNP distribution of candidate genes within the 
hypertensive population undergone to a drug therapy. Significant P value<0.05 was 
calculated for no responder vs responder ( allele 0 vs 1 and 0 vs 2). 
 
Genotypes number % number (%) P-value OR (95%CI) * 
 
Drug therapy 
Responder 
Drug therapy 
No responder 
  
AGT rs699 
0 
1 
2 
 
9 (20.5) 
26 (59) 
9 (20.5) 
 
94 (22) 
213 (49.9) 
120 (28.1) 
 
 
0.550 
0.655 
 
1 
1.277 (0.573-2.845) 
0.802 (0.303-2.118) 
AGTR1 rs5186 
0 
1 
2 
 
19 (43.2) 
21 (47.7) 
4 (9.1) 
 
207 (48.6) 
166 (39) 
53 (12.4) 
 
 
0.325 
0.699 
 
1 
1.391 (0.721-2.681) 
0.800 (0.259-2.472) 
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CYP11B2 rs1799998 
0 
1 
2 
 
10 (22.7 ) 
26 (59.1) 
8 (18.2) 
 
163 (38.2) 
194 (45.4) 
70 (16.4) 
 
 
0.050 
0.216 
 
1 
2.143 (1.000-4.591) 
1.847 (0.698-4.886) 
KIF6 rs20455 
0 
1 
2 
 
16 (36.4) 
21 (47.7) 
7 (15.9) 
 
174 (40.7) 
198 (46.4) 
55 (12.9) 
 
 
0.723 
0.535 
 
1 
1.312 (0.570-2.245) 
1.349 (0.524-3.471) 
KIF6 rs9471077 
0 
1 
2 
 
7 (15.9) 
22 (50) 
15 (34.1) 
 
69 (16.2) 
194 (45.4) 
164 (38.4) 
 
 
0.785 
0.858 
 
1 
1.134 (0.459-2.800) 
0.917 (0.357-2.357) 
KIF rs9462535 
0 
1 
2 
 
8 (18.2) 
21(47.7) 
15 (34.1) 
 
65 (15.2) 
193 (45.2) 
169 (39.6) 
 
 
0.811 
0.508 
 
1 
0.899 (0.375-2.153) 
0.736 (0.297-1.826) 
HMGCoA 
rs3761740 
0 
1 
2 
 
 
36 (81.8) 
8 (18.2) 
0 (0.0) 
 
 
354 (82.9) 
70 (16.4) 
3 (0.7) 
 
 
 
0.735 
na 
 
 
1 
1.152 (0.507-2.620) 
na 
HMGCoA rs384662 
0 
1 
2 
 
8 (18.2) 
25 (56.8) 
11 (25) 
 
127 (29.7) 
218 (50.9) 
83 (19.4) 
 
 
0.157 
0.124 
 
1 
1.819 (0.794-4.163) 
2.12 (0.813-5.534) 
* OR was adjusted for age, sex, cholesterolemia, and BMI 
 
No correlation has been found between the considered SNPs and a positive response to the 
antihypertensive drug therapy as it is possible to see from the P values reported above (table 
12). 
We have repeated the same analysis as above, correcting the pharmacological response for the 
same variables age, sex, cholesterolemia, but changing the BMI with the waist circumference. 
Obesity is a well-documented risk factor for morbidity and mortality; however, the 
association between body fat and pathology has not been fully elucidated. Even though, body 
mass index is the most common measure of obesity, it does not reflect body shape. Moreover, 
it can be e misleading, thus, waist circumference, a more accurate measure of the distribution 
of body fat, has been shown to be more strongly associated with morbidity and mortality. For 
the same reasons, we decided to correct our results for BMI and waist circumference. 
However, in both cases we didn’t see any correlation between the genetic characteristic and 
the effect of antihypertensive therapy (Table 13). 
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Table n.13 Similarly to the analysis as above, in this table is reported the SNP distribution of 
candidate genes within the hypertensive population undergone to a drug therapy. Significant 
P value<0.05 was calculated for no responder vs responder ( allele 0 vs 1 and 0 vs 2). 
 
Genotypes number % number (%) P-value OR (95%CI) * 
 
Drug therapy 
Responder 
Drug therapy 
No responder 
  
AGT rs699 
0 
1 
2 
 
9 (20.5) 
26 (59) 
9 (20.5) 
 
94 (22) 
213 (49.9) 
120 (28.1) 
 
 
0.622 
0.630 
 
1 
1.224 (0.547-2.738) 
0.787 (0.298-2.081) 
AGTR1 rs5186 
0 
1 
2 
 
19 (43.2) 
21 (47.7) 
4 (9.1) 
 
207 (48.6) 
166 (39) 
53 (12.4) 
 
 
0.384 
0.705 
 
1 
1.342 (0.691-2.607) 
0.804 (0.260-2.483) 
CYP11B2 rs1799998 
0 
1 
2 
 
10 (22.7 ) 
26 (59.1) 
8 (18.2) 
 
163 (38.2) 
194 (45.4) 
70 (16.4) 
 
 
0.058 
0.206 
 
1 
2.092 (0.975-4.491) 
1.874 (0.708-4.956) 
KIF6 rs20455 
0 
1 
2 
 
16 (36.4) 
21 (47.7) 
7 (15.9) 
 
174 () 
198 () 
55 () 
 
 
0.846 
0.507 
 
1 
1.071 (0.536-2.141) 
1.376 (0.536-3.536) 
KIF6 rs9471077 
0 
1 
2 
 
7 (15.9) 
22 (50) 
15 (34.1) 
 
69 (16.2) 
194 (45.4) 
164 (38.4) 
 
 
0.872 
0.867 
 
1 
1.077 (0.434-2.674) 
0.923 (0.359-2.372) 
KIF rs9462535 
0 
1 
2 
 
8 (18.2) 
21(47.7) 
15 (34.1) 
 
65 (15.2) 
193 (45.2) 
169 (39.6) 
 
 
0.705 
0.503 
 
1 
0.844 (0.350-2.033) 
0.733 (0.295-1.819) 
HMGCoA 
rs3761740 
0 
1 
2 
 
36 (81.8) 
8 (18.2) 
0 (0.0) 
 
354 (82.9) 
70 (16.4) 
3 (0.7) 
 
 
0.668 
na 
 
1 
1.198 (0.525-2.736) 
na 
HMGCoA rs384662 
0 
1 
2 
 
8 (18.2) 
25 (56.8) 
11 (25) 
 
127 (29.7) 
218 (50.9) 
83 (19.4) 
 
 
0.102 
0.080 
 
1 
2.062 (0.865-4.913) 
2.426 (0.899-6.547) 
* OR was adjusted for age, sex, cholesterolemia, and waist circumference 
 
Finally, we moved our attention on the pathological familial history, taking in 
consideration several diseases such as hypercholesterolemia, hypertension, acute myocardial 
infarction, and ictus. We investigated if in the both hypertensive subgroups, treated or not, 
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there was a familiarity between hypertension and the pathological conditions above 
mentioned. Also these last analyses are characterized by the lack of any statistically 
significant value, at least for ictus, hypercholesterolemia, and acute myocardial infarction, 
whereas the hypertension familiarity was confirmed into the drug-untreated subgroup. A 
borderline P-value was obtained for the hypercholesterolemia into the drug-treated subgroup, 
but not into the untreated subgroup.  
 
Table n.14 Familiarity was considered in the drug-treated subgroup referring to several 
pathological condition such as hypercholesterolemia, hypertension, acute myocardial 
infarction, and ictus. A borderline value was seen for the only hypercholesterolemia and not 
for the other conditions. P-value<0.05 was considered significant.  
 
 IPERTENSIONE   
 SI NO TOT P-value 
Hypercholesterolemia 
NO 
 
 
SI 
 
35 (11.2) 
(79.5) 
 
9 (5.7) 
(20.5) 
 
278 (88.8) 
(65.1) 
 
149 (94.3) 
(34.9) 
 
313 (100) 
(66.5) 
 
158 (100) 
(33.5) 
 
 
 
 
 
0.053 
Hypertension 
NO 
 
 
SI 
 
21 (12.1) 
(47.7) 
 
23 (7.7) 
(52.3) 
 
152 (87.9) 
(35.6) 
 
275 (92.3) 
(64.4) 
 
173 (100) 
(36.7) 
 
298 (100) 
(63.3) 
 
 
 
 
 
 
0.112 
Acute myocardial 
infarction 
NO 
 
 
SI 
 
 
33 (9.4) 
(75.0) 
 
11 (9.2) 
(25.0) 
 
 
318 (90.6) 
(74.5) 
 
109 (90.8) 
(25.5) 
 
 
351 (100) 
(74.5) 
 
120 (100) 
(25.5) 
 
 
 
 
 
 
0.939 
Ictus 
NO 
 
 
 
32 (8.7) 
(72.7) 
 
 
336 (91.3) 
(78.7) 
 
 
368 (100) 
(78.1) 
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SI 12 (11.7) 
(27.3) 
91 (88.3) 
(21.3) 
103 (100) 
(21.9) 
 
0.362 
 
 
 
Table n.15 Familiarity was considered into the untreated subgroup referring to several 
pathological condition such as hypercholesterolemia, hypertension, acute myocardial 
infarction, and ictus. Hypertension familiarity was confirmed. P-value<0.05 was considered 
significant. 
 
 IPERTENSIONE   
 SI NO TOT P-value 
Hypercholesterolemia 
NO 
 
 
SI 
 
614 (93.3) 
(57.8) 
 
413 (93.7) 
(40.2) 
 
44 (6.7) 
(61.1) 
 
28 (6.4) 
(38.9) 
 
658 (100) 
(59.9) 
 
441 (100) 
(40.1) 
 
 
 
 
 
0.824 
Hypertension 
NO 
 
 
SI 
 
585 (95.0) 
(57.0) 
 
442 (91.5) 
(43.0) 
 
31 (5.0) 
(43.0) 
 
41 (8.5) 
(57.0) 
 
616 (100) 
(56.1) 
 
483 (100) 
(43.9) 
 
 
 
 
 
0.022 
Acute myocardial 
infarction 
NO 
 
 
SI 
 
 
860 (94.0) 
(83.7) 
 
167 (90.8) 
(16.3) 
 
 
55 (6.0) 
(76.4) 
 
17 (9.2) 
(23.6) 
 
 
915 (100) 
(83.3) 
 
184 (100) 
(16.7) 
 
 
 
 
 
 
0.106 
Ictus 
NO 
 
 
SI 
 
895 (93.8) 
(87.2) 
 
132 (91.0) 
(12.8) 
 
59 (6.2) 
(81.9) 
 
13 (9.0) 
(18.1) 
 
954 (100) 
(86.8) 
 
145 (100) 
(13.2) 
 
 
 
 
 
0.207 
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7.6 Discussion of results  
 
7.61 KCNJ5 results  
 
We have resequenced the entire coding and flanking regions of KCNJ5 gene, expressing 
for the homonymous potassium channel in our 251 PA population patients. In this study we 
have characterized using an electrophysiological and biochemical methods 3 heterozygous 
missense mutations: R52H, E246K, G247R; one of these, E246K, was described for the first 
time. Furthermore, an infrequent SNP, E282Q, rs7102584 in some 5% of the cohort (12/251), 
has been identified and characterized in the similar way to others. According to our 
knowledge, this is the first study, that try to characterize the infrequent non-synonymous SNP 
E282Q, therefore, our demonstration that the Q282 channel variant encoded by this SNP does 
affect KCNJ5 behaviour in in vitro model is exciting and completely novel. We have shown 
that two of the missense mutations, R52H and E246K, influence the K
+
 ions flow across the 
membrane and affect in this way the resting membrane potential in the Xenopus oocytes 
system and aldosterone release from the human H295R cell line. It has been seen that all these 
mutations occur in region of channel, whose amino acid sequence is highly conserved in 
evolution over the species, from the fly to the human, suggesting a key role in the cytoplasmic 
ionic composition. However, it has well been demonstrated that these mutations do not occur 
in the selectivity filter region, whose importance has been widely described, but in the other 
domains. Taken together, these results indicate for the first time that not only mutations that 
lie in the selectivity filter but also outside this important region may alter KCNJ5 behaviour 
and may be associated with sporadic PA.  
To realize this study we employed two in vitro approaches based on using of Xenopus 
oocytes eggs and human H295R adenocarcinoma cell line. The human H295R cell line is a 
well-established model for the human zona glomerulosa cell, and it expresses the KCNJ5 
channel. Expression of a typical selectivity mutant KCNJ5 channel in the H295R cell has 
been reported to depolarize the cell and enhance ATII-induced aldosterone synthesis and 
release (Fig.19). We saw the same increase in ATII-induced aldosterone release with another 
selectivity mutant, delI157, and in both the E282Q SNP and the 2 missense mutations that had 
altered channel behaviour in the oocytes (Fig. 19). Expressing the KCNJ5 channels in the 
oocytes gave a similar picture. The missense mutations and the E282Q channel behaved like 
typical selectivity mutants and depolarized the oocytes in high-Na
+
 as we reported previously 
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with the typical delI157 selectivity filter mutant (Fig. 18). All of the germline mutations 
associated with FH-III and the somatic mutations within aldosteronomas, reported to date, 
have been localized within the selectivity filter of KCNJ5. This is a small but important 
domain in the protein that is expressed extracellularly and is highly conserved across the 
inward-rectifying K
+
 channels. The effect of amino acid substitution within it is well 
understood, and the PA-associated mutations in KCNJ5 typically cause a marked reduction in 
K
+
 selectivity. Hence the channels show a remarkable inward Na
+
 current, which is thought to 
depolarize the zona glomerulosa cells triggering increased aldosterone synthesis and release. 
The discovery that a mutation in or near the selectivity filter of KCNJ5 K
+
 channel is 
associated with a familial form of PA provides a novel molecular mechanism for the 
autonomous secretion of aldosterone. It is striking then that 2 of the KCNJ5 missense 
mutations we identified in our cohort and the SNP variant Q282 show substantial currents in a 
high-Na
+
 solution. The R52H and E246K channels also lack the typical inward-rectification, 
which is striking because this is a defining feature of Kir channels with K
+
 tending to move 
into the cells more easily inwards through the channel rather than in the reverse direction 
outwards. We reported similar behaviour before in a novel selectivity filter mutation in 
KCNJ5 delI157. Both in this earlier report and here (Fig. 17), the discontinuous I-V plot 
typical of a Kir channel is converted to a linear ohmic resistor in these mutants. Although the 
selectivity filter is the narrowest part of the channel and bears the important K
+
 signature 
(TXGYG) at least in glomerulosa cells, it is not the only determinant of selectivity in Kir 
channels. For example, channels mediating the pacemaker current (if) in the heart have this 
canonical signature but show almost no selectivity for K
+
 over Na
+
, and mutations in both the 
transmembrane helix (M2) and the cytoplasmic domains of Kir channels have been reported 
to affect selectivity. Although the mechanisms for these substitutions are still poorly 
understood, they are thought to involve electrostatic effects, which are relevant to the E282Q 
and E246K mutations as they both introduce positive charges in the pore region on the 
cytoplasmic side of the channel. It is also relevant that R52H and E246K channels both lose 
inward-rectification and selectivity because of amino acid substitution. However, better 
structural data on the cytoplasmic side of the GIRK4 pore are needed to resolve how these 
substitutions might alter the structure of the pore because currently there is only 
crystallographic data from the closely related GIRK2 channel.  
Findings obtained from this study are in line with others already published, confirming that 
mutation of KCNJ5 potassium channel are responsible of selectivity loss. In addition, our 
results for the first time demonstrate that not only mutation in the selectivity filter but also 
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near this region are involved in this pathological mechanism. They highlight the importance 
of KCNJ5 potassium channel in the pathophysiology of PA and specifically for its common 
sporadic form. The missense mutations and rare SNP variant we have reported in this study 
emphasize that the molecular genetics of PA is an unfinished story.  
Despite the information that we currently have about the KCNJ5 activity and functionality, 
more informations have to be gained to establish whether other SNP variants in KCNJ5 also 
have a role to play in PA and what impact germline variation in KCNJ5 might have on 
subjects with APAs carrying somatic mutations in the same gene. Furthermore, other studies 
have to be done to better clarify some molecular aspects that are still understood. It has been 
already demonstrated that KCNJ5 receptors, isolated from heart and pituitary gland, have 
been seen to be functionally modulated by G-protein subunits of G-coupled protein 
cholinergic M2 and dopaminergic D2 receptors respectively; thus, it could be reasonable to 
hypothesize the same behaviour in the adrenal gland. Indeed, from several line of evidences 
resulted that free DA is present in this area as well as D2 and D4 dopaminergic receptors have 
been isolated. However, there are no reports which prove this conclusively in the human 
adrenal glands. Another important issue that needs to be studied in deep is how KCNJ5 
mutant forms modulate the Ca
2+
 ion flow and its cytoplasmic concentration. Furthermore, it is 
important to clarify the role that this important second messenger exerts on aldosterone 
release, cellular vitality and growing, as conflicting results have been already published.  
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7.6.2 Brisighella results and conclusion 
 
In the similar way of the KCNJ5 study, to realize the second part of this work, we started 
from a population, constituted by 1546 randomized Caucasian volunteers, sampled for the 
Brisighella Heart Study between 2008-2009. We divided our population in two subgroups, 
non-hypertensive and hypertensive according to blood pressure values. The latter was in turn 
divided in further two subgroups, responder and non-responder, according to the 
antihypertensive therapy responsiveness. Since the population was randomly recruited we had 
a very heterogeneous phenotype with different biochemical parameters, and this represent an 
important limitation of the study. All the DNA samples were genotyped for the considered 
SNPs.  
Firstly, we have investigated the allelic distribution of each gene, which can be present as 
homozygous WT, heterozygous, or homozygous SNPs. From this first analysis statistically 
significant P-value has been found in the only two genes, AGT (rs699) and 
CYP11B2(1799998), and quantified as 0.004 and 0.001 respectively.  
As it is possible to see from the table 9, the allelic frequency of homozygous SNPs and 
heterozygous is much more represented in the not-hypertensive than the hypertensive 
subgroup, in both genes AGT and CYP11B2. These results indicate that the presence of at 
least one polymorphic allele has a protective effect against the pathological condition 
considered. Furthermore, taking in consideration the allelic frequency within each subgroup, 
for AGT it is possible to highlight that the homozygous SNP is much more abundant than the 
WT in both subgroups, whereas with regard to CYP11B2 the homozygous WT allele is more 
abundant than the heterozygous and homozygous SNP. This means that for the AGT gene the 
SNP could be associated with a non-pathological phenotype referring to the hypertension 
condition, whereas for the CYP11B2 gene, there is an opposite situation with a more diffused 
WT allele in hypertensive individuals. 
Similarly to the allele frequency, also in the polymorphism distribution analysis it is 
possible to highlight a wider distribution of the polymorphic allele than the WT allele within 
the same group; furthermore, a greater presence of the polymorphic allele in non-hypertensive 
group than the hypertensive it has been observed. Taken together these results, indicate that in 
this population study the presence of at least one polymorphic allele, for the AGT(rs699), 
CYP11B2 (rs1799998) and KIF6 (rs9471077) genes, is not associated with an hypertensive 
phenotype. Thus, in light of these results it is possible to say that our results are not in 
accordance with the most part of studies already published. To date, it is well known that 
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AGT polymorphism (rs699) is responsible of a Cytosine (C) – Thymine (T) substitution in the 
position 699, that leads to a missense mutation M235T (Methionine – Threonine) in the 
protein structure. From several lines of evidence resulted that individuals homozygous for the 
T allele show a higher level of angiotensinogen than the homozygous M allele, and this AGT 
concentration may consistently affect the kinetic of angiotensin I generation.
150
 However, 
conflicting results and data about the correlation of this SNP with hypertension and CAD are 
also present. Phenotypical heterogeneity, ethnic and racial differences might be responsible of 
these discordant results. Bohlender et al. investigated in detail the relationships between AGT 
concentrations and RAS cascade, focusing on the prominent role of AGT. They demonstrated 
that the enzymatic kinetics of renin are a function of AGT concentrations. This feature can be 
considered as an intermediate phenotype for cardiovascular disease.
151
 
Similarly to the AGT results, also for the CYP11B2 we obtained controversial results 
comparing with other studies. Indeed, a wide body of evidences demonstrate that the 
considered SNP, rs1799998, leads to a -344 Cytosine/Tyrosine substitution at the putative 
binding site for the steroidogenic transcription factor (SF-1), influencing enzyme expression 
and protein levels. To date, it is well known that aldosterone is one of the most important 
hypertensive factor, involved in the blood pressure regulation, by handling the H2O volume 
and the Na
+
 concentration into the blood. Thus, any type of alteration, that leads to an increase 
of the circulating aldosterone concentration, has direct implication in the blood pressure 
values. Genetic polymorphisms in aldosterone synthase gene and in particular -344C/T 
variation have been largely investigated, because of their influences on the blood pressure 
values.
152,153
 Indeed, Fontana et al. demonstrated that -344 C/T CYP11B2 polymorphism 
shows an additive effect on the aldosterone production in subject with resistant hypertension, 
with crescent levels in homozygous WT (CC), heterozygous (CT), and homozygous SNP 
(TT).
154
 This result was also confirmed by another functional study, which showed that T 
allele binds to steroidogenic factor (SF-1) with lower affinity than C allele, and the binding of 
SF-1 to CYP11B2 inhibit the expression of the enzyme, supporting the increased aldosterone 
synthase activity in T allele.
155 
Despite of a wide number of studies show a clear correlation 
between -344C/T polymorphism and the hypertensive phenotype, there are few studies that do 
not support this hypothesis.
156,157
 However, we cannot exclude a false negative results for 
these studies because of a small number of individuals. 
Finally, a possible correlation between genetic characteristics and antihypertensive 
response was investigated in our study. Gender, age, cholesterolemia, body mass index or 
alternatively waist circumference were used as covariates in addition to the genotype to 
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correct the final results. According our analysis no correlation was found between genotype 
and response to the antihypertensive therapy. 
We could explain the lack of any type of correlation between the SNPs in the considered 
genes and the tested hypotheses because of different limitations occurring in the present 
study; the two most important of which are: 
 
 Low number of individuals  
 Unselected population for hypertensive phenotype 
 
We used a randomized Italian rural population, and not a selected hypertensive patients; thus, 
selecting the hypertensive subgroups the population number lowered widely, and 
consequently the proportion between case and control was not adequate to the study. In 
particular the small sample size strongly affected the statistical power to detect any 
association between the investigated polymorphisms and both hypertensive susceptibility and 
anti-hypertensive response. Finally we didn’t add any type of biochemical validation analysis, 
for example aldosterone/angiotensinogen quantification for the two genes AGT and 
CYP11B2, to confirm or exclude the genotyping results. 
The low number of individuals and unselected population for the hypertensive phenotype 
have limited enormously our study, and biased the accuracy of our results. However, our 
findings, could lay the groundwork for further studies, as for example analysing others SNPs 
in the CYP11B2 gene, with the opportunity to identify an haplotype associated with the above 
described phenotype.  
In conclusion we can say that from this case-control study, for the reasons above 
explained, we cannot withdraw any type of information that may be used to increase our 
knowledges about hypertensive susceptibility and personalized therapy.  
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8.0 Conclusion and future perspective  
 
8.1 Aldosteronism, a curable form of secondary hypertension 
 
PA is the cause of hypertension for a significant minority of patients. Its importance lies in 
the diagnosis offering the prospect of a curable form of hypertension. The molecular basis for 
rare syndromic forms of PA and the somatic mutations that may be driving sporadic adenoma 
formation is evolving rapidly. The role of KCNJ5 for the commoner sporadic form of PA is 
less well understood. In a cohort of 251 patients with sporadic PA, we identified 2 cases with 
functional heterozygous missense mutations in KCNJ5 (R52H and E246K). These mutations 
are distinct from the mutations previously identified in the selectivity filter of KCNJ5 in 
syndromic forms of PA or as somatic mutations in sporadic APAs. Another 12 patients were 
carriers for a rare functional SNP variant of the KCNJ5 gene, rs7102584, that produces an 
E282Q amino acid substitution in the channel. We have shown that despite their location in 
the channel the functional behaviour of these variants is similar to the selectivity mutants 
previously reported. These data suggest that mutant germline KCNJ5 channels are present in 
some apparently sporadic cases of PA. The clinical implications of this are unclear. It may be 
that they have a distinct phenotype or that PA patients with an adenoma and a germline 
mutation are less likely to have a long-term cure from unilateral adrenalectomy. Also the 
frequency of the functional SNP, rs7102584, could provide a germline basis for a significant 
minority of sporadic cases (≈5%). If it turns out that these germline mutations do affect the 
way we manage sporadic PA patients, then it will be necessary to routinely screen for them as 
part of their clinical workup. 
Furthermore, a better understanding of how dopamine via D2 and D4 dopaminergic 
receptors modulates KCNJ5 potassium channel activity, and how the most important 
intracellular messenger, Ca2
+
 ion, may regulate the aldosterone release, cellular growing and 
death, could be useful for an innovative therapeutic approach of PA. 
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